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Abstract 
 
Targeting ribosome biogenesis, a cellular process frequently upregulated in cancer, 
with the novel Pol I transcription inhibitor CX-5461 is highly efficacious in pre-clinical 
models of solid and haematological cancers, which lead to the commencement of 
clinical trials. However, as is common with single-agent therapies in the mouse models 
(similar to challenges with treating human patients), the mice eventually succumb to 
disease, highlighting the need for a combination therapy approach. Based on the 
strong link between altered ribosome biogenesis and metabolism in cancer it was 
hypothesised that targeting these two processes in combination would prove 
efficacious in cancer, and acute myeloid leukaemia (AML) was chosen to test this as it 
is an aggressive malignancy with poor therapeutic options. In order to address this 
hypothesis In vitro drug synergy testing in AML cell lines was performed to identify 
promising combinations (Chapter 3), these were then tested for efficacy in in vivo 
transplant models of AML (Chapter 4). Finally, in vitro mechanistic analysis of the most 
promising drug combination was performed in order to understand the mechanisms of 
synergy (Chapter 5). 
 
In vitro testing of CX-5461 in combination with 10 clinically-approved metabolism-
modifying drugs confirmed that orlistat, dichloroacetate (DCA), ritonavir, omeprazole 
and chloroquine act synergistically with CX-5461 to reduce cell viability in multiple 
AML cell lines. Three such combination therapies were evaluated in a syngeneic mouse 
AML model. Neither orlistat nor DCA improved survival in combination with CX-5461 
compared to CX-5461 alone, however, synergy was observed with the autophagy 
inhibitor chloroquine. Interestingly, the combination of CX-5461 and chloroquine had 
limited efficacy in human cell line xenograft mouse models, despite strong in vitro 
results. As the dosing of CX-5461 and chloroquine could not be increased due to 
toxicity, mechanistic analysis was performed in order to identify an alternative to 
chloroquine with reduced toxicity, and potentially improved efficacy. 
 
CX-5461 and chloroquine were found to synergise through cell cycle arrest and cell 
death in all four cell lines tested. Metabolic flux analysis revealed that the combination 
of drugs significantly affected mitochondrial activity, indicating that the combination of 
 v 
CX-5461 and chloroquine is placing the cells in mitochondrial stress. Therefore, direct 
targeting of the mitochondria was identified as a promising approach in combination 
with ribosome biogenesis inhibition with CX-5461, and various clinically-approved 
drugs that target mitochondria were identified for future combination testing. 
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Chapter 1 Introduction 
 
1.1  Acute myeloid leukaemia: an aggressive 
malignancy with poor therapeutic options 
 
1.1.1 Epidemiology and aetiology 
Acute myeloid leukaemia (AML) is a heterogeneous cancer resulting from the clonal 
expansion of myeloid progenitor cells, leading to an accumulation of myeloid blasts in 
the peripheral blood or bone marrow 8. It is the most common acute leukaemia in 
adults 9, and approximately 1000 Australians are diagnosed with AML each year (or 4 
new cases per 100,000 people) 10. The 5-year survival rate is poor, at approximately 
30%, compared to over 90% for more common cancers such as breast and prostate 
cancer 10. The risk of developing AML increases with age and the highest risk age group 
is those over 65 11. Other risk factors include pre-existing haematological disease, 
genetic conditions (e.g. Down syndrome, Li-Fraumeni syndrome), radiation exposure, 
chemical exposure (e.g. pesticides, cigarette smoke) or previous chemotherapy 12. 
Investigation of correlations between specific risk factors and AML genetics has 
revealed that cigarette smoke and occupational chemical exposure (e.g. pesticides) are 
associated with AML with increased incidence of complex chromosomal abnormalities 
and oncogene activation 13-15. However, specific risk factors account for only a 
relatively small fraction of total AML cases, the majority of which are considered de-
novo AML (~90%)16. Of the non-de-novo cases, most arise after cytotoxic and/or 
radiation therapy (treatment-related/t-AML) or myelodysplastic syndrome (MDS) 16, a 
heterogeneous group of disorders characterised by ineffective haematopoiesis that 
progresses to AML in approximately 15% of cases 17, through complex mechanisms 
that remain to be fully elucidated. 
 
1.1.2 Genetics of AML  
While AML has a comparatively low mutational burden compared to cancers such as 
melanoma and lung carcinoma 18, there are numerous recurrent mutations which are 
found at low frequency (Table 1-1) 2. These mutations can be broadly characterised 
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into groups associated with DNA methylation, tumour suppressors, activated 
signalling, myeloid transcription factors, chromatin modifiers, cohesion, spliceosome 
and transcription factor fusions. Certain mutations have been associated with either a 
favourable, intermediate or poor outcome for patients 19 (Table 1-1). Of the most 
common mutations, the presence of mutations in phosphoprotein nucleophosmin 
(NPM1) has been associated with a favourable outcome for patients 20,21, while those 
in the signal transduction protein FMS-like tyrosine kinase 3 (FLT3), including FLT3 
internal tandem duplication (ITD), are associated with a poor outcome 3,4. Cytogenetic 
analysis also provides a powerful prognostic tool for predicting outcomes in patients 
with this disease, with approximately 50-60% of AML patients having cytogenetic 
abnormalities at diagnosis 2,22, up to 75% in t-AML 16. For example, translocations of 
the mixed-lineage leukaemia (MLL) gene/11q23, which encodes a histone 
methyltransferase involved in haematopoiesis, results in specific fusion proteins which 
are associated with a poor patient outcome 6,23. The MLL fusion gene partners, of 
which there are over 70 24, further dictate the prognosis for these cancers. Of the more 
common rearrangements, MLL-AF6/t(6;11) is associated with a very poor prognosis, 
while MLL-AF9/ t(9;11) is more favourable 25. The translocation t(15;17) is 
characteristic of a subtype of leukaemia known as acute promyelocytic leukaemia 
(APL), fusing the promyelocytic leukaemia (PML) gene and retinoic acid receptor α 
(RARα), which blocks differentiation and promotes survival of promyelocytic cells 26. 
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Category Mutation Frequency 
(%) 
Favourable (F), 
Intermediate (I) or 
Unfavourable (U) 
prognosis 
Present in 
models in 
this thesis? 
In 
vitro 
In 
vivo 
NPM1 NPM1 27 F   
Activated 
signalling 
FLT3 28 U + + 
KRAS or NRAS 12 I + + 
KIT 4 I   
PTPN11 4 I   
DNA 
methylation 
DNMT3A 26 I   
IDH1 or IDH2 20 I   
TET2 8 I +  
Tumour 
suppressors 
TP53 8 U + + 
WT1 6 I   
Myeloid 
transcription 
factors 
RUNX1 10 I   
CEBPA 6 F   
Transcription 
factor fusions 
t(15;17)/PML-RARα 9 F   
inv(16)/MYH11-CBFB 6 F   
t(8;21)/RUNX1/RUNX1T1 
(AML1-ETO) 
4 F +  
Chromatin 
modifiers 
11q23/MLL fusions 4 U + + 
Other Loss of 7 or del (7q) 10 U   
Loss of 5 or del(5q) 8 U   
 
Table 1-1: Recurrent mutations in AML with functional categorisation and prognostic 
significance 
Mutation frequency and functional characterisation adapted from 2. Prognostic significance 
adapted from 3-6. Genetic information of individual cell lines used in this thesis is in Table 3-1. 
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With such a heterogeneous genetic profile, and the evidence that single mutations are 
not sufficient to cause AML 27, it is clear that the development of AML is a multistep 
process. A ‘two-hit’ model of AML development has been proposed where ‘Class I’ 
mutations, which activate signal transduction to confer a survival or proliferation 
advantage, cooperate with ‘Class II’ mutations, which affect transcription factors to 
block differentiation 27. Common Class I mutations include FLT3 and receptor tyrosine 
kinase c-KIT, while common Class II mutations include NPM1 and transcription factor 
CCAAT/enhancer-binding protein alpha (CEBPA). Mutations in epigenetic regulators 
have more recently emerged as a third class of mutations, including tet methylcytosine 
dioxygenase 2 (TET2) and DNA methyltransferase 3 α (DNMT3α) 2. Together these 
different classes of mutation cooperate to facilitate the survival and abnormal clonal 
proliferation of myeloid progenitor cells, resulting in AML. 
 
1.1.3 Classification of AML subtypes 
Classifying subtypes of AML has proved difficult due to its inherent heterogeneity. The 
older French-American-British (FAB) classification uses cell morphology and 
cytochemical characteristics to divide AML into 10 subtypes 28 but this did not provide 
a high reproducibility and prognostic value 29,30. The more recent World Health 
Organisation (WHO) classification incorporates the FAB classification, as well as 
cytogenetic abnormalities, specific gene mutations and distinct subtypes including 
t-AML, myeloid sarcoma (a solid myeloblast tumour) and myeloid proliferations 
related to Down syndrome 8 (Table 1-2). The sheer number of subtypes of AML 
highlights the heterogeneity of this disease and the challenges this creates for 
treatment. 
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WHO subtype 
AML with recurrent genetic abnormalities 
   AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
   AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
   Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARα 
   AML with t(9;11)(p22;q23); MLLT3-MLL 
   AML with t(6;9)(p23;q34); DEK-NUP214 
   AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
   AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
   AML with mutated NPM1 
   AML with mutated CEBPA 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, not otherwise specified (NOS) 
   AML with minimal differentiation (FAB M0) 
   AML without maturation (FAB M1) 
   AML with maturation (FAB M2) 
   Acute myelomonocytic leukaemia (FAB M4) 
   Acute monoblastic and monocytic leukaemia (FAB M5) 
   Acute erythroid leukaemia (FAB M6) 
   Acute megakaryoblastic leukaemia (FAB M7) 
   Acute basophilic leukaemia 
   Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
 
Table 1-2: The WHO Classification of AML  
Outlined in the WHO Classification of tumours of haematopoietic and lymphoid tissues (4th 
Edition, 2008) 8. 
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1.1.4 Models for studying AML 
 Cell lines 
AML cells of both human and mouse origin are readily culture-adaptable, with more 
than 200 such cell lines currently described 31. These cell lines vary in the mutations 
present, the disease subtype they are derived from and their previous exposure to 
chemotherapy, allowing these various parameters to be studied in vitro. The cell lines 
used in this thesis are outlined in Table 2-1 and Table 3-1. 
 
 Mouse models 
Many of these cell lines readily engraft in mice. Established in vivo models include 
mouse AML cell lines injected into genetically matched immune-competent hosts 
(syngeneic) 32, and human AML cells injected in to immune-compromised mice 
(xenograft) 33, with many disease features, such as bone marrow involvement, 
recapitulating human disease when the cells are injected intravenously (further 
discussed in Sections 4.1.2 and 4.3.3). Some fresh/non-culture-adapted AML patient 
samples can also be successfully engrafted in immune-compromised mice generating a 
patient-derived xenograft (PDX) model. While these can be difficult to establish, 
advances in immunodeficient mouse strains has improved the success of these models 
34. Both syngeneic and cell line xenograft mouse models are used in this thesis and are 
described in Section 4.1.2. 
 
1.1.5 Current treatment and treatment challenges 
The standard treatment for the majority of AML subtypes has changed little in the last 
few decades, relying heavily on standard chemotherapeutics and hematopoietic stem 
cell transplantation (HSCT). Treatment of AML usually begins with aggressive induction 
chemotherapy, the goal of which is to achieve remission, often in a standard 7+3 
combination; 7 days of cytarabine therapy combined with 3 days of anthracycline 
therapy 35,36. Cytarabine (cytosine arabinoside) is an antimetabolite that incorporates 
into newly synthesised DNA and inhibits further DNA synthesis, and is thus particularly 
effective against rapidly diving cells including leukaemia 37, but also affects 
non-cancerous dividing cells, such as intestinal cells 38 and embryonic cells 39. 
Anthracyclines, such as daunorubicin, are mainly thought to mediate anti-cancer 
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effects through intercalating with DNA 40. Bone marrow biopsies are performed 14-21 
days post-therapy initiation to measure the efficacy of the induction therapy, after 
which induction treatment is repeated, if required, or post-remission chemotherapy, 
HSCT or registration in a clinical trial are undertaken depending on patient age, 
cytogenetics, co-morbidities and other factors 41,42. These standard therapeutic 
regimes with cytotoxic therapeutic agents achieve approximately a 20% 5-year survival 
rate overall 43, which reduces to 5-10% in older patients, who account for the majority 
of diagnoses and have a high therapy-associated mortality and increased risk of 
unfavourable cytogenetics 44,45. As these therapies are non-specific for cancer cells 
there are significant side-effects associated with their use. Myelotoxicity/bone marrow 
suppression is a common and sometimes life-threatening side effect of standard AML 
chemotherapy, resulting in conditions such as neutropenia, thrombocytopenia, 
bacteraemia, pneumonia and sepsis 46,47. Heart failure is also a common complication 
of anthracycline treatment, occurring in approximately 20% of patients due to 
anthracycline-induced cardiotoxicity, sometimes decades after the treatment 48. HSCT 
is often the most effective method of achieving remission and preventing AML 
recurrence 49, but has a high risk of treatment-associated morbidity and mortality, 
particularly in older patients due to increased levels of pre-existing comorbidities, 
requiring serious risk-benefit analysis and adjustment of the intensity of the therapy 50-
52. 
 
In contrast to other AML subtypes, there have been dramatic improvements in the 
treatment of APL in the last few decades, particularly through targeting of the 
PML-RARα fusion protein that is characteristic of this subtype. The introduction of 
differentiation therapy all-trans retinoic acid (ATRA), which binds the fusion PML-RARα 
protein leading to its degradation, in combination with standard chemotherapies such 
as cytarabine significantly improved outcomes for APL patients, with complete 
remission of greater than 90% and cure rate exceeding 80% in some cases 53-56. 
Long-term remission was further improved with the introduction of arsenic trioxide 
(ATO), which also binds the fusion protein, and may be used in combination with ATRA 
57,58. While ATRA and ATO therapy have mild, reversible side effects 59, the side effects 
of conventional chemotherapies used in combination with them, as outlined 
previously, are often severe and can be life-threatening. 
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Despite current efforts to develop more targeted therapies for AML, such as therapies 
targeting FLT3-ITD mutated AML 60, the treatment landscape of AML is predominated 
by cytarabine in combination with anthracyclines. The lack of effective therapies and 
often severe treatment-related side effects for this aggressive malignancy makes it an 
ideal focus for new therapy development, however attempting to treat such a 
heterogeneous disease presents a significant challenge. A promising approach is to 
target the oncogenic processes in cancer cells that are common between many 
different cancer types and subtypes, with the aim of improving efficacy and reducing 
the development of drug resistance. 
 
1.2  Targeting ribosome biogenesis in cancer 
1.2.1 The nucleolus and ribosome biogenesis  
Ribosome biogenesis, or the synthesis of ribosomes, is a highly conserved, complex 
process that occurs within a sub-nuclear, non-membrane bound structure known as 
the nucleolus 61. Ribosomes are encoded by hundreds of copies of the ribosomal DNA 
(rDNA) gene in head-to-tail tandem repeats in nucleolar organiser regions (NORs), 
which cluster on the short arms of five human acrocentric chromosomes (13, 14, 15, 
21, 22) 62. In eukaryotes, the repeating units consists of the rDNA gene encoding the 
18S, 5.8S and 28S ribosomal RNA (rRNA), separated by internal intergenic spacers (ITS) 
and flanked by a 5’ and 3’ external transcribed spacer (ETS) 63,64 and these rDNA genes 
are transcribed exclusively by RNA polymerase I (Pol I) . At the core region (Core) and 
upstream control element (UCE) of the rDNA promoter, transcription requires the 
formation of a pre-initiation complex (PIC), the main components of which include Pol 
I, human selectivity factor 1 (SL-1) complex, upstream binding factor (UBF), Pol-I-
associated factor RRN3 and topoisomerase II α (TopIIα) 65 (Figure 1-1). SL-1, which is a 
complex of the TATA-box-binding protein (TBP) and multiple TBP-associated factors 
(TAFs) 66, plays a crucial role in recruiting Pol I through its interaction with RRN3 67 and 
TopIIα 68. Regulation of rDNA transcription by Pol I is dynamic, with cell cycle cues and 
growth factors able to modulate the rate of rRNA transcription 69. Transcription of the 
rDNA gene generates a single polycistronic 47S transcript, which is processed into the 
mature 18S, 5.8S and 28S rRNAs 70. Functional ribosomes also require 5S RNA, 
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transcribed by RNA polymerase III (Pol III) in the nucleus 71, and various ribosomal 
proteins (RPs), transcribed by RNA polymerase II (Pol II) also in the nucleus and 
translated in the cytoplasm 72, which are imported into the nucleolus. Together these 
elements are assembled into pre‐40S and pre‐60S ribosomal subunits, which are then 
exported to the cytoplasm to form mature 80S ribosomes, which can then translate 
mRNA into protein 73. 
 
1.2.2 Elevated ribosome biogenesis in cancer  
Elevated growth and proliferation of cells is accompanied by an increased abundance 
of ribosomes to support the high protein translation requirement of the cells during 
this time 74,75. Elevated transcription of the rDNA by Pol I and subsequent increases in 
ribosome biogenesis are features common to many human cancers, as enhanced 
translational capacity is required to facilitate the proliferation of cancerous cells 76. 
Indeed, changes in the morphology and number of nucleoli has long been recognised 
as a feature of cancerous cells and is used as a diagnostic tool by pathologists as a 
marker of aggressive disease 77. Elevated ribosome biogenesis has also been observed 
in the premalignant state. For example, in a mouse lymphoma model, pre-malignancy 
is accompanied by increases in Pol I transcription, including increased total RNA per 
cell, 18S and 28S RNA, pre-RNA and expression of Pol I transcription factors 78, 
highlighting the role of increased ribosome biogenesis in malignant transformation and 
progression. 
 
1.2.3 Targeting ribosome biogenesis with the novel Pol I inhibitor 
CX-5461 
The relationship between rDNA transcription rate and cellular proliferation makes 
rDNA transcription an attractive target for broad-spectrum cancer therapies. Indeed, 
some standard cancer chemotherapies have been shown to significantly perturb 
various stages of ribosome biogenesis including rRNA transcription (e.g. doxorubicin, 
oxaliplatin), early rRNA processing (e.g. camptothecin, flavopiridol) and late rRNA 
processing (e.g. 5-fluorouracil), which might contribute to their anti-cancer properties 
79. However, a more targeted approach to ribosome biogenesis inhibition is likely to 
prove even more efficacious against cancer cells.  
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Figure 1-1: Schematic representation of ribosome biogenesis  
Transcription of the ribosomal DNA (rDNA) gene occurs within the nucleolus. Transcription 
initiation requires the formation of a pre-initiation complex (PIC) at the core and upstream 
control elements (UCE) of the rDNA promoter. The PIC consists of upstream binding factor 
(UBF), the SL-1 complex (comprised of TATA‐box‐binding protein (TBP) and five TATA‐box‐
associated factors (TAFs)), RNA polymerase I (Pol I) and RRN3. The 47S rDNA repeats are 
then transcribed by Pol I, producing a 47S precursor RNA, which is processed into 18S, 5.8S 
and 28S RNA. Ribosomal proteins (RP) and 5S RNA are imported into the nucleolus, where 
pre-40S and pre-60S subunits are then assembled from the rRNA and RPs, and exported to 
the cytoplasm to produce mature ribosomes. 
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In eukaryotes, gene transcription is performed by three different RNA polymerases: 
Pol I (which transcribes the rDNA gene), Pol II (which transcribes messenger RNA 
(mRNA), micro RNA (miRNA), small nuclear RNA (snRNA), and small nucleolar RNA 
(snoRNA) genes) and Pol III (which transcribes transfer RNA (tRNA) and 5S rRNA 
genes).80 As the only polymerase exclusively involved in the transcription of the rDNA, 
Pol I is an ideal target for inhibition of rDNA transcription without affecting global 
transcription. 
 
Identified in a screen for inhibitors of rRNA synthesis, the novel drug CX-5461 
selectively targets rDNA transcription by disrupting the interaction of SL-1 with the 
rDNA, preventing the recruitment of Pol I 81 (Figure 1-2). Importantly, CX-5461 is highly 
selective for Pol I, showing a 200-fold specificity for Pol I over Pol II, thus has limited 
effects on global transcription 81. CX-5461 inhibits rDNA transcription initiation in both 
non-malignant and malignant cells to a similar extent, however, non-malignant cells 
are approximately 30 times less sensitive to CX-5461 in terms of viability, highlighting 
the addiction of malignant cells to rDNA transcription and the therapeutic window this 
creates 81. CX-5461 has shown significant efficacy in various solid and haematological 
malignancies in vivo, for example, mediates p53-dependent apoptosis and prolonged 
survival in animal models of B-cell lymphoma and acute myeloid leukaemia 78. 
 
A Phase I dose-escalation study of CX-5461 in patients with haematological cancers, 
conducted at the Peter MacCallum Cancer Centre in Melbourne, revealed that 
administration of CX-5461 intravenously once every 3 weeks resulted in rapid, 
on-target inhibition of rDNA transcription in peripheral blood mononuclear cells 
(PBMCs) and cancer cells, and a prolonged partial response was achieved in one 
patient with anaplastic large cell lymphoma 82. In this study, the maximum tolerated 
dose was found to be 170 mg/m2, with a dose-limiting toxicity of palmar-plantar 
erythrodysesthesia, and manageable incidences of photosensitivity in 50% of patients, 
irrespective of dose. CX-5461 has also shown significant efficacy in solid tumour 
preclinical models including osteosarcoma 83, ovarian cancer 84 and breast cancer 81 
leading to the commencement of a Phase I/II clinical trial of CX-5461 in solid tumours 
in Canada (ClinicalTrials.gov Identifier: NCT02719977), with results so far indicating CX-
5461 is tolerable and has activity in patients 85. 
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Despite the remarkable potential of CX-5461 in animal models of malignancy, 
eventually the mice succumb to the disease. For example, in the aggressive syngeneic 
MLL/ENL (t[11;19][q23;p13.3]) p53 null mouse model, treatment with CX-5461 
significantly improved survival compared to the vehicle-treated mice, increasing the 
median survival from 11 days to 24 days post-transplant, however, the CX-5461-
treated mice still eventually succumb to disease 1 (Figure 1-3). This indicates that CX-
5461 as a single agent is not sufficient to completely halt cancer progression in this 
model. Thus, CX-5461 is likely to be more effective and have broader applications in 
cancer therapy if it is used in combination with other anti-cancer molecules, 
presumably that impact on different or complementary mechanisms of action to 
reduce cancer cell growth or induce cell death. 
 
 
Figure 1-2: Mechanism of action of the novel Pol I inhibitor CX-5461 
Novel cancer therapeutic CX-5461 inhibits ribosome biogenesis at the stage of rDNA 
transcription initiation by interfering with SL-1/rDNA binding, preventing the recruitment of 
Pol I to the pre-initiation complex (PIC). 
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1.3 Targeting cancer cell metabolism 
1.3.1 Metabolic rewiring in cancer  
Deregulated cellular energetics has formally been recognised as a hallmark of cancer 
since 2011, and thus is considered an important target for cancer therapies 86. Rapidly 
proliferating cells, including cancer cells, require maintenance of a higher metabolic 
rate in order to produce energy in the form of adenosine triphosphate (ATP), 
macromolecules to facilitate their growth and to maintain redox balance 87. There are 
many metabolic pathways that are dysregulated in cancer cells that could be potential 
targets for combination therapy (Figure 1-4). 
 
 
 
Figure 1-3: CX-5461 significantly improves the survival of AML-bearing mice, however 
they eventually succumb to disease 
Figure 3B from Hein et al 1. Mice were injected with mouse-derived MLL/ENL p53 null 
AML cells intravenously in the tail vein. Engraftment was confirmed through 
bioluminescent imaging (described in Section 2.6). At 7 days post-transplant treatment 
was commenced with either CX-5461 (35mg/kg every 3 days) or vehicle (NaH2PO4). 
Treatment continued until the mice reached an ethical endpoint and the survival time 
was calculated. Grey shading indicates the treatment period. ****P < 0001. N=20 
mice/group. 
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Figure 1-4: Metabolic pathways altered in cancer 
Various metabolic pathways are altered in cancer to facilitate the abnormal growth and 
proliferation of the cells, including glucose transport, glycolysis, nucleotide synthesis, fatty 
acid synthesis, cholesterol synthesis, autophagy, glutaminolysis and the electron transport 
chain (ETC). Alterations in these pathways provide the cancer cells with increased capacity 
for bioenergetics, biosynthesis and redox balance, conferring a survival and proliferation 
advantage over non-cancerous cells. FASN = fatty acid synthase, G6P= glucose 6-
phosphate, GLS = glutaminase, GLUT = glucose transporter, HMG-CoA = 3-hydroxy-3-
methyl-glutaryl-coenzyme A, NAPDH = reduced nicotinamide adenine dinucleotide 
phosphate, PDH = pyruvate dehydrogenase, PDK = pyruvate dehydrogenase kinase, PPAR = 
peroxisome proliferator-activated receptors, SLC1A5 = solute carrier family 1 member 5, 
TCA = tricarboxylic acid cycle. 
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Aerobic glycolysis (Warburg effect), the preference of some cells to metabolise 
pyruvate to lactic acid, even in the presence of oxygen, was a phenomenon first 
described by Otto Warburg almost 100 years ago 88,89, and has since been recognised 
as a feature of cancer 90. Glycolysis is a relatively inefficient means of generating ATP 
per unit of glucose when compared to mitochondrial respiration, however, 
metabolism through this pathway is thought to benefit cancer cells by providing them 
with more rapid ATP generation and increased macromolecule synthesis capacity 91. 
Targeting this pathway shifts the metabolism of pyruvate to mitochondrial oxidative 
phosphorylation which can reduce the growth of tumour cells that are dependent on 
glycolysis, while leaving normal cells unaffected 92. Mitochondrial metabolism is also 
an important process in tumour development. Functional mitochondria are present in 
many cancers, with the upregulation of one or more mitochondrial pathways providing 
the additional energy and macromolecules necessary for cancer cell growth and 
proliferation 93. Non-glucose metabolism also has an important role in tumours, 
including fatty acid 94,95 and glutamine metabolism 96,97 which are altered in 
haematological malignancies. Increased synthesis of cellular building blocks including 
nucleotides 98 and cholesterol 99,100, further fuels cell growth, including that of cancer 
cells. Autophagy, a process of intracellular recycling, provides the cells, including 
cancer cells, with nutrients in times of stress 101 and reduces oxidative stress by 
degrading dysfunctional organelles 102. Targeting these metabolic pathways could 
improve the efficacy of CX-5461, as well as reduce acquired resistance to this drug. 
 
 Metabolic rewiring in AML 
Metabolic rewiring has also been found to play a role in AML development and 
progression. Isocitrate dehydrogenase (IDH) mutations, commonly found in AML 
(Table 1-1), lead to the abnormal production of oncometabolite 2-hydroxyglutarate 
(HG), resulting in inhibition of cytochrome c oxidase (COX) activity in the mitochondrial 
electron transport chain (ETC) 103 and making cells more dependent on glutamine for 
survival 104. Indeed, glutamine dependency is a feature of AML cells with various 
genetic mutations, as knocking out solute carrier family 1 member 5 (Slc1a5), which 
transports neutral amino acids such as glutamine, has been found to decrease 
leukaemia initiation and progression in mouse models of AML, while having 
comparatively mild effects on bone marrow and blood cell development 105. 
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Mitochondria, which contribute to many core metabolic processes, are also altered in 
AML, with AML blasts having a higher mitochondrial (mt)DNA copy number and 
oxygen consumption rate, indicating an increased number of mitochondria and thus 
functional capacity, in comparison to normal hematopoietic cells 106. Dependency on 
glycolysis is another feature common to AML, as targeting glycolysis with inhibitor 
dichloroacetic acid ‘primed’ human AML cell lines with various genetic mutations for 
the cytotoxic effects of ATO treatment 107. In particular, AML cells with FLT3-ITD 
mutation, a common mutation (Table 1-1), have a significant increase in aerobic 
glycolysis compared to normal blood cells, a dependency which can be targeted 
therapeutically in vivo 108. Cholesterol pathways are also dysregulated in AML, with 
increased processing of low-density lipoprotein 109 and HMG-CoA reductase activity 110 
in AML patient cells compared to normal blood cells, in order meet the increased 
cholesterol demands of rapidly dividing tumour cells for membrane synthesis. 
Autophagy, a process of intracellular recycling, has been found to be both upregulated 
and downregulated in AML cells. A reduced rate of autophagy results in an increase in 
the number of damaged organelles 111, increasing reactive oxygen species (ROS) levels 
112, genome instability 102 and inflammation 113, creating a tumour permissive 
environment for AML cells 114. Conversely, increased levels of autophagy can have a 
cytoprotective role in response to cellular stress, including chemotherapy, and have 
been shown to play a role in the maintenance of leukemic stem cells 115. Both fatty 
acid synthesis and oxidation have been shown to play a key role in AML cell 
maintenance, including through bone marrow adipocytes providing AML cells with 
fatty acids which promote AML cell survival 116. 
 
1.3.2 Metabolic changes accompanying drug insensitivity 
Given the role metabolic pathways play in supporting cancer cell growth, stress 
responses and survival it is unsurprising that many have also been linked to both 
intrinsic and acquired insensitivity to chemotherapy. 
 
Chemotherapy-resistant prostate cancer cells have an increased expression of HMG-
CoA reductase (HMGCR), a critical enzyme in cholesterol synthesis, and knocking down 
or inhibiting the function of this enzyme with simvastatin re-sensitised the cells to 
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chemotherapy 99. In glioma cells resistant to standard chemotherapy temozolomide, 
upregulation of autophagy was found to be associated with poor prognosis in patients 
and chemoresistance, and genetic or chemical inhibition of autophagy re-sensitised 
the cells to temozolomide 117. 
 
Metabolic changes have also been implicated in chemotherapy-resistance in AML. In 
cytarabine-resistant cells from patient-derived xenograft mouse models, a high 
oxidative phosphorylation (OXPHOS) phenotype was observed including increased 
expression of genes involved in lipid metabolism, elevated ROS, and increased 
mitochondrial mass and activity 118. Targeting mitochondrial function re-sensitised the 
cells to the effects of cytarabine, indicating mitochondrial activity is playing an 
important role in AML cell resistance to cytarabine. Statins, which target cholesterol 
synthesis, are toxic to both AML cell lines and patient samples through preventing 
protective cholesterol responses to chemotherapeutics cytarabine and daunorubicin 
100. 
 
Together these findings highlight the important role metabolism plays in the response 
of cancer cells to chemotherapy and in acquired resistance, making targeting cancer 
metabolism an ideal angle for combination therapy, such as with ribosome biogenesis 
inhibition. 
 
1.4  Combination therapy rationale 
Targeting metabolism in combination with CX-5461 is a logical approach as ribosome 
biogenesis is intimately linked to energy production and thus metabolism. Indeed, the 
process of ribosome biogenesis can account for up to 80% of energy consumption in a 
rapidly dividing cell 74. In return, increased numbers of ribosomes provide more 
proteins in the cell which are involved in signalling and are building blocks in 
metabolism. As outlined in Section 1.3.2, adaptive metabolic responses play an 
important role in drug resistance, and targeting these pathways re-sensitises cancer 
cells to chemotherapy. Interestingly, RNA sequencing (RNAseq) analysis of mouse 
leukemic cells performed by our laboratory demonstrated that short-term CX-5461 
treatment induced multiple changes in metabolic gene expression including 
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upregulation of transcription of enzymes involved in fatty acid and cholesterol 
synthesis (Figure 1-5, Hein & Blackburn, unpublished), which confirms that ribosome 
biogenesis and metabolism are intimately linked and provides a clue as to how these 
cells might be overcoming their sensitivity to CX-5461. Thus, targeting these two 
aspects of cancer cells is a promising approach to improve efficacy. 
 
 
1.5  Hypothesis 
Combining the novel Pol I inhibitor CX-5461 with metabolism-modifying drugs will 
improve efficacy in acute myeloid leukaemia. 
 
To examine this hypothesis the following aims were addressed. 
1.6  Aims 
1. Identify established metabolism-modifying therapies that work synergistically 
with CX-5461 to target AML in vitro (Chapter 3) 
 
 
Figure 1-5: Changes in mRNA levels of metabolic genes in MLL/ENL NRAS AML cells 
after 10 hours of CX- 5461 treatment in vivo 
Fold change compared to untreated cells. False discovery rate (FDR) < 0.1. Hatched 
columns contribute to the pathway in the opposite direction to others in the same 
pathway. Hein & Blackburn, unpublished. Chol synth = cholesterol synthesis, FA = 
fatty acid, FC = fold change, TG = triglyceride.  
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A panel of human and mouse AML cells lines will be used to identify established 
metabolism-modifying drugs that enhance the effects of CX-5461 to reduce AML cell 
number in vitro. 
2. Test promising combination therapies in in vivo syngeneic and xenograft 
models of AML (Chapter 4). 
Metabolism-modifying drugs that are found to act synergistically with CX-5461 to 
reduce AML cell number in vitro (Chapter 3) will be tested for their efficacy in 
improving survival in vivo in transplant models of AML. 
3. Investigate the mechanism/s of synergy for promising drug combinations 
(Chapter 5). 
Promising drug combinations will be identified based on the studies in Chapters 3 and 
4. Given the published effects of the drugs as individual agents, mechanistic analysis 
will be performed to determine how the drugs act synergistically together. 
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Chapter 2 Methods 
2.1 Cell lines and tissue culture 
Human cell lines MV4-11 (ACC 102), THP-1 (ACC 16), MOLM-13 (ACC 554), KG-1 (ACC 
14), NB-4 (ACC 207) and SKM-1 (ACC 547) were purchased from the German Collection 
of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). Mouse 
MLL/AF9 NRAS cells were generated by others using fetal liver transduction to 
introduce the MLL/AF9 fusion protein with green fluorescent protein (GFP) tag and 
NrasG12D mutation with luciferase tag 32. Cells were maintained in RPMI-1640 media 
(Gibco, via ThermoFisher Scientific, Cat no. 11875093) supplemented with 20% heat-
inactivated fetal bovine serum (HI-FBS, Sigma-Aldrich, Cat no. F9423-500mL) and 
GlutaMAX (Gibco, Cat no. 35050061) at 37°C in 5% (human cells) or 10% CO2 (mouse 
cells). Cell lines were certified to be free of mycoplasma contamination through 
polymerase chain reaction (PCR) testing. Cells were sub-cultured every 3-4 days, at a 1 
in 2 (human) or 1 in 3-4 (mouse) split, by adding the existing cell mixture to fresh 
media. When media removal was required, cells were centrifuged at 450 x g for 5 
minutes, unless specified otherwise. 
 
Cell line name Origin Culture conditions Doubling time 
(approximate hours 
[h]) 
MV4-11 DSMZ: ACC 102 RPMI 1640 + 20% HI-FBS + 
Glutamax, 37°C with 5% CO2 
50 
THP-1 DSMZ: ACC 16 RPMI 1640 + 20% HI-FBS + 
Glutamax, 37°C with 5% CO2 
72 
MOLM-13 DSMZ: ACC 544 RPMI 1640 + 20% HI-FBS + 
Glutamax, 37°C with 5% CO2 
50 
KG-1 DSMZ: ACC 14 RPMI 1640 + 20% HI-FBS + 
Glutamax, 37°C with 5% CO2 
38 
SKM-1 DSMZ: ACC 547 RPMI 1640 + 20% HI-FBS + 
Glutamax, 37°C with 5% CO2 
48 
MLL/AF9 NRAS 32 RPMI 1640 + 20% HI-FBS + 
Glutamax, 37°C with 10% CO2 
24 
Table 2-1: Cell line origin and growth conditions 
*Doubling times based on DSMZ information and personal observation. See Table 3-1 
for genetic information. 
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2.2 Buffers 
Buffer  Composition 
Western solubilisation 
buffer 
0.5mM EDTA, 20mM HEPES, 2% (w/v) SDS pH 7.9 
Western sample loading 
buffer (6X) 
2% (w/v) SDS, 0.4M tris-HCl pH 6.8, 48% (v/v) glycerol, 58mM 2-
mercaptoethanol, 0.25% (w/v) bromophenol blue 
SDS-PAGE buffer  25mM tris, 190mM glycine, 0.1% (w/v) SDS 
Semidry transfer buffer 
(Bjerrum Schafer-Nielson 
Buffer with SDS) 
48mM tris, 39mM glycine, 0.00375% (w/v) SDS, 20% (v/v) 
methanol 
Tris-buffered saline (TBS) 50mM tris, 150mM NaCl 
Tris-buffered saline with 
tween (TBST) 
0.1% (v/v) tween-20 in TBS 
Skim milk blocking buffer 
(SMBB) 
5% (w/v) skim milk in TBST 
Bovine serum albumin 
(BSA) blocking buffer 
(BSABB) 
1% (w/v) BSA in TBST 
Flow cytometry staining 
buffer (FCSB) 
2% FBS and 0.5% Tween-20 in PBS 
Red cell lysis buffer 144mM NH4Cl,17mM tris-HCl pH 7.65 
Table 2-2: Buffer composition 
EDTA = ethylenediaminetetraacetic acid, FBS = fetal bovine serum, HEPES = 4-(2-
hydroxyethyl)-1 piperazineethanesulfonic acid, SDS = Sodium dodecyl sulphate, HCl = 
hydrochloric acid, SDS-PAGE = sodium dodecyl sulphate polyacrylamide gel 
electrophoresis, NaCl = sodium chloride, PBS = phosphate-buffered saline, NH4Cl = 
ammonium chloride. 
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2.3 Antibodies and dyes 
Antibody Species Supplier Assay Concentration 
used 
Buffer 
LC3B Rabbit Cell signalling #2775S WB 1:3000  BSABB 
P62/Sequestome Mouse Abnova #H00008878-
M01 
WB 1:4000 SMBB 
Beclin 1 Rabbit Cell signalling #3495S WB 1:1000  SMBB 
ATG7 Rabbit Cell signalling #8558S WB 1:750-1:1000 SMBB 
BrdU (B44 clone) Mouse BD Pharmingen 
#347580  
FC 1:50 FCSB 
Anti rabbit-HRP Goat Bio-Rad #170-6515 WB 1:3000 SMBB or 
BSABB 
Anti mouse-HRP Goat Bio-Rad #170-6516 WB 1:3000 SMBB or 
BSABB 
Beta Actin-HRP 
(C4) 
Mouse Santa Cruz # sc-
47778 HRP 
WB 1:10 000 SMBB or 
BSABB 
Anti mouse 
Alexafluor 488 
Goat Invitrogen #A11001 FC 1:500 FCSB 
DAPI N/A Sigma #10236276001 FC 1g/mL FCSB 
Table 2-3: Antibodies and dyes 
HRP = horseradish peroxidase, WB = western blot, FC = flow cytometry, DAPI = 
4′,6-diamidino-2-phenylindole, SMBB = skim milk blocking buffer, BSABB = bovine 
serum albumin (BSA) blocking buffer. See Table 2-2 for buffer composition. 
 
2.4 Chemicals and drugs 
MTT (Thiazolyl blue tetrazolium bromide, Sigma, Cat no. M2128) was dissolved in PBS 
to make a 5mg/mL solution, filter sterilised, aliquoted and stored at -20°C. 
Neutral red (Sigma, Cat no. N4638) was dissolved in ddH2O at 3.3mg/mL, filter 
sterilised and stored at 4°C for up to 2 months. 
Luciferin (Xenolight D-luciferin K+ Salt, Perkin Elmer, Cat no. 122799) was dissolved in 
PBS to make a 5mg/mL solution, filter sterilised, aliquoted and stored at -20°C in the 
dark. 
BrdU (5-bromo-2’-deoxyuridine; Sigma, Cat no. 10280879001) was dissolved in double-
distilled water (ddH2O) to make a 10mM solution, filter sterilised, aliquoted and stored 
at --20°C. 
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CX-5461: For in vitro work, CX-5461 (Cylene) was dissolved in 50mM NaH2PO4 pH4.5 to 
make a 10mM stock solution, aliquoted and stored at -20°C in the dark. For in vivo 
work, CX-5461 solution was prepared fresh from powder before dosing using the same 
vehicle as in vitro. 
Orlistat: For in vitro work, orlistat (Sigma-Aldrich, Cat no. O4139) was dissolved in 
dimethyl sulfoxide (DMSO) to make a 15mM stock solution, aliquoted and stored at -
20°C. For in vivo work, orlistat was extracted from Xenical capsules (Roche), adapted 
from the methods of Kridel et al 119. The contents of a Xenical capsule were placed in 
250µL absolute ethanol for 20 minutes (min), vortexed every 10 min, then 500µL PEG-
400 (BioUltra, Sigma, Cat no. 91893) was added, vortexed and left for 10 min, then 
vortexed again. The tube was spun at 14 000 x g for 5 min to pellet the filler material, 
then the resulting supernatant was removed, and stored at -20°C. 
Chloroquine: For in vitro work, chloroquine diphosphate salt (Sigma, Cat no. C6628) 
was dissolved in PBS to make a 50mM stock solution, filtered sterilised and stored at 
4°C in the dark for up to 3 months. For in vivo work, chloroquine solution was prepared 
using 50mM NaH2PO4 pH4.5. 
Dichloroacetate (DCA): For in vitro work, DCA liquid (Sigma, Cat no. D54702) was 
diluted in PBS to make a 100mM solution, the pH adjusted to 6.9-7.5, then filter 
sterilised and stored at 4°C. For in vivo work, DCA solution was prepared in 50mM 
NaH2PO4 pH4.5. 
Ritonavir: For in vitro work, ritonavir powder (Sigma, Cat no. SML0491) was dissolved 
in DMSO to make a 15mM stock solution, aliquoted and stored at -20°C. For in vivo 
work, ritonavir powder (Selleckchem, Cat no. S1185) was dissolved in 7.5% ethanol in 
PBS and used immediately. 
Omeprazole: For in vitro work, omeprazole powder (Sigma, Cat no. O104) was 
dissolved in DMSO to make a 150mM stock solution, aliquoted and stored at -20°C in 
the dark. For in vivo work, omeprazole powder (Selleckchem, Cat no. S1389) was 
dissolved in 7.5% ethanol in PBS and used immediately. 
Metformin: Metformin/1,1-dimethylbiguanide hydrochloride powder (Sigma, Cat no. 
D150959) was dissolved in PBS to make a 50mM stock solution, then filter sterilised 
and stored at 4°C. 
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Simvastatin: Simvastatin powder (Sigma, Cat no. S6196) was dissolved in DMSO to 
make a 10mM solution, aliquoted and stored at -20°C. 
Fenofibrate: Fenofibrate powder (Sigma, Cat no. F6020) was dissolved in DMSO to 
make a 100mM stock solution, aliquoted and stored at -20°C. 
Bezafibrate: Bezafibrate powder (Sigma, Cat no. B7273) was dissolved in DMSO to 
make a 100mM stock solution, aliquoted and stored at -20°C. 
Rosiglitazone: Rosiglitazone powder (Sigma, Cat no. R2408) was dissolved in DMSO to 
make a 50mM solution, aliquoted and stored at -20°C. 
Bafilomycin A1: Bafilomycin A1 powder (Selleckchem, Cat no. S1413) was dissolved in 
DMSO to make a 150µM solution, aliquoted and stored at -20°C. 
 
2.5 Viability assays and synergy analysis 
In Chapter 3, three different methods of measuring total viable cell number were 
utilised in order to determine if any of the drugs were impacting on the mechanism of 
action of the viability assay; the neutral red assay, the MTT assay and Coulter counts. 
 
2.5.1 Neutral red 
The neutral red assay estimates viable cell number based on the uptake and binding of 
the neutral red dye in the lysosomes of the cells 120. Uptake and retention of the dye 
will only occur if a pH gradient is present in the lysosomes, as the dye then becomes 
charged when it enters the lysosome and accumulates. Maintenance of active pH 
gradients through ATP production is a characteristic of a viable cell, therefore, the 
amount of retained dye is proportional to the number of viable cells. However, if a 
drug interferes with the accumulation of neutral red without affecting the viability of 
the cell this assay will not be an accurate measure of cell viability. 
 
2.5.2 MTT 
The MTT assay is based on the conversion of the water-soluble MTT tetrazolium salt 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to coloured formazin 
crystals via succinate dehydrogenase in the mitochondria 121. This process requires 
functional mitochondrial enzymes, which is a characteristic of viable cells. Therefore, 
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the amount of converted MTT is proportional to the number of viable cells. However, 
if a drug interferes with normal mitochondrial enzyme function without affecting the 
overall viability of the cell the MTT assay will not be an accurate measure of cell 
viability. 
 
2.5.3 Coulter count 
A physical particle counting method is a ‘gold-standard’ measure of cell viability. The 
Z2 Coulter Counter (Beckman Coulter) counts and determines the size of cells by 
utilising changes in electrical resistance when a cell suspended in a conductive liquid 
passes through an aperture. Viable and dead cells can then be distinguished by their 
size. 
 
2.5.4 Measuring total viable cell number 
Cells were seeded in 96-well round-bottom plates at a pre-determined density so that 
the cells were still in the exponential growth phase at the end of the assay. At the time 
of plating, drug dilutions (with equal final concentration of vehicle) were added to the 
plate in quadruplicate wells and the cells cultured for 96 h. 
• Coulter count: Following treatment, a 1:100 dilution was made of the cells in 
Isoflow Sheath Fluid (Beckman Coulter, Cat no. A48466) and counting 
performed using the Z2 Coulter counter (Beckman Coulter). Gating was 
performed on events with volume 200fL+. 
• MTT: Following treatment 20μL of 2.5mg/mL MTT solution was added to each 
well and the plates incubated at 37°C for 1-2 h. The media was removed and 
replaced with DMSO. The resulting solutions were transferred to a flat-bottom 
96 well plate and the absorbance read at 570nm using an Epoch Microplate 
Spectrophotometer (BioTek). 
• Neutral red: Following treatment the media was removed and replaced with 
200μL /well pre-warmed media containing neutral red (200μL of 3.3mg/mL 
neutral red stock solution/20mL media) and the plates incubated at 37°C for 3 
h. The plates were washed 3 times with PBS then the contents solubilised in 3:1 
methanol:acetic acid de-stain solution. The resulting solutions were transferred 
to a flat-bottom 96 well plate and the absorbance read at 540nm using an 
Epoch Microplate Spectrophotometer (BioTek). 
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N=1 for testing suitability of MTT or neutral red as viability assays with the different 
metabolism-modifying drugs. 
 
2.5.5 GI50 and synergy analysis 
The cell lines were treated with the drugs as single agents at a range of concentrations 
in order to determine the dose-response curves for viability. Viability (as a % of the 
vehicle-treated cells) was calculated as an average of n=3 experiments. The 
concentration resulting in 50% growth inhibition (GI50) values were calculated using 
sigmoidal dose-response curve analysis in Prism (GraphPad Software, San Diego, USA). 
A non-linear curve (sigmoidal) was fitted to the data points. Where a sigmoidal dose 
curve could not be fitted, an estimate only of the GI50 was shown. 
 
Synergy analysis of n=3 experiments was performed using the Chou-Talalay 
Combination Index method 122. This method is based on the median-effect equation, 
which incorporates various well-established equations in biochemistry and biophysics, 
including the Michaelis-Menten model of enzyme kinetics and the Scatchard equation 
which describes the affinity of a ligand with a binding site. Dose response curves are 
fitted, or predicted, to the data points of the effects of the single drugs and used to 
determine if a drug combination effect is synergistic. Non-constant ratio synergy 
analysis was performed using CompuSyn software (ComboSyn Inc.) using the viability 
results to determine the ‘effect’ (as 1 – [%viability/100]) and synergy defined as a 
combination index of 0.75 or lower, based on recommended guidelines for 
categorising synergism 123. Where the viability was 100% the effect was entered as 
0.001 as an effect of 0 cannot be entered. 
 
2.6 Tumour models and in vivo drug studies 
In Chapter 4, metabolism-modifying drugs that were found to act synergistically with 
CX-5461 in vitro (Chapter 3) were tested for their tolerability in non-tumour-bearing 
mice, followed by efficacy testing (improving survival in vivo in transplant models of 
AML). Animal experimentation was approved by the Animal Experimentation Ethics 
Committee at ANU (under protocol A2015/12). 
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2.6.1 Tolerability studies 
Tolerability of the drugs as single agents and in combination were tested in non-
tumour-bearing mice. 8-12 week old female C57Bl/6 Jax mice (provided by Australian 
Phenomics Facility, Canberra, Australia), were administered drugs as below in groups 
of approximately 3/dosing schedule. Dosing of the single agents was performed over a 
2-3 week period with daily weighing, followed by a week of monitoring only. In some 
cases, if the mice were tolerating the drug well (no weight loss) after 1-2 weeks of 
dosing, an additional cohort of mice was started at a higher drug dose. In cases where 
the tolerability of the vehicle was unknown, a vehicle only treated group was also 
tested. Once the MTD or tolerable range of the metabolism drug was established, 
combination tolerability testing with CX-5461 was commenced. The dosing schedules 
were as follows: 
• Orlistat: 240mg/kg/day orlistat or vehicle (33% ethanol, 67% polyethylene 
glycol-400 [PEG-400]) by intraperitoneal injection at 15L/10g mouse body 
weight using 50µL Hamilton syringes (Hamilton Company, Nevada, United 
States, Cat no. 20701). 
• Chloroquine: 50-400mg/kg/day chloroquine dissolved in PBS, dosed by oral 
gavage (using 20ga plastic feeding tubes, Instech, Cat no. FTP-20-38) at 
100L/10g body weight. 
• CX-5461 and chloroquine: 50-100mg/kg/day chloroquine with 30-35mg/kg CX-
5461 dissolved in 50mM NaH2PO4, dosed by oral gavage at 100L/10g body 
weight. 
• CX-5461 and DCA: 200mg/kg/day DCA with 35mg/kg CX-5461 dissolved in 
50mM NaH2PO4, dosed by oral gavage at 100L/10g body weight. 
• Omeprazole: 100-400 mg/kg/day omeprazole dissolved in 7.5% ethanol in PBS, 
dosed by oral gavage at 100L/10g body weight. 
• Ritonavir: 50-400 mg/kg/day ritonavir dissolved in 7.5% ethanol in PBS, dosed 
by oral gavage at 100L/10g body weight. 
Weight was monitored daily as a sign of drug toxicity, and the percentage weight 
change from the initial weight calculated. Mice were euthanised if they lost more than 
20% body weight from their initial weight. The maximum tolerated dose was defined 
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as a maximum weight loss of 10% of initial, from which the mice recovered over the 
next couple of days. 
 
2.6.2 Efficacy studies 
 Syngeneic model 
5 x 105 MLL/AF9 NRAS cells were injected intravenously (tail vein) in 8-10 week old 
female C57Bl/6 Jax mice (provided by Australian Phenomics Facility, Canberra, 
Australia). Engraftment was confirmed 7 days post-transplant through the following 
procedure: intraperitoneal injection of 200L/mouse 5mg/mL XenoLight D-Luciferin K 
Salt Substrate (Perkin Elmer) in PBS, 5 min wait, induction of anaesthesia using 
Isofluorane gas (Cat # ISOF 03, Provet), followed by bioluminescent imaging using an 
IVIS Spectrum machine (Perkin Elmer) on automatic acquire settings. Living Image 
software (Perkin Elmer) was used for visualisation and quantification of the 
bioluminescence. Mice were randomised into groups of 5-8 based on tumour burden 
and dosing commenced. 
 
 Human cell line xenograft models 
8-12 week old female NOD-scid-gamma (NSG) mice (provided by the Australian 
Phenomics Facility) were injected intravenously (tail vein) with 2 x 106 human AML cell 
lines (MV4-11 GFP luc or MOLM-13 GFP luc cells), or irradiated with 1 Gray (Gy) single 
dose, whole-body irradiation, then injected with cells the next day (THP-1 GFP luc 
cells). See Section 2.6.3 for generation of the GFP luc human cell lines. Mice were 
placed on Baytril (Enrofloxacin 25mg/mL oral solution, ProVet, Cat no. BAYT O) in 
drinking water immediately following irradiation, or for the non-irradiated mice at 
least 3 days before the first bioluminescent image, and antibiotic treatment continued 
for the duration of the experiment. Engraftment was confirmed 3-7 days post-
transplant through bioluminescent imaging as above, mice randomised into groups of 
8 based on tumour burden and dosing commenced. Groups of 3-6 mice were used for 
characterising the disease model. 
 
 Dosing schedules 
Mice were dosed as follows in groups of 5-8/treatment, at 100L/10g body weight 
unless indicated otherwise: 
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• CX-5461 and orlistat: treatment groups received dosing by oral gavage of CX-
5461 vehicle (50mM NaH2PO4 buffer) or CX-5461 at 35mg/kg Monday, 
Wednesday and Friday, intraperitoneal injection of orlistat vehicle (33% 
ethanol, 67% PEG-400) at 15L/10g mouse body weight using 50µL Hamilton 
syringes (Cat no. 20701) or orlistat solution daily Monday-Friday, or the 
combination of the two drugs. 
• CX-5461 and chloroquine: treatment groups received dosing by oral gavage of 
either vehicle (50mM NaH2PO4 buffer), CX-5461 at 30mg/kg Monday, 
Wednesday and Friday, chloroquine at 50-80mg/kg daily Monday-Friday or the 
combination of the two drugs. 
• CX-5461 and DCA: treatment groups received dosing by oral gavage of either 
vehicle (50mM NaH2PO4 buffer), CX-5461 at 30mg/kg Monday, Wednesday and 
Friday, DCA at 200mg/kg daily Monday-Friday or the combination of the two 
drugs. 
Ensure (Abbott Nutrition, Cat no. S619.185) was mixed with powder from the food 
pellet bags and water to form a paste, which was provided daily for the duration of 
dosing to help the mice maintain weight. Dosing was continued until an ethical 
endpoint was reached (e.g. hunching, difficulty breathing, reluctance to move, >20% 
weight loss), at which point the mice were euthanised. The treatment groups were not 
blinded to the researcher who was determining the ethical endpoint. 
 
 Weight changes 
Weight was monitored 5-7 days/week as an indicator of general health, and the 
percentage weight change from the initial weight calculated. Mice were euthanised if 
they lost more than 20% body weight from their initial weight. 
 
 Survival analysis 
Differences in survival times were determined using Kaplan-Meier survival curves in 
Prism (GraphPad Software), followed by a Log-rank test. The Bonferroni corrected 
threshold was applied for comparison of multiple survival curves, such that a P value of 
<0.0083 was considered significant for these analyses. 
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 Bioluminescent imaging analysis 
Quantification of total bioluminescence was performed using the Living Image 
software (Perkin Elmer). Rectangular regions of interest (ROI) of the same size was 
placed over each mouse in the image and the total flux (photons/second) calculated. 
For image visualisation the colour scale on the images was adjusted until the areas of 
disease burden could be easily visualised. Images from the same day are all on the 
same scale, however, images from different days of the same experiment are on 
different scales due to the differences in disease burden. 
 
 Spleen weight 
When the mice reached an ethical endpoint, the mice were euthanised and the spleen 
was removed and weighed. 
 
 Full blood counts 
When the mice reached an ethical endpoint, blood was collected through terminal 
cardiac puncture under anaesthesia with isofluorane and transferred to a tube 
containing 0.5M EDTA. Samples were diluted 1:4 in 2% fetal bovine serum in PBS and 
full blood count (FBC) analysis run on the ADVIA hematology system (Siemans) for FBC 
+ differential. 
 
2.6.3 Generation of GFP-luc tagged human AML cell lines 
Green fluorescent protein (GFP)-luciferase (luc) tagged human AML cell lines were 
generated to inject into mice for the drug efficacy studies, as outlined in Section 
2.6.2.2. Retroviral gene delivery was performed using MSCV-GFP-luc2 constructs (a gift 
from Ricky Johnstone at the Peter MacCallum Cancer Centre in Melbourne). This 
construct was transfected into 293T cells using polyethylenimine (PEI) transfection, 
and the resulting retroviral particles collected and concentrated using the Retro-X 
concentrator (Clontech, Cat no. 631455) according to the manufacturer’s instructions. 
The concentrated retrovirus was then used to transduce the MV4-11, THP-1 and 
MOLM-13 human AML cell lines through retroviral spin infection with retronectin-
coated plates (Takara Cat no T202), according to the manufacturer’s instruction. 
Transduced cells were identified by GFP positivity and cell sorted using flow cytometry. 
The resulting cell lines were named ‘(cell line) GFP luc’. Luciferase activity was 
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confirmed in vitro, and in vitro sensitivity to CX-5461 was compared between the 
parental and tagged cell lines. The tagged cells were all found to express luciferase and 
to have the same sensitivity to CX-5461 as the parental lines (results not shown). 
 
2.7 Cell cycle and cell death analysis by flow 
cytometry 
In Chapter 5, flow cytometry was used to perform cell cycle and cell death analysis. 
Cells were seeded in 96-well round-bottom plates at a pre-determined density so that 
the cells were still in the exponential growth phase at the end of the assay. Drugs were 
added at the indicated timepoints. 30 min before harvesting BrdU was added to a final 
concentration of 10M. Cells were washed once with PBS then fixed in 150µL/well 
80% ethanol for at least 3 h at 4C. The ethanol was removed and DNA was denatured 
for 30 min by adding 100µL/well 2N HCl with 0.5% (v/v) Triton X-100, then neutralised 
with 100µL/well 0.1M Na2B4O7.10H2O (pH 8.5). Cells were stained with 20L of 1:50 
anti-BrdU antibody in PBS containing 2% FBS and 0.5% Tween-20 at room temperature 
for 30 min, washed once with PBS containing 2% FBS, then stained with 20L 1:500 
Alexa Fluor 488 secondary antibody in PBS containing 2% FBS and 0.5% Tween-20 at 
room temperature in the dark for 30 min and washed once with PBS containing 2% 
FBS. Samples were resuspended in PBS containing 2% FBS and 1g/mL DAPI (Table 
2-3), incubated for 15 min in the dark at room temperature and analysed using an LSR-
II flow cytometer (BD) or iQue Screener PLUS (Intellicyt). The gating strategy is shown 
in Figure 2-1. Results are presented as the percent of cells in each cell cycle phase. N=3 
experiments were performed and the mean results shown. 
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Figure 2-1: Gating strategy used for cell cycle analysis 
First, cells were gated based on their forward scatter (FSC, size) and side scatter (SSC; 
granularity) area (A) parameters. Next, doublets were excluded based on FSC-A versus 
FSC-height (H). Cells that were stained DAPI positive (+ve), indicating DNA content, 
were then selected, then the different cell cycle phases were gated based on Alexa 
Fluor (AF) 488 positivity, as a marker of BrdU incorporation/DNA synthesis, and DAPI, 
as a marker of DNA content. Cells with sub G1 DNA content (DAPI fluorescence) were 
considered “dead” cells (including dying/apoptotic cells 124). 
 
2.8 Western blot 
In Chapter 5, western blotting was used to analyse the expression levels of autophagy-
related proteins. 
 
1 x 106 cells were treated with the indicated conditions overnight. Cells were then 
harvested and lysed in western solubilisation buffer (Table 2-2). Protein lysates were 
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quantified using the DC protein assay (Bio-Rad, Cat no. 5000111) according to the 
manufacturer’s instructions, then equal protein amounts of protein were separated by 
SDS-PAGE, transferred to Immobilon-P polyvinylidene difluoride (PVDF) membrane 
(Millipore) through 30 min semi-dry transfer using the Biorad system, blocked with 5% 
skim milk or 1% BSA in Tris-buffered saline/0.1% Tween-20 (Table 2-2) for 1 h at room 
temperature, then incubated with primary antibody overnight at 4°C, followed by HRP 
conjugated secondary antibody (Table 2-3). Membranes were imaged with Clarity 
Western ECL Substrate (Bio-Rad, Cat no. 1705061) on a ChemiDoc Touch Imaging 
System (Bio-Rad). Image analysis and quantification was performed using Image Lab 
(Bio-Rad). Loading was normalised using beta-actin levels on the same blot. N=3 
experiments were performed and the mean quantification shown. 
 
2.9  Transmission electron microscopy 
In Chapter 5, electron microscopy was performed with assistance from the Centre for 
Advanced Microscopy at the Australian National University, for the purpose of 
examining autophagy structures. 
 
1 x 106 cells were treated for 24 h with the indicated conditions. Cells were then 
harvested (450 x g spin speed) and fixed overnight in 2.5% glutaraldehyde and 4% 
paraformaldehyde in PBS at 4°C, then secondary fixation was performed with 1% 
osmium tetroxide for 1 h at room temperature. Cells were embedded in agarose than 
stained overnight with 2% aqueous uranyl acetate at 4°C. Graduated dehydration was 
performed in increasing concentrations of ethanol for at least 30 min each (30%, 50%, 
70%, 90%, 100%, 100%, 100%), then the sample was infiltrated with increasing 
concentrations of LR white resin for at least 1 h each (25%, 50%, 75%, 100%, 100%, 
100%). Samples were polymerised overnight at 60°C. Ultrathin sections (approximately 
60-70nm) were prepared and stained with 2% uranyl acetate for 15 min and lead 
citrate for 10 min and imaged on the Hitachi HA7100 Transmission Electron 
Microscope. At least 10 cells/treatment were imaged. Samples were de-identified 
before imaging, and re-identified once counting of the autophagy structures was 
complete. 
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2.10 Creation of inducible shRNA human AML cell 
lines 
Glycerol stocks of the SMART vector human inducible lentiviral shRNA (murine 
cytomegalovirus (mCMV) promoter, with turbo red fluorescent protein (RFP) reporter) 
were purchased from Dharmacon. The following targeting sequences were selected: 
• Beclin 1 (BECN1) #1: Cat no. V3SH11252-227864843: 
GAGAGCTTTTGTCCACTGC (targets 3 prime untranslated region (3'UTR) and 
open reading frame (ORF)). 
• BECN1 #2: Cat no. V3SH11252-230157716: TATTGATTGTGCCAAACTG 
(targets ORF). 
• ATG7 #1: Cat no. V3SH11252-226351133: CAACACATCAGTTTGAGAT 
(targets Non-Coding and ORF). 
• ATG7 #2: Cat no. V3SH11252-229968263: CAAGGAAACCAGCACCATG 
(targets 5'UTR, Non-Coding and ORF). 
The SMARTvector inducible non-targeting shRNA vector (Cat no. VSC11655) was used 
as a control. 
 
Bacteria were expanded in Luria broth overnight, then plasmid DNA extracted using 
the NucleoBond Xtra Maxiprep kit (Macherey Nagel Cat no. 740414.50), according to 
the manufacturer’s instructions. DNA concentration was quantified via Nanodrop. The 
Trans-lentiviral shRNA packaging kit (Dharmacon, Cat no. DHA-TLP5912) was used to 
transfect the plasma DNA into 293T cells, according to the manufacturer’s instructions. 
After 72 h, the resulting virus was collected, concentrated using the Retro-X 
concentrator (Clontech, Cat no. 631455) according to the manufacturer’s instructions 
and frozen at -80°C. Lentiviral spin infection was then performed on MV4-11, THP-1 
and MOLM-13 cells in the same manner as the retroviral spin infection in Section 2.6.3. 
Puromycin selection at 1µg/mL was performed for 1 week to select the transduced 
cells. shRNA cell lines were maintained in RPMI with GlutaMAX (Gibco, Cat no. 
35050061) and 20% tetracycline (TET) system approved/tetracycline-free HI-FBS 
(Clontech #631367), which was also used for shRNA induction experiments. 
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Cells were treated with 1µg/mL doxycycline and knockdown of the target proteins was 
confirmed at 72 h and 96 h post-induction (N=1, results not shown), as such 72 h was 
selected as the timepoint for combining shRNA knockdown and CX-5461 treatment. 
 
2.10.1 Combining shRNA knockdown with CX-5461 treatment 
Induction of the shRNA was performed by treating the shRNA cell lines with 1µg/mL 
doxycycline for 72 h, the cells were then counted, media removed and plated at 
10,000 cells/well in a 96 well plate with fresh doxycycline and CX-5461 at a range of 
concentrations. After 96 h of CX-5461 treatment cell viability was assessed using the 
MTT assay (as in Section 2.5.4). Protein extraction of cells +/- doxycycline treatment 
was performed at 3 and 7 days post doxycycline induction and western blot analysis 
for BECN1, ATG7 and LC3B expression was performed as in Section 2.8. 
 
2.11 Extracellular flux analysis 
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of AML 
cell lines were measured using a Seahorse XFe96 extracellular flux analyser (Seahorse 
Bioscience). A mitochondrial stress test was performed, which uses various inhibitors 
to measure the respiratory capabilities of the mitochondria, including the maximum 
respiration. Cells were pre-treated with indicated compounds for 24 h, or injection of 
drugs performed at the time of the assay (acute treatment), washed and resuspended 
in unbuffered DMEM (Seahorse, Cat no. 102353-100) containing 10mM D-glucose, 
4mM L-glutamine and 1mM pyruvate, pH 7.4 +/- 0.05. The Seahorse culture plate was 
coated with 25μL/well of 22.4 μg/mL Cell-Tak (Corning Cell-Tak Cell and Tissue 
Adhesive, 1 mg Cat. # 354240), in 0.1M NaHCO3 (pH=8) for 20 min. The plate was then 
washed twice with sterile water. Cells were plated at 100,000 cells/well in the coated 
Seahorse culture plate and spun at 200 x g with zero braking for 1 min to ensure cell 
attachment, then incubated at 37°C for 40 min in a non-CO2 incubator. Using the 
Seahorse XFe96 extracellular flux analyser, OCR and ECAR were then measured at 37°C 
following a mitochondrial stress test using sequential injections of ± drugs (for acute 
treatment), ATP synthase inhibitor oligomycin (1M), proton ionophore 
carbonylcyanide p-trifluoromethoxy-phenylhydrazone (FCCP, 0.4M for THP-1, 
0.75M for MOLM-13), and a mixture of the mitochondrial complex III inhibitor 
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antimycin A and the complex I inhibitor rotenone (1M of each). Three readings were 
conducted for the basal levels and after each of the injections. N=3 experiments were 
performed and the mean results shown. One-way ANOVA was performed with a 
Tukey’s multiple comparison test, the adjusted p-value is shown. Parameters were 
defined as follows: energy map/profile = basal levels of OCR versus ECAR, basal 
respiration rates = OCR in the absence of inhibitors, maximal respiration rate = OCR 
following mitochondrial uncoupling with FCCP, spare respiratory capacity = difference 
in the OCR between the maximum respiration rate and basal rate, acute response = 
difference in the OCR following drug injection and basal respiration. 
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Chapter 3 Identifying metabolism-
modifying drugs that synergise with 
CX-5461 in vitro 
 
3.1  Introduction 
The novel Pol I inhibitor CX-5461 has been shown to be effective in mouse models of 
AML, however, resistance to the drug eventually develops 1 (Section 1.2.3). Rational 
combination therapies with CX-5461 are required to enhance its efficacy and reduce 
the development of drug resistance. Metabolic reprogramming, a hallmark of cancer 
86, is a well-described process by which cancer cells become resistant to 
chemotherapy. In addition, changes in metabolic gene expression in cancer cells 
following CX-5461 treatment (Hein et al, unpublished) suggests that targeting 
metabolic pathways may be a promising approach in combination therapies with CX-
5461. 
 
In order to address this hypothesis 6 AML cell lines were selected to evaluate 
established metabolism-modifying drugs in combination with CX-5461 in vitro, 
addressing Aim 1: ‘Identify established metabolism-modifying therapies that work 
synergistically with CX-5461 to target acute myeloid leukaemia in vitro’. 
 
3.1.1 Selection of AML cell lines 
AML cell lines covering the various genetic abnormalities commonly observed in AML 
patients (Table 1-1) were chosen to evaluate these drug combinations (Table 3-1). Four 
cell lines that express an MLL fusion protein, a particularly aggressive subtype of AML 
with a poor prognosis for patients 6,23, were selected for the initial testing of all drug 
combinations. Three of these four cell lines are of human origin; MV4-11, MOLM-13 
and THP-1. The fourth is a mouse-derived MLL/AF9 NRAS cell line, generated by fetal 
liver transduction with a construct expressing the MLL/AF9 fusion protein tagged with 
green fluorescent protein (GFP) and mouse NrasG12D mutation tagged with luciferase 
32. These four cell lines were used to evaluate a panel of metabolism-modifying drugs 
in combination with CX-5461. The most promising combinations were then tested in a 
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further two cell lines selected based on the absence of MLL translocations and the 
presence of p53 mutations to cover more of the genetic diversity of AML (Table 1-1). 
These cell lines were the KG-1 and SKM-1 cell lines. 
 
3.1.2 Selection of metabolism-modifying drugs to test in 
combination with CX-5461 
Metabolism-modifying drugs were selected based on the literature reported to target 
the main metabolic pathways altered in AML (Section 1.3.1.1) and those implicated in 
chemotherapy insensitivity (Section 1.3.2). While there is still the need for 
development of new compounds targeting metabolism in cancer, there are also many 
established metabolism-modifying drugs that could be repurposed as cancer therapies. 
Cell line Origin 
of cells 
Patient information P53 
status 
Other 
mutations 
Fusion 
protein 
MV4-11 Human 10-year-old with acute 
monocytic leukaemia 
(AML FAB M5), at 
diagnosis 
WT FLT3-ITD, 
KRAS 
MLL/AF4 
MOLM-
13 
Human 20-year-old with AML FAB 
M5a, at relapse after 
initial myelodysplastic 
syndromes, relapse 
WT FLT3-ITD MLL/AF9 
THP-1 Human 1-year-old with acute 
monocytic leukaemia 
(AML), relapse 
Null NRAS MLL/AF9 
MLL/AF9 Mouse - WT NRAS MLL/AF9 
KG-1 Human 59-year-old with 
erythroleukaemia that 
developed into acute 
myeloid leukaemia (AML), 
relapse 
Null NRAS, 
TET2 
AML1-ETO 
SKM-1 Human 76-year-old with acute 
monoblastic leukaemia 
(AML M5) following 
myelodysplastic 
syndromes 
Mt KRAS  -  
Table 3-1: Genetic characteristics of AML cell lines used for in vitro evaluation. 
Patient and genetic information according to the DSMZ German Collection of 
Microorganisms and Cell Cultures. Common AML mutations with functional 
characterisation are shown in Table 1-1. Cell line growing conditions are shown in 
Table 2-1. 
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Since it can take in excess of $2.6 billion and over a decade to take a new 
pharmaceutical drug from development to the clinic 125 the utility of established 
metabolism-modifying drugs is clear as typically they are readily available, low cost and 
have relatively low toxicity compared to standard chemotherapeutics. Also, their safe 
dose in humans has already been established making them ready for clinical trials, 
which would facilitate the translation of any novel combination cancer therapies with 
these drugs to the clinic. Based on this, the therapies selected include dichloroacetate, 
metformin, chloroquine, orlistat, omeprazole, ritonavir, simvastatin, fenofibrate, 
bezafibrate and rosiglitazone (Table 3-2), which were selected for testing. These drugs 
were selected based on their known inhibition of key metabolic pathways altered in 
cancer (Figure 3-1), which could potentially be upregulated by AML cells to subvert the 
effects of CX-5461. 
 
Drug Traditional Use Proposed mechanism of action in cancer 
Dichloroacetate Treatment for lactic 
acidosis 
Activation of PDH through inhibition of 
PDK, reversal of glycolytic phenotype 
Metformin* Anti-diabetic Activates AMPK, inhibits the electron 
transport chain complex I 
Chloroquine * Anti-malarial Inhibits autophagy through interfering 
with lysosomal function 
Orlistat Weight loss Inhibits fatty acid synthase 
Omeprazole* Proton pump 
inhibitor/heartburn 
Inhibits fatty acid synthase 
Ritonavir* Anti-retroviral Inhibits glucose transporter GLUT 4 
Simvastatin* Treatment for 
hypercholesterolemia 
Inhibits HMG-CoA reductase and 
cholesterol synthesis 
Fenofibrate Treatment for 
hypercholesterolemia 
PPARα agonist, lowers cholesterol 
Bezafibrate Treatment for 
hypercholesterolemia 
PPARα agonist, lowers cholesterol 
Rosiglitazone Anti-diabetic PPAR agonist, lowers cholesterol 
Table 3-2: Candidate metabolism-modifying drugs for evaluation with CX-5461 and their 
proposed mechanism of action in cancer. 
*On the World Health Organisation’s Model List of Essential Medicines 7, a list of safe and cost-
effective medicines for common medical conditions and diseases globally. 
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Figure 3-1: Metabolic pathways targeted by the drugs selected for evaluation with CX-5461 
Various metabolic pathways are altered in cancer cells, facilitating their growth and 
proliferation, and even chemotherapy resistance. There are many established metabolism-
modifying therapies which target these pathways. Ritonavir, a HIV medication, reduces 
glucose uptake by inhibiting the GLUT 4 glucose transporter. Dichloroacetate (DCA) shuttles 
pyruvate from glycolysis to mitochondrial respiration by inhibiting pyruvate dehydrogenase 
kinase (PDK), an inhibitor of pyruvate dehydrogenase (PDH). Metformin, a diabetes 
medication, inhibits complex I of the mitochondrial electron transport chain (ETC). 
Anti-malarial chloroquine inhibits autophagy by interfering with lysosomal function 
preventing the fusion of lysosomes with autophagosomes. Weight loss medication orlistat 
and proton pump inhibitor omeprazole both disrupt fatty acid synthesis by inhibiting the 
fatty acid synthase (FASN) enzyme. Cholesterol medications fenofibrate and bezafibrate, and 
anti-diabetic rosiglitazone interfere with cholesterol synthesis by acting as peroxisome 
proliferator-activated receptor (PPAR) agonists, therefore interfering with gene regulation of 
cholesterol synthesis. Cholesterol medication simvastatin inhibits cholesterol synthesis by 
inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. 
 
 41 
 Targeting the glycolytic phenotype 
Dichloroacetate (DCA) is a drug that has historically been used as a treatment for lactic 
acidosis as it reduces lactate production. It does this by directing the metabolism of 
pyruvate to mitochondrial oxidation and away from glycolysis through inhibition of 
pyruvate dehydrogenase kinases (PDKs), therefore activating pyruvate dehydrogenase 
(PDH) 126. DCA has more recently been investigated as an anti-cancer agent due to its 
ability to reverse the Warburg effect/glycolytic phenotype, a characteristic of cancer 
cells, through this same process 127. DCA has been tested in many solid cancers, 
including breast cancer where it has been shown to be cytostatic as a single agent 92, 
and enhanced apoptosis in combination with mitochondrial-targeting agents arsenic 
trioxide 128 and phenylarsonous acid (PENAO) 129. DCA has also shown efficacy in blood 
cancers; promising pre-clinical testing of DCA in multiple myeloma has led to the 
commencement of a Phase II clinical trial of DCA in plateau phase multiple myeloma in 
Australia (DiCAM trial; ANZCTR #ACTRN12615000226505). In pre-clinical models of 
B-chronic lymphocytic leukaemia (B-CLL) DCA was shown to have anti-leukemic effects 
in patient samples and cell lines and to synergise with p53 activator Nutlin-3 130, as 
well as to reduce viability of AML cells in combination with arsenic trioxide 107. Given 
the literature which shows that targeting glycolysis with DCA can ‘prime’ AML cells for 
death by other agents 107, combination therapy with DCA could be a promising 
approach. 
 
 Targeting mitochondrial function 
Metformin is an anti-diabetic medication which lowers blood glucose concentrations in 
part through targeting the key energy sensor 5' adenosine monophosphate-activated 
protein kinase (AMPK), thereby decreasing hepatic glucose production and increasing 
glucose uptake 131, although the exact mechanisms were previously not well 
understood. Further investigation of the actions of metformin led to the discovery that 
it inhibited complex I of the mitochondrial electron transport chain 132, and thus was 
able to modulate the function of the mitochondria. The investigation of metformin as a 
cancer therapeutic began when retrospective analysis of cancer incidence in diabetic 
patients revealed that metformin-treated patients had a significantly lower risk of 
developing cancer, compared to those on insulin or other therapies 133. Given the 
previous findings that metformin could modulate mitochondrial function, this was 
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investigated in various cancer cells and in vivo cancer models. Metformin induced 
apoptosis and reduced tumour growth in preclinical models of acute myeloid 
leukaemia through inhibition of electron transport chain complex I 134. Metformin 
treatment also induced apoptosis and cell cycle arrest alone and in combination with 
dexamethasone in multiple myeloma through inhibiting the expression of insulin 
growth factor-I receptor (IGF-IR) 135, indicating more than one potential mode of action 
in cancer. It has also been found to be effective in solid tumours such as ovarian cancer 
136 and neuroblastoma 137. Such promising preclinical results in a wide range of tumour 
models has led to the initiation of hundreds of clinical trials with cancer patients 
utilising metformin based on its metabolism-modifying properties, including trials for 
breast cancer (ClinicalTrials.gov Identifiers: NCT01266486 and NCT01310231), lung 
cancer (ClinicalTrials.gov Identifier: NCT02115464), prostate cancer (ClinicalTrials.gov 
Identifier: NCT01243385), multiple myeloma and chronic lymphocytic leukaemia 
(ClinicalTrials.gov Identifier: NCT02948283) and AML (ClinicalTrials.gov Identifier: 
NCT01849276). In a clinical trial of patients with advanced prostate cancer, metformin 
+ castration was found to reduce the disease marker prostate-specific antigen (PSA) 
levels by 7 fold compared to the placebo + castration group (ClinicalTrials.gov 
Identifier: NCT01620593). This supports that metformin can modulate metabolic 
responses in cancer patients. Given the role that mitochondria play in AML cells 106, 
combination therapy with metformin could be a promising approach, particularly as its 
efficacy as a metabolism-modifying therapy is already well-established in humans. 
 
 Targeting autophagy 
Chloroquine has a long history of use in humans including as an antimalarial drug, with 
its efficacy thought to be due to its inhibition of heme polymerase through an 
unknown mechanism, leading to the accumulation of free heme which is toxic to the 
parasite 138. Chloroquine and its derivate hydroxychloroquine have also been used to 
treat some immune disorders like rheumatoid arthritis based on its immune 
suppressive effects 139, in part through inhibition of inflammatory cytokine signalling 
140 and toll-like receptor signalling through raising endosomal and lysosomal pH 141. 
Chloroquine has also been recognised to have anti-cancer properties for many decades 
142, and was subsequently found to inhibit autophagy through interfering with 
lysosomal function, thus preventing the fusion of lysosomes with autophagosomes 143. 
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Inhibition of autophagy through chloroquine has since been studied as a therapeutic 
target in various cancer models, with chloroquine acting to reduce the growth of 
hepatocellular carcinoma in vitro and in vivo 144, reducing the growth and metastasis of 
breast cancer 145, including through inducing mitochondrial damage and impairing DNA 
break repair 146, and inhibiting proliferation, inducing apoptosis and cell cycle arrest in 
vitro in acute promyelocytic leukaemia 147. Clinical trials of chloroquine or 
hydroxychloroquine have commenced in various malignancies including breast cancer 
as a single agent (ClinicalTrials.gov Identifier: NCT02333890) or in combination with 
standard chemotherapy (ClinicalTrials.gov Identifier: NCT01446016) and in relapsed 
and refractory multiple myeloma where a 30% response rate was achieved after 2 
cycles with a combination of bortezomib, cyclophosphamide and chloroquine 
(ClinicalTrials.gov Identifier: NCT01438177). Given the role autophagy has been 
demonstrated to play in AML cell survival 115, combination treatment with chloroquine 
could be a promising approach. 
 
 Targeting fatty acid synthesis 
Orlistat is a weight-loss medication that reduces fat absorption by inhibiting pancreatic 
and gastric lipases through binding to the active site of the enzymes and preventing 
enzyme activity 148. In the search for novel agents targeting fatty acid synthesis, a 
process upregulated in cancer, an activity-based proteomics screen revealed that 
orlistat was also a novel inhibitor of the thioesterase domain, key for the function of 
the enzyme, of fatty acid synthase (FASN) and was efficacious in an in vivo mouse 
model of prostate cancer 119. Orlistat has since been tested in vitro and in vivo in 
various cancer models including leukaemia 149 and multiple myeloma 150. Despite these 
promising results, clinical development of orlistat as a cancer therapy has been 
hindered by its poor oral bioavailability 151, as such there are currently no clinical trials 
in cancer with this drug. The search for novel inhibitors of FASN with improved 
bioavailability revealed that certain proton pump inhibitors, including omeprazole, also 
inhibit the thioesterase domain of FASN 152. Omeprazole is traditionally a medication 
to treat reflux and has proton pump inhibitor activity by inhibiting the gastric H+,K+-
ATPase 153. Before omeprazole was identified as a FASN inhibitor, it had been shown to 
inhibit proliferation and modulate autophagy in vitro in pancreatic cancer cells, 
hypothesised to be due to its effects on the lysosomal transport pathway 154. It has 
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also been shown to reduce invasion and metastasis in models of triple negative breast 
cancer in vitro and in vivo, hypothesised to be due to its action as an aryl hydrocarbon 
receptor (AHR) ligand 155. This more recently discovered mechanism of action of 
omeprazole as a FASN inhibitor has led to the commencement of a Phase II clinical trial 
to improve the efficacy of neoadjuvant chemotherapy in breast cancer 
(ClinicalTrials.gov Identifier: NCT02595372) with results yet to be published. Given that 
fatty acids have been shown to promote AML cell survival 116, combination therapy 
with orlistat or omeprazole and CX-5461 could be a promising approach. 
 
 Targeting glucose uptake 
Ritonavir is an anti-retroviral human immunodeficiency virus (HIV) medication that 
prevents the formation of mature, infectious HIV particles by inhibiting the action of 
the HIV protease enzyme to cleave the gag-pol polyproteins, an essential step in the 
HIV lifecycle 156. First approved for clinical use in the 1990’s, ritonavir is now more 
commonly used to boost the effects of other protease inhibitors due to its inhibition of 
liver cytochrome P450 3A-mediated metabolism, increasing the concentration of other 
protease inhibitors and improving their efficacy 157. Metabolic side effects, including 
insulin resistance and type II diabetes, have long been associated with the use of 
retroviral protease inhibitors in the treatment of HIV, leading to the discovery that 
these drugs inhibit glucose uptake 158. Given the association of increased glucose 
uptake with cancer cells, this is of great interest as a potential cancer therapy. 
Ritonavir is an inhibitor of glucose transporter type 4 (GLUT4) and has been shown to 
be effective in models of multiple myeloma 159 and chronic lymphocytic leukaemia 
(CLL) 160 in combination with metformin. Current clinical trials with ritonavir in cancer 
include in combination with external beam radiation in patients with brain metastasis 
(ClinicalTrials.gov Identifier: NCT00637637) and in patients with relapsed and 
refractory multiple myeloma and CLL in combination with metformin (ClinicalTrials.gov 
Identifier: NCT02948283) with results yet to be published. Given the role that glucose 
plays in both glycolysis and mitochondrial metabolism, which have both been shown 
to be dysregulated in AML 106,107, combination treatment with ritonavir could be a 
promising approach. 
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 Targeting cholesterol metabolism 
The cholesterol-lowering medication simvastatin inhibits the action of the enzyme 
HMG-CoA reductase to convert HMG-CoA to mevalonate, which is a rate-limiting step 
in cholesterol synthesis 161. Given that cholesterol synthesis is upregulated in cancer, 
simvastatin was tested as a single agent and found to reduce proliferation and colony-
forming potential of AML cell lines in vitro, and to sensitise the cells to the effects of 
cytarabine 162. In multiple myeloma cell lines, simvastatin was found to induce cell 
cycle arrest and death 163. In a clinical trial of simvastatin in breast cancer, 
immunohistochemistry analysis revealed that several weeks of treatment resulted in 
increased apoptosis and reduced the levels of proliferative markers in the primary 
tumours 164. Fibrates and glitazones are other classes of cholesterol-modifying agents 
that activate specific transcription factors of the superfamily of nuclear hormone 
receptors, known as peroxisome proliferator-activated receptors (PPARs). Fibrates are 
agonists of PPARα and glitazones are agonists of PPAR, and the downstream 
consequences of the activation of these factors is the lowering of blood triglycerides 
and cholesterol 165. Fenofibrate has been shown to induce apoptosis in triple-negative 
breast cancer 166 and mantle cell lymphoma 167. In a clinical trial of patients with 
various relapsed and progressive cancers when given fenofibrate in a 5-drug 
metronomic regimen with thalidomide, celecoxib, etoposide and cyclophoshamide, 
31% of patients achieved progression-free survival after 27 weeks treatment 
(ClinicalTrials.gov Identifier: NCT00357500). Bezafibrate was found to inhibit 
proliferation and induce cell cycle arrest in an in vitro model of lung adenocarcinoma 
168. In chronic myeloid leukaemia (CML), glitazones were shown to target the 
leukaemia stem cell pool 169 and rosiglitazone synergised with carboplatin to induce 
apoptosis and reduce cell growth in a mouse model of lung cancer 170. Given the 
dysregulation of cholesterol metabolism in AML cells 110, combination treatment with 
simvastatin, fenofibrate, bezafibrate or rosiglitazone could be a promising approach. 
 
Together this literature indicates that metabolism-modifying agents can both have 
efficacy against cancer cells as single agents and/or sensitise cancer cells to the effects 
of other anti-neoplastic drugs, and thus potentially be effective as cancer therapeutics. 
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 Metabolism-modifying drugs that potentially modulate ribosome biogenesis 
In addition to their metabolism-modifying mechanism of action, some of the drugs 
that were selected for testing in combination with CX-5461 also have reported effects 
on ribosome biogenesis. The key considerations when evaluating these studies include 
the concentration of drug used, the cell type and the duration of treatment. 
 
Metformin activates AMPK 131, which has been shown to downregulate rRNA synthesis 
through impairing the interaction between TIF-1A and SL-1 171. Treatment of MCF7 
breast cancer cells with 2.5mM metformin for 4 hours resulted in a significant 
reduction in rRNA transcription, following AMPK activation and subsequent activation 
of histone demethylase KDM2A at the rDNA promoter 172. Gene expression analysis of 
human peripheral blood mononuclear cells from patients treated with 100 mg 
ritonavir once or twice daily for 14 days, has shown significant modulation of 13 genes 
involved in ribosome biogenesis and assembly 173, although it is not clear whether 
these are upregulated or downregulated. Omeprazole treatment has been shown to 
decrease expression of the transcription factor c-myc, a key regulator of ribosome 
biogenesis 174, in human peripheral blood mononuclear cells cultured for 21 days in 
vitro with 1µM omeprazole175. However, it was not confirmed in this study if the rate 
of rDNA transcription was decreased. Chloroquine is known to intercalate with DNA 
176, which could reduce the rate of rDNA transcription. 
 
While none of the metabolism modifying agents selected for testing in these studies is 
a selective inhibitor of ribosome biogenesis, as evidenced above, some of these agents 
may dysregulate factors involved in ribosome biogenesis. This must also be taken into 
consideration when examining promising combination therapies with CX-5461. 
 
3.1.3 Determination of drug concentrations to be used for testing 
In order to evaluate the drugs at biologically relevant concentrations, a maximum 
concentration for testing was selected for each drug based on the literature, taking 
into consideration, if reported, achievable plasma concentrations in patients and/or 
mice, concentrations reported in in vitro studies and concentrations known to achieve 
on-target effects for the mechanisms being investigated in cancer. 
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CX-5461. A maximum concentration of 1M was used for CX-5461 in order for the 
drug to remain an on-target inhibitor of Pol I and not Pol II or Pol III 81. 
DCA. With repeated dosing of DCA, plasma concentrations of around 1-2mM are 
achievable 177, as such 5mM was chosen as the maximum concentration for testing. 
Metformin. When used as an antidiabetic medication, metformin serum levels average 
around 700M 178, however, 10mM was selected as a maximum concentration as 
metformin has been shown to inhibit mitochondrial complex I activity in the millimolar 
range in leukaemia cells 134. 
Chloroquine. In studies of malaria-infected patients, chloroquine plasma 
concentrations peak at around 1-2M during a 3 day course of chloroquine treatment 
179 and similar levels were observed in malaria-infected mice 180, however for the 
purpose of studying autophagy inhibition a maximum concentration of 40M was 
selected as chloroquine is well established to inhibit autophagy at this concentration 
111,181. 
Orlistat. There is minimal absorption of orlistat when taken through the traditional 
oral route in humans 151 and testing of injectable orlistat has not been performed in 
humans thus far. However, in mice that have been injected with orlistat solution by 
intraperitoneal injection, plasma concentrations have been measured to reach 10M 
and been predicted to reach approximately 16M with a higher dosing schedule 119. As 
such, a maximum concentration of 30M was selected for in vitro testing. 
Omeprazole. Omeprazole inhibits the thioesterase domain of FASN at a micromolar 
range, with a concentration that inhibits the activity of the enzyme by 50% (IC50) of 
approximately 30M 152. As such, 200M was the highest concentration utilised for 
testing to ensure maximum inhibition of FASN. 
Ritonavir. Ritonavir plasma levels in patients peak at approximately 25-30M 182 and 
glucose uptake has been shown to be significantly inhibited by 50M of ritonavir158. As 
such, ritonavir was tested up to a maximum concentration of 50M. 
Simvastatin. In healthy human volunteers, plasma levels of approximately 20M 
simvastatin were readily achieved 183, therefore a maximum concentration of 40M 
was utilised for testing. 
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Fenofibrate and bezafibrate. Plasma levels of approximately 30M fenofibrate and 
bezafibrate are achievable in healthy volunteers 184, therefore a maximum 
concentration of 100M was used for testing. 
Rosiglitazone. Rosiglitazone levels reach approximately 2M in the plasma of patients 
185, as such 30M maximum was used for testing. 
 
3.1.4 Analysis of drug synergy 
Determining synergistic drug combinations is of great interest in the medical field as, in 
general, lower concentrations of the individual drugs are used, resulting in less severe 
side effects and reduces the occurrence of drug resistance 186. To be defined as 
synergistic (also known as super-additive), the combination effects of the drugs must 
be in excess of what would be predicted given the individual effects of the drugs. If the 
combination effect matches what is expected given the individual drug potencies the 
combination is considered additive, while if the effect is less than predicted the 
combination is considered antagonistic. Various methods of analysis exist for 
determining drug synergy; one such well-established method is the Chou-Talalay 
Combination Index method 122. The Combination Index (CI) method provides a 
quantitative measure of synergy between two or more drugs; an additive effect has a 
CI = 1, a synergistic effect has a CI<1 and an antagonistic effect has a CI>1. This method 
has been incorporated into a freely-available program called CompuSyn. Further 
details of this method are included in Section 2.5.5. 
 
3.1.5 Assays for measuring cell viability 
Total viable cell number was chosen as the read-out for the analysis, rather than a 
more narrow effect such as cell death, as this read-out can evaluate multiple 
consequences of drug treatment over time (e.g. cell cycle arrest, apoptosis, 
senescence, cell death). The mechanism of action mediating altered cell viability would 
be determined once promising combinations had been identified, to help identify the 
mechanisms of synergy (see Chapter 5). In order to evaluate the effects of the 
metabolism drugs with CX-5461, colourimetric viability plate-based assays were 
utilised (Section 2.5). There are a number of such assays including the neutral red 
assay and the thiazolyl blue tetrazolium bromide (MTT) assay. The neutral red assay 
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estimates viable cell number based on the uptake and binding of the neutral red dye in 
the lysosomes of the cells, which can only occur in viable cells (Section 2.5.1) 120. The 
MTT assay is based on the conversion of the water-soluble MTT tetrazolium salt (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to coloured formazin 
crystals via succinate dehydrogenase in the mitochondria (Section 2.5.2)121. 
Alternatively, cell counting using the Coulter counter, which measures particle number 
and size, was used as a control to determine the suitability of the assays with the 
different drugs (Section 2.5.3). 
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3.2  Results 
3.2.1 Optimising conditions for viability testing 
In order to ensure that the cells are in an exponential growth phase at the time that 
viability is assessed, various plating densities were evaluated with viable cell number 
determined using the neutral red assay after 96 h culturing in untreated conditions 
(Figure 3-2). Importantly, a 96 h timepoint was chosen as this provided the cells time 
to divide at least 1-2 times in untreated conditions (refer to Table 2-1 for doubling 
times of each cell line). This is important as cells often display a lag phase on replating, 
and if the cells become confluent they may be contact inhibited and run out of 
nutrients which reduces the proliferation rate. Human AML cell lines were plated at a 
range of 0.5-10 x 104 cells/well and the mouse AML cell lines at 0.25-5 x 104 cells/well. 
 
Figure 3-2 shows that after 96 h culturing in untreated conditions the MV4-11, THP-1 
and SKM-1 cells were in the exponential growth phase from 0.5-5 x 104 cells/well 
plated then plateau in number at higher plating densities, indicating they were 
confluent. The MOLM-13 and MLL/AF9 NRAS cells were in exponential growth phase 
from 0.5-2 x 104 cells/well plated then become confluent at higher plating densities. 
The KG-1 cells were in exponential growth phase from 0.5-3 x 104 cells/well plated 
then become confluent at higher plating densities. Thus, for the MV4-11, THP-1 and 
SKM-1 cell lines 4 x 104 cells/well, KG-1 2 x 104 cells/well, MOLM-13 1.5 x 104 cells/well 
and MLL/AF9 NRAS 1 x 104 cells/well were chosen as optimal plating densities for the 
96 h drug treatment viability assays. 
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Figure 3-2: Determining cell plating density for viability assays 
AML cell lines MV4-11, THP-1, MOLM-13, MLL/AF9 NRAS, KG-1 and SKM-1 were plated 
at a range of cell numbers per well in a 96 well plate and cultured in untreated 
conditions for 96 h. Total viable cell number was determined using the neutral red 
assay (Methods section 2.5.1). Graphs show the meanSD of n=2-3 experiments. 
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The accuracy of the viability assay used (neutral red or MTT) was confirmed using a 
physical counting method (Coulter count), using the MV4-11 cell line. When comparing 
the effect of these drugs between the neutral red assay and Coulter counting (Figure 
3-3), the results were consistent for CX-5461, orlistat, ritonavir, DCA, omeprazole, 
fenofibrate, bezafibrate and rosiglitazone. Interestingly, treatment with metformin 
and simvastatin resulted in an underestimate of viability, while chloroquine treatment 
resulted in an overestimation of viability with the neutral red assay. As the neutral red 
assay measures the uptake and retention of the neutral red dye in the lysosomes 120 
this suggests that the drugs are affecting the number and/or function of the lysosomes 
in the MV4-11 cells. Simvastatin has been reported to induce autophagy (which, at 
least in the short term, would result in a decrease in lysosomes) as a cytoprotective 
effect in leukaemia cells 187 and metformin is a well-known autophagy inducer in 
cancer cells due to activation of AMPK and downstream reduction in mTOR 188,189, so 
this underestimation of cell viability with neutral red is consistent with the literature. 
The overestimation of cell viability with neutral red following chloroquine treatment is 
also unsurprising given the inhibitory effect chloroquine has on autophagy 143, 
resulting in the accumulation of lysosomes and thus artificially inflating the neutral red 
readings. 
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Figure 3-3: Comparison of neutral red and Coulter count results for cell viability. 
MV4-11 cells were treated with the indicated drugs for 96 h then cell viability was 
simultaneously assayed using neutral red staining and Coulter counting in order to 
determine if any of the drugs were inferring with the mechanism of action of the neutral 
red assay. Graphs show the meanSD of 2-4 technical replicates per data point, n=1. 
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In light of these results, metformin, simvastatin and chloroquine were further tested 
using the MTT assay and compared to Coulter counting to measure cell viability (Figure 
3-4). The results of the MTT and Coulter counts correlate for chloroquine treatment, 
but again this did not correlate for metformin and simvastatin. As the MTT assay 
measures the activity of mitochondrial reductases 121, these results suggest that 
metformin and simvastatin are affecting the function of the mitochondria. Metformin 
has previously been reported to have various effects on mitochondrial function 
including complex I inhibition 134, limiting respiration and citric acid cycle activity 190 
and inhibiting ATP synthase 191 which could affect the results of the MTT assay. Statins, 
 
 
Figure 3-4: Comparison of MTT assay and Coulter count results for cell viability. 
MV4-11 cells were treated with the indicated drugs for 96 h then cell viability was 
simultaneously assayed using MTT staining and Coulter counting in order to determine if 
any of the drugs were inferring with the mechanism of action of the MTT assay. Graphs 
show the meanSD of 2-4 technical replicates per data point, n=1. 
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including simvastatin, have been reported to induce mitochondrial dysfunction by 
inhibiting complex III in muscle cells 192 and could potentially also affect the 
mitochondria in leukaemia cells. Any future viability evaluation with these drugs 
should not be metabolism-based, instead a method such as cell counting through 
high-throughput flow cytometry would be preferable as this technique would not be 
affected by the mechanism of action of the drugs. This technique was not available in 
house at the commencement of testing, but has since been set up and could be used 
for future evaluation of cell viability with suspension cells such as AML. Since a suitable 
assay for measuring cell viability was not identified for metformin and simvastatin at 
the time the experiments were conducted, these drugs were not evaluated further. As 
the aim of the study is to evaluate combination therapies with CX-5461 this was also 
tested with the MTT assay and found to correlate with the Coulter counts, and thus 
the MTT assay was deemed accurate to determine cell viability following CX-5461 
treatment. The results of the viability assay comparison testing are summarised in 
Table 3-3. 
 
3.2.2 Dose-response curves and GI50s of drugs as single agents 
Each drug was tested as a single agent across a range of concentrations (Section 3.1.3) 
in 4 cell lines (MV4-11, THP-1, MOLM-13 and MLL/AF9 NRAS). Total viable cell number 
 
Drug Suitability with 
neutral red? 
Suitability with 
MTT? 
CX-5461 Yes Yes 
Orlistat Yes Not tested 
Ritonavir Yes Not tested 
Metformin * No No 
DCA Yes Not tested 
Simvastatin * No No 
Omeprazole Yes Not tested 
Fenofibrate Yes Not tested 
Bezafibrate Yes Not tested 
Chloroquine No Yes 
Rosiglitazone Yes Not tested 
Table 3-3: Summary of suitability testing of viability assays for each drug as a single 
agent. 
*These drugs were not carried forward for further evaluation. 
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after 96 h of treatment was determined using the assay appropriate for each drug 
(Table 3-3). For each drug and cell line the concentration versus the cell viability was 
graphed (Figure 3-5-Figure 3-8). The dose resulting in a 50% growth inhibition (GI50) 
was then calculated for each cell line after fitting a non-linear dose curve to the data 
points (Methods Section 2.5.5). GI50 values are summarised in Table 3-4. 
 Ribosome biogenesis 
In response to treatment with ribosome biogenesis inhibitor CX-5461 (up to a 
maximum concentration of 1µM, as justified in Section 3.1.3), dose-response curves 
from 100% viability to close to 0% viability were achieved in the MLL/AF9 NRAS (Figure 
3-8) and MV4-11 (Figure 3-5) cell lines, with the MLL/AF9 NRAS cells being the most 
sensitive by about 10-fold. In the MOLM-13 cell line (Figure 3-6) viability plateaued at 
approximately 200nM, thus a true GI50 could not be determined. Given the effects CX-
5461 is known to have on cell cycle in this cell line 1 it is possible that this plateau is 
due to CX-5461 inducing cell cycle arrest in the cells, particularly at 200nM or higher. 
The THP-1 cell line (Figure 3-7) showed no sensitivity to CX-5461 treatment. 
 
 Glucose uptake and glycolysis 
In response to treatment with glucose uptake inhibitor ritonavir (up to a maximum 
concentration of 50µM, as justified in Section 3.1.3) dose-response curves from 100% 
viability to close to 0% viability were achieved in the MLL/AF9 NRAS cells, MOLM-13 
and MV4-11, in ascending order of GI50. The THP-1 cell line showed some limited 
sensitivity at the higher concentrations of ritonavir only. 
 
In response to treatment with glycolysis inhibitor DCA, no dose-response curves were 
achieved in any of the cells lines, however, at the maximum concentration of 5mM (as 
justified in Section 3.1.3) viability of the MLL/AF9 NRAS cells dropped to approximately 
30%. The MV4-11 and THP-1 cell lines showed a small drop in viability at 5mM, while 
there was no change in the MOLM-13 cell line. 
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 Fatty acid synthesis 
In response to treatment with fatty acid synthesis inhibitor orlistat (up to a maximum 
concentration of 30µM, as justified in Section 3.1.3) dose-response curves from 100% 
viability to close to 0% viability were achieved in the MV4-11 and MOLM-13 cell lines. 
Drugs 
Maximum 
concentration 
tested* 
GI50±SD 
Human  Mouse 
MV4-11 
(MLL/AF4, 
p53 WT) 
MOLM-13 
(MLL/AF9, 
p53 WT) 
THP-1 
(MLL/AF9, 
p53 null) 
MLL/AF9 
NRAS 
(p53 WT) 
Ribosome biogenesis  
CX-5461 (nM) 1000 115.6±27 ~200 >1000 10.3±2 
Glucose uptake and glycolysis  
Ritonavir(μM) 50 41.0±0.2 40.4±11 >50 13.3±3 
DCA (mM) 5 >5 >5 >5 ~4 
Fatty acid synthesis  
Orlistat (μM) 30 19.2±3 23.4±2 >30 ~30 
Omeprazole (μM) 200 ~180 >200 >200 125.6±2 
Autophagy  
Chloroquine (μM) 40 >40 >40 >40 25.9±5 
Cholesterol synthesis  
Fenofibrate (μM) 100 >100 >100 >100 25.5±4 
Bezafibrate (μM) 100 >100 >100 >100 >100 
Rosiglitazone (μM) 30 >30 >30 >30 >30 
 
Table 3-4: GI50 values of drugs as single agents 
Data from Figure 3-5 - Figure 3-8. Colour code: No colour = Sensitive (>25% drop in cell 
viability at maximum concentration Light grey = Some sensitivity (10-25% drop in cell viability 
at maximum concentration) Dark grey = Not sensitive (<10% drop in cell viability at maximum 
concentration). * Justified in Section 3.1.3. 
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At 30µM orlistat the viability of the MLL/AF9 NRAS cells dropped to approximately 
60%, while the THP-1 cells showed no sensitivity. 
 
In response to treatment with fatty acid synthesis inhibitor omeprazole (up to a 
maximum concentration of 200µM, as justified in Section 3.1.3) a dose-response curve 
from 100% viability to close to 0% viability was achieved in the MLL/AF9 NRAS cell line. 
At 200µM treatment, viability of the MV4-11 and MOLM-13 cells had dropped to 30% 
and 80%, respectively, while the THP-1 cells showed no sensitivity. 
 
 Autophagy 
In response to treatment with autophagy inhibitor chloroquine (up to a maximum 
concentration of 40µM, as justified in Section 3.1.3) a dose-response curve from 100% 
viability to close to 0% viability was achieved in the MLL/AF9 NRAS cell line. The 
MV4-11, MOLM-13 and THP-1 cell lines showed limited or no sensitivity to 
chloroquine, up to 40µM. 
 
 Cholesterol synthesis 
In response to treatment with cholesterol synthesis inhibitors fenofibrate, bezafibrate 
and rosiglitazone (up to a maximum concentration of 100µM, 100µM,and 30µM, 
respectively, as justified in Section 3.1.3) dose-response curves from 100% viability to 
close to 0% viability were achieved in the MLL/AF9 NRAS cell line, with the exception 
of bezafibrate where viability went down to approximately 80% with 100µM 
treatment. The MV4-11, MOLM-13 and THP-1 cell lines showed no sensitivity to any of 
the three cholesterol synthesis inhibitors, even at the maximum concentrations tested. 
 
 Summary of dose-response curve testing 
In summary, the mouse-derived MLL/AF9 NRAS cells showed some sensitivity (defined 
as >10% drop in cell viability at the highest concentration tested) to all of the 
metabolism modifying drugs tested and was the most sensitive of the four cell lines to 
CX-5461 treatment. Of the human AML cell lines tested, MV4-11 cells were the most 
sensitive to the metabolism modifying drugs overall and to CX-5461, followed by 
MOLM-13, then THP-1 which showed no, or limited, sensitivity to any of the 
metabolism drugs, or to CX-5461, up to the maximum concentrations used for testing. 
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ritonavir) and fatty acid synthesis (targeted by orlistat and omeprazole) for survival. 
 
 
Figure 3-5: Dose response curves and GI50s of drugs as single agents in MV4-11 cells. 
MV4-11 cells were cultured for 96 h in the presence of the indicated drugs at a range of 
concentrations, up to a maximum rational concentration for testing (Section 3.1.3). 
Total viable cell number was determined using MTT (for chloroquine) or neutral red 
assays (for all other drugs). The dose resulting in a 50% growth inhibition (GI50) values 
were calculated after fitting a non-linear curve to the data points (Methods Section 
2.5.5). Graphs show the meanSD of n=3 experiments. 
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The cells had limited or no sensitivity to chloroquine, DCA, fenofibrate, bezafibrate and 
 
 
 
Figure 3-6: Dose response curves and GI50s of drugs as single agents in MOLM-13 cells. 
MOLM-13 cells were cultured for 96 h in the presence of the indicated drugs at a range 
of concentrations, up to a maximum rational concentration for testing (Section 3.1.3). 
Total viable cell number was determined using MTT (for chloroquine) or neutral red 
assays (for all other drugs). The dose resulting in a 50% growth inhibition (GI50) values 
were calculated after fitting a non-linear curve to the data points (Methods Section 
2.5.5). Graphs show the meanSD of n=3 experiments. 
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rosiglitazone, suggesting that when autophagy (targeting by chloroquine), glycolysis 
 
 
 
Figure 3-7: Dose response curves and GI50s of drugs as single agents in THP-1 cells. 
THP-1 cells were cultured for 96 h in the presence of the indicated drugs at a range of 
concentrations, up to a maximum rational concentration for testing (Section 3.1.3). Total 
viable cell number was determined using MTT (for chloroquine) or neutral red assays 
(for all other drugs). The dose resulting in a 50% growth inhibition (GI50) values were 
calculated after fitting a non-linear curve to the data points (Methods Section 2.5.5). 
Graphs show the meanSD of n=3 experiments. 
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(targeted by DCA) and cholesterol synthesis (targeted by fenofibrate, bezafibrate and  
 
 
 
Figure 3-8: Dose response curves and GI50s of drugs as single agents in MLL/AF9 NRAS 
cells. 
MLL/AF9 NRAS cells were cultured for 96 h in the presence of the indicated drugs at a 
range of concentrations, up to a maximum rational concentration for testing (Section 
3.1.3). Total viable cell number was determined using MTT (for chloroquine) or neutral 
red assays (for all other drugs). The dose resulting in a 50% growth inhibition (GI50) 
values were calculated after fitting a non-linear curve to the data points (Methods 
Section 2.5.5). Graphs show the meanSD of n=3 experiments. 
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3.2.3 Combination testing of metabolism drugs with CX-5461 (4 
main cell lines) 
Based on the results from the viability assays with the drugs as single agents (Table 
3-4), non-constant ratio combination testing was performed with five concentrations 
of CX-5461 and three concentrations of the metabolism drugs, up to the GI50s 
previously determined or the maximum concentration tested, whichever was lower. 
Total viable cell number was determined after 96 h of treatment and the combination 
index calculated using CompuSyn (Methods section 2.5.5). Synergy was defined as a 
combination index below 0.75 (based on recommended guidelines for categorising 
synergism 123)and drug combinations were considered promising if synergy was 
observed in 2 or more cell lines. Figure 3-9 to Figure 3-16 show the viability results and 
CI values, which are summarised in Table 3-6. 
 
 CX-5461 + ritonavir 
The best combination effect of CX-5461 and ritonavir was observed in the MLL/AF9 
NRAS cell line (Figure 3-9d), where 14/15 of the drug combinations tested were 
synergistic, particularly at the highest concentration of ritonavir used (12µM). In the 
MOLM-13 cell line (Figure 3-9b) 9/15 of the drug combinations were synergistic, 
particularly with the lowest dose of ritonavir used (25µM). In the MV4-11 cell line 
(Figure 3-9a) none of the combinations had a synergistic effect on cell viability. The 
THP-1 cell line (Figure 3-9c), combination testing resulted in no obvious change in 
viability from the single agents, however, the CIs indicated the combinations were 
synergistic (with 50 µM ritonavir) or highly antagonistic (>1000; with 15 or 30µM 
ritonavir). These CI appear to result from calculation artefacts, the cause of such 
calculation artefacts is discussed in Section 3.1.3.  
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Figure 3-9: Combination testing of CX-5461 with ritonavir in AML cell lines. 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or ritonavir (rit), as single agents or in combination. Total 
viable cell number was determined using the neutral red assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed in 
the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values were 
greater than 1000, ‘>1000’ only was displayed. 
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 CX-5461 + orlistat 
In the MV4-11 cell line (Figure 3-10a) 10/15 of the combinations of CX-5461 and 
orlistat were synergistic, particularly with concentrations of >50nM CX-5461 and 8µM 
or 11µM orlistat. In the MOLM-13 cell line (Figure 3-10b) 11/15 of the combinations 
were synergistic. In contrast, none of the combinations of CX-5461 and orlistat in the 
MLL/AF9 NRAS cell line (Figure 3-10d) were synergistic. The THP-1 cell line (Figure 
3-10c) did not provide useful CI readouts due to calculation artefacts, as for the CX-
5461 and ritonavir combination (see Section 3.2.3.9). 
Figure 3-10: Combination testing of CX-5461 with orlistat in AML cell lines. 
 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or orlistat (orl), as single agents or in combination. Total 
viable cell number was determined using the neutral red assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed in 
the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values were 
greater than 1000, ‘>1000’ only was displayed. 
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 CX-5461 + omeprazole 
The best combination effect of CX-5461 and omeprazole was observed in the MOLM-
13 cell line (Figure 3-11b), where all 15 combinations were synergistic. In the MLL/AF9 
NRAS (Figure 3-11d) one combination was synergistic, the lowest of each of the drugs 
used (2nM CX-5461 with 30µM omeprazole). In contrast, none of the combinations of 
CX-5461 and omeprazole were synergistic in the MV4-11 cell lines (Figure 3-11a). The 
THP-1 cell line (Figure 3-11c) did not provide useful CI readouts due to calculation 
artefacts (see Section 3.2.3.9). 
Figure 3-11: Combination testing of CX-5461 with omeprazole in AML cell lines. 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or omeprazole (ome), as single agents or in 
combination. Total viable cell number was determined using the neutral red assay. 
Graphs show the meanSD of n=3 experiments. To determine if a combination was 
synergistic, the combination index (CI) of each data point was calculated using 
CompuSyn and displayed in the inlayed table (CI <0.75 considered synergistic, shaded 
green). Where CI values were greater than 1000, ‘>1000’ only was displayed. 
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 CX-5461 + chloroquine 
There was a strong combination effect of CX-5461 + chloroquine in the MOLM-13 cell 
line (Figure 3-12b), with doses of chloroquine as low as 5M resulting in a synergistic 
effect on cell viability when combined with CX-5461, and a total of 12/15 synergistic 
combinations. In the MV4-11 cell line (Figure 3-12a) 9/15 of the combinations were 
synergistic, particularly with CX-5461 and 40M chloroquine. In the MLL/AF9 cell line 
(Figure 3-12d) 5/15 of the combinations are synergistic, particularly with combinations 
of 10nM or 12nM CX-5461 with 20M or 25M chloroquine. Interestingly, in the THP-
1 cell line (Figure 3-12c) there is a decrease in viability with increasing concentrations 
of CX-5461 and 40M chloroquine, dropping to approximately 50% viability with the 
1000nM CX-5461 combination and 3/15 of the combinations are synergistic. In 
contrast to the combinations with other metabolism-modifying drugs were the CIs 
result from calculation artefacts, this appears to be the only true combination effect in 
the THP-1 cell line. 
Figure 3-12: Combination testing of CX-5461 with chloroquine in AML cell lines. 
 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or chloroquine (CQ), as single agents or in combination. 
Total viable cell number was determined using the MTT assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed 
in the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values 
were greater than 1000, ‘>1000’ only was displayed. 
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CX -5 4 6 1  (n M )
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2 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0
2 0 0.721 0.804 0.806 0.927 0.906
3 0 1.474 1.246 0.974 0.849 0.851
4 0 0.943 0.775 0.756 0.722 0.593
Co m b in a t io n  in d e x (C I)
CX -5 4 6 1  (n M )
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b) MOLM-13
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4 6 8 1 0 1 2
1 5 1.127 1.211 1.104 1.054 0.889
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 CX-5461 + DCA 
Of the four cell lines, the MLL/AF9 cell line (Figure 3-13d) had the most robust 
combination effect with CX-5461 + DCA treatment, with all combinations testing being 
synergistic. In the MOLM-13 cell line (Figure 3-13b) 6/15 of the combinations were 
synergistic, particularly in combination with 5mM DCA. In the MV4-11 cell line (Figure 
3-13a) 3/15 of the combinations were synergistic. Again, the THP-1 cell line (Figure 
3-13c) did not provide useful CI readouts due to calculation artefacts, see Section 
3.2.3.9. 
Figure 3-13: Combination testing of CX-5461 with DCA in AML cell lines. 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured 
for 96 h in the presence of CX-5461 or DCA, as single agents or in combination. Total 
viable cell number was determined using the neutral red assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed 
in the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values 
were greater than 1000, ‘>1000’ only was displayed. 
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3 0.449 0.887 1.411 1.218 1.259
5 1.520 0.746 0.652 0.536 0.176
Co mb in ation  in d ex (CI)
CX-5461 (n M)
DCA (mM)
100 300 500 700 1000
1 396.850 5.190 6.280 7.512 396.850
3 >1000 >1000 224.11 >1000 >1000
5 >1000 >1000 >1000 >1000 >1000
Co mbin ation  in dex (CI)
CX-5461 (n M)
DCA (mM)
25 50 75 100 125
1 0.786 0.993 1.042 1.037 1.039
3 0.610 0.853 0.129 1.124 1.002
5 0.615 0.756 0.876 0.906 0.635
Combination index (CI)
CX-5461 (nM)
DCA (mM)
4 6 8 10 12
1 0.524 0.623 0.588 0.584 0.498
2 0.319 0.458 0.650 0.572 0.470
3 0.400 0.437 0.409 0.311 0.151
DCA (mM)
Combinatio n  ind ex (CI)
CX-5461 (nM)
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 CX-5461 + fenofibrate 
In the MLL/AF9 NRAS cell lines (Figure 3-14d) 1/15 of the combinations of CX-5461 and 
fenofibrate are synergistic (12nM CX-5461 with 5M fenofibrate). While in the MV4-11 
cell line (Figure 3-14a) none of the combinations of CX-5461 and fenofibrate were 
synergistic. The combination data in the MOLM-13 (Figure 3-14b) and THP-1 (Figure 
3-14c) cell lines did not provide useful CI readouts due to calculation artefacts, see 
Section 3.2.3.9. 
Figure 3-14: Combination testing of CX-5461 with fenofibrate in AML cell lines. 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or fenofibrate (fen), as single agents or in combination. 
Total viable cell number was determined using the neutral red assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed 
in the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values 
were greater than 1000, ‘>1000’ only was displayed. 
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100 300 500 700 1000
30 0.100 0.319 0.530 0.655 0.956
60 0.109 0.399 0.569 0.509 0.744
100 0.089 0.299 0.399 0.549 0.771
Combination  index (CI)
CX-5461 (nM)
Fenofibrate (μM)
25 50 75 100 125
30 1.053 1.173 1.119 1.105 0.968
60 1.001 1.091 1.177 1.031 0.854
100 0.886 1.152 1.132 0.900 0.869
Combination index (CI)
CX-5461 (nM)
Fenofibrate (μM)
100 300 500 700 1000
30 0.620 0.833 0.712 0.592 0.933
60 0.974 0.703 0.504 0.727 0.759
100 0.684 0.540 0.444 0.537 0.634
Combination  ind ex (CI)
CX-5461 (nM)
Fen ofibrate (μM)
4 6 8 10 12
5 0.970 0.982 0.967 0.966 0.748
10 0.809 0.987 1.097 1.016 0.854
20 1.206 1.317 1.218 1.225 0.830
Comb in atio n  ind ex (CI)
CX-5461 (nM)
Fenofibrate (μM)
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 CX-5461 + bezafibrate 
In the MV4-11 (Figure 3-15a), MOLM-13 (Figure 3-15b) and MLL/AF9 NRAS (Figure 
3-15d) cell lines none of the combinations of CX-5461 and bezafibrate were synergistic. 
The THP-1 cell line (Figure 3-15c) did not provide useful CI readouts due to calculation 
artefacts, see Section 3.2.3.9. 
Figure 3-15: Combination testing of CX-5461 with bezafibrate in AML cell lines. 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or bezafibrate (bez), as single agents or in combination. 
Total viable cell number was determined using the neutral red assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed 
in the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values were 
greater than 1000, ‘>1000’ only was displayed. 
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30 0.113 0.260 0.348 0.548 0.881
60 0.102 0.244 0.419 0.494 0.657
100 0.082 0.223 0.382 0.519 0.679
Combination index (CI)
CX-5461 (nM)
Bezafibrate (μM)
25 50 75 100 125
30 0.916 1.236 1.277 1.280 1.208
60 0.887 1.239 1.402 1.281 1.208
100 0.825 1.164 1.357 1.289 0.986
Combination index (CI)
CX-5461 (nM)
Bezafibrate (μM)
100 300 500 700 1000
30 967.206 >1000 >1000 >1000 >1000
60 >1000 >1000 >1000 >1000 >1000
100 >1000 >1000 >1000 >1000 >1000
Combination index (CI)
CX-5461 (nM)
Bezafibrate (μM)
4 6 8 10 12
30 1.500 1.512 1.207 1.060 0.871
60 0.938 1.108 1.134 1.287 1.097
100 12.727 1.744 1.370 1.202 0.977
Combinatio n  ind ex (CI)
CX-5461 (nM)
Bezafibrate (μM)
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 CX-5461 + rosiglitazone 
In the MV4-11 (Figure 3-16a), MOLM-13 (Figure 3-16b) and MLL/AF9 NRAS (Figure 
3-16d) cell lines none of the combinations of CX-5461 and rosiglitazone were 
synergistic. The THP-1 cell line (Figure 3-16c) did not provide useful CI readouts due to 
calculation artefacts, see Section 3.2.3.9. 
Figure 3-16: Combination testing of CX-5461 with rosiglitazone in AML cell lines. 
AML cell lines a) MV4-11, b) MOLM-13, c) THP-1 and d) MLL/AF9 NRAS were cultured for 
96 h in the presence of CX-5461 or rosiglitazone (rosi), as single agents or in combination. 
Total viable cell number was determined using the neutral red assay. Graphs show the 
meanSD of n=3 experiments. To determine if a combination was synergistic, the 
combination index (CI) of each data point was calculated using CompuSyn and displayed 
in the inlayed table (CI <0.75 considered synergistic, shaded green). Where CI values were 
greater than 1000, ‘>1000’ only was displayed. 
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Co mb ination  index (CI)
CX-5461 (n M)
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10 1.145 1.206 1.321 1.265 1.140
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30 0.949 1.331 1.507 1.244 1.332
Comb ination  index (CI)
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100 300 500 700 1000
10 2.560 2.631 2.854 2.686 3.088
20 4.272 4.876 5.383 5.537 5.757
30 6.198 6.712 7.117 7.338 7.743
Rosig litazon e (μM)
Combination  in dex (CI)
CX-5461 (n M)
4 6 8 10 12
10 1.608 1.293 1.270 1.181 0.934
20 0.968 1.167 1.349 1.189 1.060
25 1.238 1.290 1.292 1.156 1.280
Comb in ation  ind ex (CI)
CX-5461 (n M)
Rosiglitazo ne (μM)
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 Apparent CI calculation artefacts 
In many cases in the THP-1 cell line, and in some cases in the MOLM-13 cell line, 
combination testing resulted in no change in viability from the single agents, however 
this resulted in a CI being calculated that indicated the combination was either highly 
synergistic or highly antagonistic. For example, in the THP-1 cell line with ritonavir 
treatment (Figure 3-9c). These CI appear to result from calculation artefacts, the cause 
of such calculation artefacts is discussed in Section 3.3.2. 
 
 Summary of combination testing 
The combination testing results are summarised in Table 3-6. In summary, evaluation 
of CX-5461 with various metabolism-modifying drugs identified that CX-5461 and 
chloroquine was the most promising combination, with synergy observed in all four 
cell lines tested. Other promising combinations with CX-5461 were orlistat, ritonavir, 
omeprazole and DCA. Calculation artefacts were pronounced in the THP-1 cell line, and 
in some cases the MOLM-13 cell line, highlighting some of the limitations of the 
synergy testing which are further discussed in Section 3.3.2. A schematic summary of 
the results of the in vitro combination testing are shown in Figure 3-19. 
 
3.2.4 Dose-response curves, GI50s and combination testing of 
chloroquine with CX-5461 (additional cell lines) 
The most promising of the drug combinations, CX-5461 and chloroquine, was tested in 
additional human AML cell lines KG-1 and SKM-1, which were selected based on 
increasing the range of genetic characteristics being tested to include non-MLL 
mutants and p53 mutants (Table 3-1). These additional cell lines were tested as above, 
firstly with the drugs as a single agent over a range of concentrations, the total viable 
cell number determined using the MTT assay and the GI50 calculated (Figure 3-17). The 
cell viability of SKM-1 cells was not affected by CX-5461 or chloroquine up to the 
maximum concentration used (as justified in Section 3.1.3). KG-1 cells exhibited 
approximately a 40% decrease in total viable cell number at the maximum chloroquine 
concentration (40M) tested and a GI50 of approximately 600nM with CX-5461. In 
response to CX-5461 treatment, they exhibit a similar dose-response curve to the 
MOLM-13 cells (Figure 3-6), where the viability plateaus out. 
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Non-constant ratio combination testing was then performed, as above, and shown in 
Figure 3-18. In the KG-1 cell line (Figure 3-18a), 3/15 of the combinations of CX-5641 
and chloroquine were synergistic, with the greatest combination effect observed with 
combinations of 500nM and 700nM CX-5461. In the SKM-1 cell line (Figure 3-18b), all 
15 combinations of CX-5461 and chloroquine were synergistic, particularly in 
combination with 40µM chloroquine. These results show that the combination of CX-
5461 and chloroquine is effective in non-MLL mutant and p53 mutant AML cell lines. 
 
Figure 3-17: Dose response curves and GI50s of CX-5461 and chloroquine in additional 
AML cell lines 
AML cell lines a) KG-1 and b) SKM-1 were cultured for 96 h in the presence of the indicated 
drugs at a range of concentrations, up to a maximum concentration for testing. Total 
viable cell number was determined using the MTT assay (Methods Section 2.5.2). The dose 
resulting in a 50% growth inhibition (GI50) values were calculated after fitting a non-linear 
curve to the data points (Methods Section 2.5.5). Graphs show the mean SD of n=3 
experiments. 
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Drugs 
Maximum 
concentration 
tested* 
GI50±SD 
Human 
SKM-1 (No fusion, 
p53 mutant) 
KG-1 (AML1-ETO, 
p53 null) 
CX-5461 (nM) 1000 >1000 ~600 
Chloroquine (μM) 40 >40 >40 
 
Table 3-5: GI50s of CX-5461 and chloroquine in additional AML cell lines 
Data from Figure 3-18. Colour code: No colour = Sensitive (>25% drop in cell viability at 
maximum concentration Light grey = Some sensitivity (10-25% drop in cell viability at 
maximum concentration) Dark grey = Not sensitive (<10% drop in cell viability at 
maximum concentration).* Justified in Section 3.1.3. 
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Figure 3-18: Combination testing of CX-5461 and chloroquine in additional AML cell 
lines. 
AML cell lines a) KG-1 and b) SKM-1 cell lines were cultured for 96 h in the presence of 
CX-5461 or chloroquine (CQ), alone or in combination. Total viable cell number was 
determined using the MTT assay. Graphs show the meanSD of n=3 experiments. In order 
to determine if a combination was synergistic the combination index of each data point 
was calculated using CompuSyn and displayed in the inlayed table (synergism was 
designated as a combination index (CI) value <0.75, shown in green). 
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CX-5461 in 
combination 
with: 
Synergistic combinations (out of 15) 
Cell line 
Human Human Human Mouse Human Human 
MV4-11 
(MLL/AF4, 
p53 WT) 
MOLM-13 
(MLL/AF9, 
p53 WT) 
THP-1 
(MLL/AF9, 
p53 null) 
MLL/AF9 
NRAS 
(p53 WT) 
KG-1 
(AML1-ETO, 
p53 null) 
SKM-1 
(No fusion, 
p53 
mutant) 
Ritonavir 0 9 5* 14 NT NT 
Orlistat 10 11 3* 0 NT NT 
Omeprazole 0 15 5 1 NT NT 
Chloroquine 9 12 3 5 3 15 
DCA 3 6 0 15 NT NT 
Fenofibrate 0 11* 13* 1 NT NT 
Bezafibrate 0 0 14* 0 NT NT 
Rosiglitazone 0 0 3* 0 NT NT 
Table 3-6: Summary of combination testing results 
Data summarised from Figure 3-9 to Figure 3-16 and Figure 3-18. Synergism was defined as a CI 
below 0.75. NT = not tested. * indicates results which are likely calculation artefacts from CI 
analysis. 
 85 
 
  
 
 
Figure 3-19: Schematic summary of evaluating combinations of metabolism-modifying 
drugs with CX-5461. 
For combination testing, 4 cell lines were used for evaluation, with the exception of CX-
5461 + chloroquine where 6 cell lines were used. 
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3.3 Discussion 
This chapter aimed to test CX-5461 for synergy in combination with 
metabolism-modifying drugs in a panel of AML cell lines. 
 
3.3.1 Dose-response curve analysis 
Dose-response analysis of the drugs as single agents (Table 3-4 and Table 3-5) revealed 
the cell lines varied widely in their sensitivity, however, some patterns emerged. 
 
The mouse-derived MLL/AF9 NRAS showed at least some sensitivity to all the drugs 
tested, and was more sensitive than the human cell lines, suggesting a greater reliance 
on ribosome biogenesis and a range of metabolic pathways compared to the human 
AML cell lines. 
 
In terms of specific biological pathways, targeting ribosome biogenesis with CX-5461 
was the most effective single-agent approach, with 5/6 cell lines showing at least some 
sensitivity up to the maximum concentration of 1µM (as justified in Section 3.1.3), 
which is consistent with the well-established role of ribosome biogenesis in malignant 
transformation and progression 78. Ritonavir was highly effective in reducing cell 
viability, with 4/4 cell lines tested showing at least some sensitivity to the drug as a 
single agent. Confirming ritonavir’s on-target activity as a glucose uptake inhibitor, at 
the concentrations used in these experiments, would be important to support this 
process as a promising therapeutic target. In the MLL/AF9 NRAS and THP-1 cells, this 
may correlate with a dependence on glycolysis as these cells show at least some 
sensitivity to DCA as a single agent. As single agents, orlistat, omeprazole and 
chloroquine were effective in reducing cell viability, as 3/4, 3/4 and 4/6 of the cell lines 
tested, respectively, showed at least some sensitivity to the drugs. Confirming orlistat 
and omeprazole’s on target activity as fatty acid synthesis inhibitors and chloroquine’s 
as an autophagy inhibitor, at concentrations used in these experiments, would be 
important to support these processes as promising therapeutic approaches. MLL/AF9 
NRAS was the only cell line of the four tested to show a reduction in cell viability in 
response to fenofibrate, bezafibrate and rosiglitazone treatment as single agents. 
Confirmation on-target activity of these drugs as cholesterol synthesis inhibitors, at the 
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concentrations used in these experiments, would be important to determine if this 
process is a promising therapeutic approach, as it is possible that full inhibition of this 
pathway was not achieved with the concentrations used. 
 
The mutation status of the cell lines also appears to play a role in the sensitivity of the 
cell lines to the drugs as single agents. In particular, cell lines with wild type p53 status 
were more sensitive to CX-5461 than those with mutant or null p53 status. In order of 
most to least sensitive; MLL/AF9 NRAS (p53 WT), MV4-11 (p53 WT), MOLM-13 (p53 
WT), KG-1 (p53 null), SKM-1 (p53 mutant) and THP-1 (p53 null). This is consistent with 
the reported p53-dependent effects of CX-5461 in AML in Hein et al. 1, (further 
discussed in Section 5.1.1), however, this same study found no correlation between 
p53 status and cell viability (in terms of cell death). The discrepancy between the 
literature and the results in this thesis could be due to the smaller panel of cell lines 
used in this thesis, or to the different methods used to measure viability (i.e. neutral 
red or MTT vs. cell death by propidium iodide exclusion). No other pattern between 
mutation status and drug sensitivity was apparent, given the small panel of cell lines 
utilised. 
 
3.3.2 Combination testing and synergy analysis 
The combination testing was successful in identifying several metabolism-modifying 
therapies that work synergistically with CX-5461 to reduce cell viability of AML cells in 
vitro (Table 3-6), with CX-5461 and chloroquine being the most promising combination 
as synergy was observed for all 6 cell lines tested. This suggests a potential role for 
autophagy in sensitising AML cells to CX-5461 treatment, across a broad range of 
mutations, including p53, MLL fusion and NRAS status (Table 3-1). Targeting fatty acid 
synthesis was also promising as a means to sensitise AML cells to CX-5461, as synergy 
was seen with CX-5461 + orlistat and CX-5461 + omeprazole in multiple cell lines. This 
is consistent with the sensitivity of the cell lines to the fatty acid synthesis inhibitors as 
single agents (Table 3-4). Combination testing results also suggest that reversing the 
glycolytic phenotype with DCA and inhibiting glucose uptake with ritonavir are 
promising strategies when combined with CX-5461 treatment, in addition to being 
promising single-agent approaches (Table 3-4). None of the cholesterol-modifying 
drugs synergised with CX-5461 treatment in any of the cell lines, suggesting that 
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cholesterol metabolism might not play a pro-survival role in the response of AML cells 
to ribosome biogenesis inhibition with CX-5461. 
 
However, several caveats must be considered when interpreting the results of the 
synergy testing. First, the results of the combination testing must be interpreted with 
caution in the context of the targets of the drugs as many established metabolism-
modifying therapies have multiple known targets in healthy tissues as well as cancer. 
For example, omeprazole is known to inhibit fatty acid synthase 152, modulate the 
lysosomal transport pathway 154 and act as an AHR ligand 155. As outlined in Section 
3.1.2.7, some of the metabolism-modifying agents have the potential to modulate 
ribosome biogenesis under certain conditions. This can make biological interpretation 
of the synergy results difficult, unless further mechanistic analysis, including genetic 
approaches and alternative inhibitors, is conducted. For this reason, promising 
combinations from the in vitro testing, that also act synergistically to improve survival 
in vivo (Chapter 4), were subjected to mechanistic analysis to determine how they act 
synergistically together (Chapter 5). A limitation of the studies is that mechanistic 
analysis was not performed to confirm the action of all the drugs utilised in these 
studies as metabolism-modifying agents, nor for their effects on ribosome biogenesis. 
 
In addition, a limited range of drug concentrations can be tested: if the concentration 
of either drug is too high it is difficult to determine if the combination is synergistic as 
the ‘effect’ of the single agents is already close to 1. For this reason, the maximum 
concentrations of the single agents was capped at approximately the GI50. This gives 
the assay a limited dynamic range and some drug combinations of interest might be 
missed if synergism is only observed at higher concentrations. Further in vivo testing of 
any promising drug combinations does not suffer from this same limitation, but has 
different limitations, such as that the maximum drug dosage is dependent on 
tolerability. 
 
Another limitation of the synergy testing is that the algorithms underlying the 
CompuSyn program were unable to calculate a reliable CI where there was not a 
complete dose-response curve of the single drug. There were many instances where a 
dose-response curve was not achieved with the drugs as single agents, particularly in 
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the THP-1 cell line (Figure 3-7), and to a lesser extent in the MOLM-13 cell line (Figure 
3-6). In order to calculate the CI values, the CompuSyn program requires a dose-
response curve of the effects of the drugs as single agents. In the case where a curve 
cannot be fitted across the data points, the curve is predicted, thus likely to be 
inaccurate and will affect the results of the synergy testing. This issue is particularly 
pronounced for the THP-1 cell line, which has no or limited sensitivity to all the drugs 
tested, where many combinations, according to the CI, appear highly antagonistic (e.g. 
CX-5461 + DCA, Figure 3-13c) or synergistic (e.g. CX-5461 + fenofibrate, Figure 3-14c), 
despite the viability curves indicating the combinations have a similar effect on cell 
viability to the single drugs alone. Thus, CI values must be interpreted with caution in 
the case where one or both of the drugs do not produce a dose-dependent curve as a 
single agent. The only drug combination which does appear to have CI values that 
were not affected by calculation artefacts in the THP-1 cell line is CX-5461 + 
chloroquine (Figure 3-12c). 
 
3.3.3 Summary of synergy testing 
In summary, metabolism-modifying drugs ritonavir, orlistat, omeprazole, chloroquine 
and DCA were found to act synergistically with ribosome biogenesis inhibitor CX-5461 
in vitro in multiple AML cell lines. These promising combinations were then taken 
forward for in vivo testing to determine if they synergise to improve the survival of 
tumour bearing mice (Chapter 4). 
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Chapter 4 Testing promising 
combination therapies in vivo in 
transplant models of AML 
 
4.1  Introduction 
Testing potential cancer therapeutics in applicable mouse models is important for 
determining the efficacy of compounds in a more complex whole organism setting and 
prioritising the transition of only the most effective compounds to human clinical 
trials. This chapter addresses Aim 2: ‘Test promising combination therapies in in vivo 
syngeneic and xenograft models of AML’.  
 
Metabolism-modifying drugs that were found to act synergistically with CX-5461 to 
reduce AML viability in vitro (Chapter 3) were tested for their efficacy in improving 
survival in vivo in transplant models of AML. Compared to in vitro assays, several 
factors can play important roles in these in vivo pre-clinical mouse models including 
the microenvironment, the type of transplant model and the method of tracking 
disease. Testing potential drug combinations in the context of the tumour 
microenvironment is important, as it modulates cancer cell growth and drug 
resistance. 
 
4.1.1 The leukaemia microenvironment 
The primary tumour microenvironment of leukaemia cells is the bone marrow, and to 
a lesser extent secondary lymphoid organs such as the spleen and lymph nodes. The 
bone marrow niche consists of osteoblasts, osteoclasts, the sympathetic nerve system, 
blood vessels, immune cells such as macrophages, endothelial cells, mesenchymal 
stem cells (MSCs) and haematopoietic stem cells (HSCs) 193. As the location of the 
HSCs, the bone marrow niche regulates the survival, proliferation and differentiation 
of these cells, and is the site of production of all blood cells including erythrocytes, 
monocytes and lymphocytes 194. The bone marrow niche is also thought to be the 
primary reservoir of leukemic stem cells, which possess self-renewing properties like 
HSCs and differentiate into leukemic blasts, such that the bone marrow niche dictates 
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disease progression, drug resistance and relapse through interactions with the 
leukaemia cells 195. 
 
Leukemic blasts hijack this supportive environment to support their own survival and 
proliferation (Figure 4-1). These AML cells reprogram the surrounding cells to their 
advantage, such as reprogramming bone marrow adipocytes to increase lipolysis, 
resulting in the increased transfer of fatty acids from adipocytes to leukemic cells to 
support their metabolic processes 196. One mechanism via which AML cells can signal 
to surrounding cells is through excreted vesicles called exosomes. The plasma of AML 
patients has been reported to be rich in exosomes containing immunosuppressive 
components which interfere with the anti-tumour immune response 197. AML-derived 
 
Figure 4-1: The leukaemia microenvironment 
The bone marrow environment is the main niche of AML cells and includes osteoblasts 
(blue), stromal cells (orange) and immune cells such as T cells (yellow). The AML cell signals 
to the surrounding cells through soluble factors (triangles), vesicles known as exosomes 
(which contain factors such as signalling molecules) and through direct cell-to-cell 
interactions. In response, the stromal cells provide the AML cells with nutrients and growth 
factors, supporting their survival and proliferation. Normal osteoblast function, immune cell 
function and haematopoiesis is also inhibited. In this manner the bone marrow niche 
becomes more favourable to the tumour cells and can also increase their chemotherapy 
resistance. 
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exosomes are able to remodel the bone architecture and stromal cell compartment, 
reducing the activity of osteoblasts and also the ability of the stromal cells to support 
normal haematopoiesis, thus providing a competitive advantage to AML cells 198. 
Soluble factors are also utilised by AML cells to signal to surrounding cells. 
Cytokine-mediated crosstalk between MSCs and AML cells was shown to reduce 
apoptosis and increase the proliferation of primary AML patient cells in an in vitro 
co-culture model 199, which is in agreement with evidence that AML cells increase the 
numbers of fibroblasts, which produce pro-survival cytokines and result in reduced 
chemotherapy sensitivity 200. AML cells have also been found to communicate to 
surrounding cells through direct cell-to-cell contact including through gap-junction 
mediated mechanisms 201 and also via vascular cell adhesion molecule 1 (VCAM-1) and 
very late antigen-4 (VLA-4) signalling, activating nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) pro-survival signalling and leading to 
chemoresistance 202. 
 
While this is a simplistic view of the bone marrow niche that does not take into 
account the vast complexities of such a system 203, it is clear that the bone marrow 
niche plays a significant role in the survival of AML cells and their response to 
chemotherapy, highlighting the importance of evaluating promising combination 
therapies in this context, as it will influence the effects of the drugs on the tumour 
cells. 
 
4.1.2 Types of in vivo transplant models utilised 
Various types of in vivo mouse transplant models have been developed which differ in 
the type of cells which are injected (donor cells) and the location within the recipient 
where the cancer develops. For the studies in this thesis, an established MLL/AF9 NRAS 
mouse AML cell line 32 was injected intravenously (IV) into C57Bl/6 mice, an 
immunocompetent strain. This is a syngeneic (strain and species matched), orthotopic 
(tumours develop in the organ of origin) model. Cell line xenograft models (human cell 
lines injected into immunocompromised mice) were also utilised. For these studies, 
established human AML cell lines were injected into NOD/SCID/gammanull (NSG) mice, 
which lack functional B lymphocytes, T lymphocytes and natural killer cells, thus would 
mount a limited immune response against the human AML cells 204. This method of 
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transplant is well characterised for the human AML cell lines selected for these 
experiments (MV4-11, THP-1 and MOLM-13) 33 205 206 207 208 209. 
A comparison of the observed features of these two types of models is outlined in 
Table 4-2 and the subsequent benefits or limitations of these models discussed in the 
Sections 4.3.3 and 4.3.6. 
Heterotopic tumour models involve the transplant of tumour cells in an organ that is 
not the organ of origin, typically tumour cells are injected subcutaneously into the 
flank of the mouse where the resulting solid tumour can be easily detected and 
measured with calipers. Indeed, such models have been used for in vivo evaluation of 
AML cell lines including MV4-11 210-212, MOLM-13 206,213,214 and THP-1 215,216. However, 
the flank of the mouse is far removed from the natural microenvironment for 
leukaemia, thus only orthotopic AML models were chosen to test the efficacy of the 
promising combinations identified in Chapter 3. To facilitate the monitoring of the 
engraftment and development of leukaemia, live animal imaging with luciferase-
tagged cells was employed. 
 
4.1.3 Live animal imaging with luciferase tagged tumours 
As orthotopic models of AML do not provide simple visualisation of the tumours, an 
alternative method of measuring disease progression was required. Orthotopic AML 
models do not normally feature high numbers of circulating leukaemia cells until close 
to the ethical endpoint, in the case of the THP-1 xenograft model there is very little 
circulating disease even at ethical endpoint 207, thus the number of leukaemia cells in 
the blood is not a robust early measure of tumour burden in these particular models. 
Live animal imaging of luciferase tagged leukaemia cell lines was used as the measure 
of tumour burden to overcome this issue (Methods section 2.6). Specifically, the 
leukaemia cell lines must be tagged with the luciferase enzyme. A few days following 
IV injection of the leukaemia cells, the mice are injected with the luciferin substrate, 
anaesthetised and imaged with IVIS Spectrum, a specialised imaging machine for 
measuring bioluminescence and fluorescence in live rodents. The luciferase enzyme in 
the AML cells converts luciferin to oxyluciferin and energy is released in the form of 
bioluminescence 217 which is detected by the camera in the IVIS Spectrum. This 
technique provides a non-invasive method of confirming engraftment and tracking 
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disease progression in the same mice over time, and also allows the tumour burden in 
different areas of the mouse to be visualised 217. The MLL/AF9 NRAS cell line is a 
well-established mouse AML cell line which expresses the luciferase enzyme 32, 
whereas the human AML cell lines used in the in vitro screening in the previous 
chapter were transduced to express the luciferase enzyme, as part of this thesis 
project (Methods Section 2.9). 
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4.2  Results 
 
4.2.1 Tolerability testing of metabolism drugs +/- CX-5461 in 
non-tumour bearing mice 
In order to determine a tolerable dose of the metabolism drugs for in vivo experiments 
testing was performed in healthy, non-cancer bearing mice of the relevant background 
strain (C57BL/6). The tolerability of CX-5461 had already been established by our lab, 
being a standard dosing schedule of 30-35mg/kg dosed 3 times per week by oral 
gavage, with a vehicle of 50mM NaH2PO4 1. In these studies, weight is measured 
regularly as weight loss is used as a sign of drug toxicity, and general health is also 
monitored (Methods Section 2.6.1). The maximum tolerated dose (MTD) is defined as 
the dose which causes a maximum weight loss of 10% from which the mice recover 
within a week. Once the MTD or tolerable range of the metabolism drug was 
established, combination tolerability testing with CX-5461 was commenced. 
 
 Tolerability of orlistat 
The published method of orlistat administration in vivo is through extraction from 
commercially-available Xenical capsules, then dosing at 240mg/kg/day injected IP, as 
15µL/10g body weight 160. Orlistat solubility required a high percentage of ethanol 
(33%), thus the vehicle was also tested. Mice were treated with orlistat at the 
published dosing schedule for 3 weeks, weighed daily, and a vehicle only group 
included. Figure 4-2 shows that all mice in the vehicle only group maintained their 
weight over a 3 week period of dosing, and at the final weigh-in 1 week after dosing 
was completed, indicating the vehicle was tolerated. In the orlistat treated group two 
of the mice tracked with the vehicle only mice, however one mouse lost approximately 
5% body weight during dosing which then stabilised at this level for the remainder of 
the dosing period. It was determined that 240mg/kg was a tolerable dose, which is 
consistent with the literature 119. Combination tolerability testing with CX-5461 was 
not performed with orlistat due to the favourable toxicity results of orlistat as a single 
agent. 
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Figure 4-2: Tolerability of metabolism-modifying drugs as single agents in non-tumour 
bearing mice 
Non-tumour bearing C57Bl/6 mice were weighed and dosed with the indicated drug 
regimes daily for 21 days, followed by monitoring only for 1 week. If no weight change 
was observed after 2 weeks of dosing, the dose was increased and continued for a 
further 1-2 weeks. Weight change is shown, as a percentage of the initial 
weight. -10%, -15% and -20% weight changes are indicated by dotted lines, as >10% 
weight loss is a sign of drug toxicity and >20% weight loss requires euthanasia, according 
to ethical requirements. N=3 mice/dosing regime. 
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 Tolerability of chloroquine +/- CX-5461 
Tolerability testing of chloroquine was commenced at 50mg/kg dosed daily by oral 
gavage. As the vehicle was phosphate-buffered saline (PBS), a vehicle only group was 
not included. Figure 4-2 shows that the mice maintained their weight after 1 week of 
treatment with 50mg/kg chloroquine, thus a separate group with 100mg/kg was 
started. After 2 weeks of dosing the 50mg/kg treated group were still maintaining 
 
 
Figure 4-3: Tolerability of CX-5461 + DCA or chloroquine in non-tumour bearing mice 
Non-tumour bearing C57Bl/6 mice were weighed and dosed with the indicated drug 
regimes daily for 14-21 days, followed by monitoring only for 1 week. Grey areas indicate 
dosing days. Weights are graphed for each individual mouse as weight change, a 
percentage of the initial weight. -10%, -15% and -20% weight changes are indicated by 
dotted lines, as >10% weight loss is a sign of drug toxicity and >20% weight loss requires 
euthanasia, according to ethical requirements. N=2-3 mice/dosing regime. 
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weight so their dosing was increased to 200mg/kg for a further 2 weeks during which 
no toxicity was observed. The 100mg/kg treated group were still maintaining weight 
after 2 weeks of dosing and as such, dosing was increased to 400mg/kg daily. After 3 
doses the mice rapidly lost weight and the experiment was terminated. Autopsies 
revealed the mice had bloated stomachs and intestines, and pale organs suggesting 
anaemia. From these single-agent studies, it was determined that 50, 100 and 
200mg/kg of chloroquine were tolerable daily dosing schedules in healthy C57Bl/6 
mice, while 400mg/kg was not. These results are consistent with the published 
literature, where daily doses of 50-100mg/kg/day chloroquine have been used as a 
single agent in various cancer models without significant toxicity 218-220, and the oral 
50% lethal dose (LD50) of chloroquine in mice is reported to be 500mg/kg 221. 
 
Based on these studies combination tolerability testing of CX-5461 with chloroquine 
was performed. Typically when testing combination therapies, a lower dose than the 
MTD is trialled. Thus, dosing of 80 or 100mg/kg chloroquine was performed daily 
Monday to Friday (reduced from 7 days a week) with 35mg/kg CX-5461 (Monday, 
Wednesday and Friday). As chloroquine is soluble in water-based vehicles, for these 
experiments it was dissolved in 50mM NaH2PO4, as is CX-5461. Figure 4-3 shows that 
35mg/kg CX-5461 in combination with 80 or 100mg/kg chloroquine was not tolerated, 
as the mice rapidly lost weight from day 8 of dosing onwards. A lower dose of CX-5461 
(30mg/kg) with 80mg/kg chloroquine was potentially intolerable as one mouse 
maintained weight, while the other lost almost 20% of its weight and required 
euthanasia after 2 weeks of dosing, whereas 30mg/kg CX-5461 and 50mg/kg 
chloroquine was found to be tolerable, with weight loss of less than 5% throughout the 
experiment. 
 
 Tolerability of DCA + CX-5461 
Previous work in our laboratory established the in vivo toxicity of DCA as a single agent 
based on dosing through drinking water, estimated to be equivalent to 200mg/kg/day. 
As DCA is soluble in water-based vehicles, for these experiments it was dissolved in 
50mM NaH2PO4, as is CX-5461. Dosing was commenced at 200mg/kg/day DCA with 
35mg/kg CX-5461 (Monday, Wednesday and Friday) by oral gavage. Figure 4-3 shows 
that the mice maintained weight over the two-week schedule (with a maximum weight 
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loss of 5% after 13 days) and over the following 2 weeks after dosing, thus this dosing 
schedule was determined to be tolerable. The MTD was not reached, thus higher 
doses of both drugs could potentially be used. 
 
 Tolerability of omeprazole 
Omeprazole dosing was tested at 100 or 125 mg/kg/day by oral gavage, dissolved in 
7.5% ethanol in PBS 155,222 (Figure 4-2). After 2 weeks toxicity was not observed thus 
the dose was increased to 200 or 400 mg/kg/day respectively for a further 2 weeks, 
with no observable toxicity. Thus omeprazole at 400mg/kg/day is a tolerable dosing 
schedule in healthy C57BL/6 mice. This is consistent with the published literature, 
where doses of 75-100mg/kg/day of omeprazole have been used in various cancer 
models as a single agent without significant toxicity 155,222 and the oral LD50 in mice has 
been reported to be in excess of 4g/kg 223. Combination tolerability testing of CX-5461 
and omeprazole was not completed due to time constraints, and thus not followed up 
for testing in tumour models. 
 
 Tolerability of ritonavir 
Ritonavir dosing was tested at 50 or 60 mg/kg/day by oral gavage, dissolved in 7.5% 
ethanol in PBS 159,224,225 (Figure 4-2). After 2 weeks toxicity was not observed thus the 
dose was increased to 200 or 400 mg/kg/day respectively for a further 2 weeks, with 
no observable toxicity. Thus ritonavir at 400mg/kg/day is a tolerable dosing schedule 
in healthy C57BL/6 mice. This is consistent with the published literature, where doses 
of 30-50mg/kg/day of ritonavir have been used in various cancer models as a single or 
combination agent without significant toxicity 159,224,225, and the oral LD50 in mice is 
reported to be in excess of 2.5g/kg 226. Combination tolerability testing of CX-5461 and 
ritonavir was not completed due to time constraints, and thus not followed up for 
testing in tumour models. 
 
 Summary 
In summary, tolerable doses of orlistat, chloroquine, omeprazole and ritonavir as 
single agents in healthy C57BL/6 mice were determined, in addition to tolerable 
combination dosing with CX-5461 and DCA, and CX-5461 and chloroquine. Results of 
the MTD testing are summarised in Table 4-1. 
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4.2.2 Treatment of MLL/AF9 NRAS in vivo 
The MLL/AF9 NRAS syngeneic mouse model is a well-established model in our 
laboratory 1. Specifically, 5 x 105 MLL/AF9 NRAS cells were injected into recipient 
C57Bl/6 mice and engraftment confirmed 7 days post-transplant by bioluminescent 
imaging, as previously established. The mice were then randomised into groups and 
treatment commenced, at a regime informed by the previous tolerability testing 
(Figure 4-2 and Figure 4-3). ‘Survival’ was defined as the time taken post-transplant 
until the mice reached an ethical endpoint and required euthanasia due to symptoms 
Drug/s Vehicle Method of 
administration 
Tolerable 
doses 
Intolerable 
doses 
Maximum 
tolerated 
dose (if 
achieved) 
Orlistat 33% 
ethanol, 
66% PEG 
400 
15µL/10g 
injected IP, 
daily 
240mg/kg - - 
Omeprazole 7.5% 
ethanol in 
PBS 
100µL/10g by 
oral gavage, 
daily 
100, 125, 
200, 
400mg/kg 
- - 
Ritonavir 7.5% 
ethanol in 
PBS 
100µL/10g by 
oral gavage, 
daily 
50, 60, 200, 
400mg/kg 
- - 
Chloroquine PBS 100µL/10g by 
oral gavage, 
daily 
80, 100, 
200mg/kg 
400mg/kg >200mg/kg, 
<400mg/kg 
CX-5461 + 
DCA 
50mM 
NaH2PO4 
100µL/10g by 
oral gavage, 
daily (DCA), 
M,W,F (CX-
5461) 
35mg/kg 
CX-5461 + 
200mg/kg 
DCA 
- - 
CX-5461 + 
chloroquine 
50mM 
NaH2PO4 
100µL/10g by 
oral gavage, 
daily M-F 
(chloroquine), 
M,W,F (CX-
5461) 
30mg/kg 
CX-5461 + 
50mg/kg 
chloroquine  
35mg/kg 
CX-5461 + 
100mg/kg 
chloroquine, 
35mg/kg 
CX-5461 + 
80mg/kg 
chloroquine 
~30mg/kg 
CX-5461 + 
80mg/kg 
chloroquine 
 
Table 4-1: Summary of drug tolerability studies in non-tumour bearing mice 
Data from Figure 4-2 and Figure 4-3. 
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such as weight loss, reluctance to move and hunching. Median survival times and 
subsequent statistical analysis of survival times are shown in Appendix Tables 4-1 and 
4-2. 
 
 CX-5461 + orlistat 
Orlistat treatment did not alter survival compared to the vehicle-treated mice (median 
survival of 17 days post-transplant for both groups) (Figure 4-4a), whereas CX-5461 
treatment alone significantly improved survival compared to the vehicle and orlistat 
groups, (median survival of 29 days). The combination of CX-5461 and orlistat had a 
significantly worse outcome on survival than CX-5461 alone (median survival of 25 
days). 
 
This antagonistic effect was also reflected in the spleen weights (Figure 4-4b. Disease-
induced splenomegaly was not altered with orlistat treatment, whereas CX-5461 
treatment prevented spleen enlargement and the drug combination resulted in an 
intermediate spleen weight. 
 
Figure 4-4c illustrates a difference in patterning of the bioluminescence between the 
groups. For example, at 14 days post-transplant the bioluminescent signal in the 
vehicle and orlistat treated groups had spread throughout the body, with a higher 
concentration in the midsection. In comparison, the CX-5461 and combination-treated 
mice had no visible bioluminescent signal in the midsection and reduced levels in the 
head and pelvic regions. At day 21 post-transplant, the CX-5461 and combination-
treated groups still had minimal bioluminescent signal in the mid-section, whereas the 
disease had progressed in the head and pelvic areas, more in the combination-treated 
group. At day 28 post-transplant the bioluminescent signal in the head and pelvic areas 
had increased the remaining three mice of the CX-5461 only group, which were the 
only mice remaining of all four treatment regimes. Quantification of the 
bioluminescent imaging revealed that the orlistat-treated mice had significantly 
elevated total body bioluminescence (BLI) at 14 days post-transplant compared to the 
vehicle-treated groups, while the CX-5461 and combination-treated groups had a 
significantly lower BLI (Figure 4-4d). 
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The weights of the mice remained stable in all the treatment groups for the duration 
of the experiment, indicating the dosing regime was tolerable in tumour-bearing mice 
(Appendix Figure 4-1). 
 
 
Figure 4-4: Combination therapy of CX-5461 and orlistat does not improve survival in 
vivo in a syngeneic transplant model of MLL/AF9 NRAS AML 
Mice were transplanted with MLL/AF9 NRAS cells via the tail vein, imaged by 
bioluminescence to confirm engraftment at day 7 and therapy initiated. Mice were 
dosed with vehicle (50mM NaH2PO4), 240mg/kg orlistat daily, 35mg/kg CX-5461 
Monday, Wednesday, Friday, or the combination, until they reached an ethical 
endpoint. N= 5 mice/treatment group. A) Kaplan-Meier survival curves. Log-rank test 
with Bonferroni corrected threshold was applied for comparison of multiple survival 
curves, such that a P value of <0.0083 was considered significant. Key comparisons: * = 
significant compared to vehicle, # = significant compared to CX-5461. The grey area 
indicates the dosing period. B) Spleen weight at ethical endpoint. Mean weight ± SD 
shown. One-way ANOVA was performed with a Tukey’s multiple comparison test, the 
adjusted p-value is shown. NS P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 
0.0001. Compared to vehicle, unless indicated by a bar. C) Bioluminescent images. 
Imaging was performed weekly from 7 days post-transplant. The day 7 images are 
shown on a lower image colour scale to the subsequent weeks images, in order to 
show that engraftment has occurred. D) The total bioluminescence (BLI) of each 
mouse was quantified from the images. Mean BLI ± SD shown One-way ANOVA was 
performed with a Tukey’s multiple comparison test, the adjusted p-value is shown. 
Compared to vehicle, unless indicated by a bar. 
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MLL/AF9 NRAS: CX-5461 + orlistat 
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 CX-5461 + DCA 
Similarly to orlistat, DCA treatment alone did not alter survival compared to vehicle 
treatment (Figure 4-5a). Furthermore, DCA did not confer a survival advantage over 
30mg/kg CX-5461 treatment alone (20 days) or combination treatment (19.5 days). 
Note that as CX-5461 was administered at a lower dose in this experiment (30mg/kg, 
down from 35mg/kg) compared to the CX-5461 + orlistat experiment, (Figure 4-4) the 
survival advantage with CX-5461 treatment reduced from 12 to 5 extra days compared 
to the vehicle. This lower dose of CX-5461 was used to allow any effective 
combinations to be more apparent and reduce potential dosing side effects 
considering the extra burden that the tumour cells place on the mice, compared to the 
healthy mice used in the tolerability studies. 
 
The DCA treated mice had significantly smaller spleens at endpoint than the vehicle-
treated mice, (approximately 20% reduction, Figure 4-5b), and while there was no 
survival advantage, this indicates that DCA as a single agent was able to impact tumour 
burden in vivo, consistent with in vitro results (Figure 3-8). Both CX-5461 and the 
combination-treated mice had spleens that were the same weight as those of a non-
tumour bearing mouse. 
 
As with the previous experiment, the bioluminescent imaging shows that by day 14 
post-transplant the disease in the vehicle and the DCA treated mice had spread 
throughout the body, concentrating particularly in the mid-section (Appendix Figure 4-
2). However, in line with the spleen weights being significantly lower in the DCA 
treated mice, the disease levels in the mid-section were marginally lower compared to 
the vehicle. Figure 4-5c shows that at day 14 post-transplant the BLI of the vehicle and 
DCA treated mice did not differ, whereas the CX-5461 and combination-treated mice 
had significantly lower BLI than the vehicle and DCA treated mice. There was no 
significant difference between the BLI of the CX-5461 and combination-treated groups. 
There were not enough mice remaining at day 21 to perform robust statistical analysis 
comparing the BLI of the CX-5461 and combination-treated groups at this timepoint. 
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The majority of the mice maintained their weight for the duration of the experiment, 
with the exception of one mouse in the combination-treated group, indicating the 
dosing regimes were tolerable in tumour-bearing mice (Appendix Figure 4-3). 
 
Figure 4-5: Combination therapy with CX-5461 and DCA does not improve survival in 
vivo in a syngeneic transplant model of MLL/AF9 NRAS AML 
Mice were transplanted with MLL/AF9 NRAS cells via the tail vein, imaged by 
bioluminescence to confirm engraftment at day 7 and therapy initiated. Mice were 
dosed with vehicle (50mM NaH2PO4), 200mg/kg DCA daily Monday-Friday, 30mg/kg CX-
5461 Monday, Wednesday, Friday, or the combination, until reaching an ethical 
endpoint. N=8 mice/ treatment group. A) Kaplan-Meier survival curves. Log-rank test 
with Bonferroni corrected threshold was applied for comparison of multiple survival 
curves, such that a P value of <0.0083 was considered significant. Key comparisons: * = 
significant compared to vehicle. The grey area indicates the dosing period. B) Spleen 
weight at ethical endpoint. Mean weight ± SD shown. One-way ANOVA was performed 
with a Tukey’s multiple comparison test, the adjusted p-value is shown. NS P > 0.05, *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. Compared to vehicle, unless indicated by 
a bar. C) The total bioluminescence (BLI) of each mouse was quantified from the 
bioluminescent images (Appendix Figure 4-2). Mean BLI ± SD shown One-way ANOVA 
was performed with a Tukey’s multiple comparison test, the adjusted p-value is shown. 
Compared to vehicle, unless indicated by a bar. 
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MLL/AF9 NRAS: CX-5461 + DCA 
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 CX-5461 + chloroquine 
A dosing regime of 30mg/kg CX-5461 and 80mg/kg chloroquine was chosen in order to 
use the maximal concentrations of the drugs in the mice, however this was lowered to 
50mg/kg chloroquine when slight weight loss was observed by day 19. Figure 4-6a 
shows that chloroquine treatment alone did not alter survival compared to the vehicle-
treated mice (15 days compared to 14 days respectively). CX-5461 only treatment 
resulted in a 5 day survival advantage compared to the vehicle-treated mice (20 days) 
and the combination-treated mice extended this to 23 days post-transplant, a 
statistically significant 3 day survival advantage compared to the CX-5461 only group. 
 
The spleen weights of the vehicle and chloroquine treated groups were not 
significantly different at endpoint, neither were the CX-5461 and combination-treated 
groups (Figure 4-6b). Both the CX-5461 and combination-treated groups had spleens 
that were the same weight as a non-tumour bearing mouse and significantly smaller 
than both the vehicle and chloroquine groups. 
 
The bioluminescent imaging was comparable to the previous experiments, specifically 
by day 14 post-transplant the vehicle-treated mice had disease spread throughout the 
body but concentrated in the particularly in the mid-section, while the CX-5461 treated 
mice show no disease in the mid-section and minimal disease in the head (Appendix 
Figure 4-4). The bioluminescent patterning of the chloroquine treated group was 
similar to the vehicle group, whereas the combination-treated group was comparable 
to the CX-5461 group. This is consistent with the total BLI quantification (Figure 4-6c) 
with high BLI in the vehicle and chloroquine groups, and significantly lower BLI in the 
CX-5461 and combination-treated groups. 
 
The weight changes (Figure 4-6d) demonstrate that the vehicle, chloroquine and CX-
5461 as single-agent dosing regimes were tolerable, with the exception of one mouse 
in the CX-5461-treated group which lost more than 10% body weight at day 20. 
However, more than half of the combination-treated mice had lost 10% of their body 
weight by day 20 post-transplant. In response to this, the dose of chloroquine was 
dropped from 80 to 50mg/kg in an attempt to avoid further weight loss, however five 
of the mice continued to decline in weight and reached 20% weight loss, thus required 
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euthanasia. This pronounced weight loss indicates that the initial combination dosing 
regime used in this experiment was not well tolerated in tumour-bearing mice, thus a 
dosing regime of 50mg/kg chloroquine in combination with 30mg/kg CX-5461 from the 
beginning of dosing would be preferable. 
 
Interestingly, one of the toxic effects of combining CX-5461 and chloroquine was 
anaemia. Figure 4-6e illustrates the red cell parameters from a full blood count 
analysis of cardiac blood collected at the experiment ethical endpoint, with normal 
reference ranges for comparison. While the total number of red blood cells was in the 
normal range for the vehicle and CX-5461-treated mice, these were slightly elevated 
for the chloroquine treated mice and approximately half the lower limit of the normal 
range in the combination-treated mice, indicating anaemia. The same trend was 
observed for haemoglobin levels and the hematocrit. The mean corpuscular volume 
(MCV), or the average size of the red blood cells, followed the same trend as the 
number of red blood cells. Together these parameters suggest that the dosing regime 
of CX-5461 with chloroquine used in this experiment resulted in pronounced anaemia, 
which may explain the weight loss (Figure 4-6d). Although, it should be noted that the 
blood samples were not collected at the same timepoint post-transplant, and as such, 
there is a possibility that the additional time that the combination-treated mice were 
bearing the tumour cells contributed to the anaemia, in addition to the drugs 
administered. 
 
In conclusion, of the 3 combination therapies tested, the combination of CX-5461 and 
chloroquine was the only one that improved survival in the MLL/AF9 NRAS model 
compared to CX-5461 treatment alone. The synergy is clear, as chloroquine alone had 
no impact on survival compared to the vehicle-treated mice. However, profound 
weight loss and anaemia in the combination-treated group indicated that the 
treatment regime was not tolerated and requires optimising for future experiments. 
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Figure 4-6: Combination therapy with CX-5461 and chloroquine significantly improves 
survival in vivo in a syngeneic transplant model of MLL/AF9 NRAS AML 
Mice were transplanted with MLL/AF9 NRAS cells via the tail vein, imaged by 
bioluminescence to confirm engraftment at day 7 and therapy initiated. Mice were dosed 
with vehicle (50mM NaH2PO4), 80mg/kg chloroquine (CQ) daily Monday-Friday (dropped 
to 50mg/kg as of day 19), 30mg/kg CX-5461 Monday, Wednesday, Friday, or the 
combination, until reaching an ethical endpoint. N=8 mice/ treatment group. A) Kaplan-
Meier survival curves. Log-rank test with Bonferroni corrected threshold was applied for 
comparison of multiple survival curves, such that a P value of <0.0083 was considered 
significant. Key comparisons: * = significant compared to vehicle, # = significant 
compared to CX-5461.The grey area indicates the dosing period. B) Spleen weight at 
ethical endpoint. Mean weight ± SD shown. One-way ANOVA was performed with a 
Tukey’s multiple comparison test, the adjusted p-value is shown. NS P > 0.05, *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. Compared to vehicle, unless indicated by a 
bar. C) The total bioluminescence (BLI) of each mouse was quantified from the 
bioluminescent images (Appendix Figure 4-4). Mean BLI ± SD shown One-way ANOVA 
was performed with a Tukey’s multiple comparison test, the adjusted p-value is shown. 
Compared to vehicle, unless indicated by a bar. D) The weights of the mice were 
monitored daily during the dosing period and the weight changes as % of initial weight 
shown. Grey = dosing days. E) Full blood count analysis at ethical endpoint. Red blood cell 
count, haemoglobin levels, haematocrit and mean corpuscular volume (MCV) are shown. 
Grey areas indicate the average and reference ranges based off Charles River guidelines 
for C57Bl/6 females North American Colonies (January 2008 – December 2012). N=2-
5/group. 
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4.2.3 Creation of GFP-luc tagged human AML cell lines and 
characterising the disease model in vivo in NSG mice 
The synergism of CX-5461 and chloroquine was also tested in human cell line 
xenografts. In order to track the human leukaemia cell lines both in vivo by live-animal 
bioluminescent imaging and potentially ex vivo through flow cytometry, the cell lines 
were tagged with GFP and luciferase (described in Methods Section 2.9). In brief, 
retroviral particles containing the MSCV-GFP-luc2 construct were used to transduce 
the MV4-11, THP-1 and MOLM-13 human leukaemia cell lines through retroviral spin 
infection. The transduced cells were then identified by GFP positivity and cell sorted 
(results not shown), and the resulting cells named ‘(cell line) GFP luc’. 
 
In order to characterise the disease produced by these cells in vivo, a small cohort of 
immunocompromised NSG mice (which lack functional B, T and natural killer (NK) cells) 
were injected with 2 x 106 cells IV via the tail vein. For the THP-1 cells, the day before 
injection the mice were irradiated with 1Gy single dose (sub-lethal dose) in order to 
facilitate the engraftment of the leukaemia cells by disrupting the complex host bone 
marrow environment227 (irradiation has been shown to result in various changes to the 
bone marrow environment including cytokine release,228 229 and lymphodepletion in 
immunocompetent models 230). The other cell lines were injected without irradiation 
of the host mice. Health monitoring was performed daily and bioluminescent imaging 
was performed every 2 days (MOLM-13 GFP luc) or weekly ( THP-1 and MV4-11 GFP 
luc) to track the progression of the disease. This continued until an ethical endpoint 
was reached. The features of each of the xenograft models are summarised in Table 
4-2 and compared to those of the MLL/AF9 NRAS syngeneic model. 
 
Figure 4-7a shows the overall survival of the three models. The MOLM-13 GFP luc cells 
produced the most aggressive disease, with a median survival of 14 days post-
transplant, followed by the MV4-11 GFP luc cells at 22 days post-transplant. 
Interestingly, the MV4-11 GFP luc cells generated a more aggressive disease than that 
published in the literature, 36 days survival post-transplant for the same number of 
cell injected 33, which may be explained by genetic drift in either the MV4-11 GFP luc 
cell line or in the NSG mouse colony, or by selection of more aggressive clones during 
the transduction process. With the exception of one mouse which became unwell at 
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44 days post-transplant, the mice in the THP-1 GFP luc group remained well at 52 days 
post-transplant and the experiment was concluded, thus a true survival time was not 
established. 
 
Bioluminescent imaging (Figure 4-7c ) in the MOLM-13 GFP luc model indicated 
engraftment was faintly visible at day 3 post-transplant, and was well established at 
day 5 post-transplant, indicating that day 4 post-transplant would be an ideal 
timepoint to confirm engraftment and begin drug treatment. Over the next week of 
imaging, the bioluminescent signal in the upper body and hind limbs increased rapidly, 
appearing to disseminate more broadly by day 14. Since the literature reported that 
hind limb paralysis is a predominant feature of this model the prone (back) position 
was also imaged. Bioluminescent signals across and either side of the spine, indicating 
peripheral organ involvement, were visible from day 7 onwards, as well as in the skull, 
which is consistent with the literature 206. The average total BLI of the mice increased 
rapidly over the 14 day period, to a level higher than that observed in the THP-1 or 
MV4-11 GFP luc groups at day 7 and day 14 post-transplant (Figure 4-7d). In the 
MV4-11 GFP luc model, engraftment was visible in the hind limbs at 7 days 
post-transplant, increasing in intensity at 14 and 21 days post-transplant and spread to 
the midsection and front limbs. In the THP-1 GFP luc model bioluminescence was first 
detected in the pelvic region at 7 days post-transplant, spreading to more distal 
regions at day 14, and continuing to increase predominately in the pelvic and 
midsection regions over the next 3 weeks. The BLI was similar to the MV4-11 GFP luc 
group at day 7 and 14 post-transplant (but significantly less than the MOLM-13 GFP 
luc), however, it surpassed the maximum average BLI of the MOLM-13 GFP luc group 
(at day 14) when the mice reached day 28 post-transplant. 
 
The spleens of the MOLM-13 GFP luc and MV4-11 GFP luc-bearing mice were 
significantly enlarged to approximately four times the normal weight (Figure 4-7b), 
consistent with the literature 33. Splenomegaly was not observed in the THP-1 GFP luc 
model. The literature reports that the spleens of THP-1 bearing mice were 2-3 times 
normal size 208, however, these published experiments were conducted at 10 weeks 
post-transplant, it is possible that the spleens of the mice in this study may have been 
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larger if the experiment was continued for a further 3 weeks. What is clear from these 
results is that spleen enlargement is not an early occurrence in this model. 
 
 
 
Figure 4-7: Characterisation of human AML cell line xenograft models 
Mice were transplanted with 2 x 106 human AML cell line cells in the tail vein (following 1 
Gy single dose irradiation for the THP-1 GFP luc cells), Methods Section 2.6.2.2. General 
health was monitored daily and the mice were euthanised once an ethical endpoint was 
reached. N=5 for MV4-11 GFP luc, N= 6 for THP-1 GFP luc, N=3-4 mice/imaging day for 
MOLM-13 GFP luc. A) Kaplan Meier survival curves. B) Spleen weight at ethical endpoint, 
mean ± SD. The fold change from a normal NSG spleen shown. C) Bioluminescent imaging. 
Due to ethical requirements regarding the frequency of imaging, a cohort of mice was 
injected with the MOLM-13 GFP luc cells then divided into 3 groups which were imaged 
on different days. Due to hind limb paralysis observed in a pilot study, these mice were 
imaged both supine (face up) and prone (face down), in order to visualise the spine. 
Different image colour scales are used between and within the different cell lines. D) 
Quantification of total bioluminescence (BLI), prone measurements not included for 
MOLM-13 GFP luc. Not significant (NS) P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** 
P ≤ 0.0001. E) Weight changes as % initial weight. F) Images of enlarged organs at autopsy 
i) Liver of a THP-1 GFP luc injected mouse at 52 days post-transplant ii) Left (L) and right 
(R) ovaries of a MV4-11 GFP luc injected mouse at 22 days post-transplant, compared to 
the ovary of a non-tumour bearing NSG mouse of a similar age and weight iii) Ovaries and 
fallopian tubes of a MV4-11 GFP luc injected mouse at 22 days post-transplant. 
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The predominant features at endpoint varied between the three models. The 
dominant feature of the MOLM-13 GFP luc model was hind limb paralysis, which likely 
contributed to the rapid weight loss of 10-20% body weight over 1-2 days (Figure 4-7e) 
for which the mice required euthanasia. The development of hind limb paralysis is 
consistent with the reported literature 206, likely due to infiltration of cancer cells in 
the central nervous system and cord compression, as observed by a high 
bioluminescent signal around the spine (Figure 4-7b). All of the mice also had enlarged 
ovaries on one or both sides (consistent with the strong bioluminescent signal 
observed just below the midsection in the imaging, and sporadic lymph node 
enlargement, which are both reported features of this model 206,231. In the MV4-11 GFP 
luc model hind limb paralysis at the ethical endpoint was occasionally observed, which 
is a reported feature of the model 205 and explains the rapid weight loss at day 22 
(Figure 4-7e), as was ovary enlargement on one or both sides, which has not previously 
been reported. Interestingly, in the THP-1 GFP luc models the livers were massively 
enlarged due to the presence of numerous solid tumours (Figure 4-7f), explaining the 
strong bioluminescent signal from this area during imaging (Figure 4-7c), and the 
weights of the mice increasing during the course of the experiment, with two mice 
reaching more than 10% weight gain by day 52 (Figure 4-7e). The enlargement of the 
liver is a previously reported feature of this model207. Other features of this model 
included lymph node enlargement and tumours behind the eyes and under the skin, 
which have not previously been reported. Due to the irregularities of this model 
compared to other established AML transplant models, the THP-1 GFP luc model was 
not selected for further survival experiments. 
 
The predominant features of the four different orthotopic AML used in this thesis are 
summarised in Table 4-2. A comparison of the features of these AML transplant 
models to those of human AML patients is discussed in Section 4.3.3. 
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4.2.4 Treatment of human cell line xenografts 
As the most promising drug combination in the MLL/AF9 NRAS model, CX-5461 + 
chloroquine was tested in human cell line xenograft survival experiments using the 
MOLM-13 GFP luc and MV4-11 GFP luc models (Methods Section 2.6.2.2). Using the 
conditions previously established in the model characterisation experiments (Figure 
4-7) NSG mice were injected with 2 x 106 cells IV in the tail vein, then imaged at day 4 
Disease 
characteristics 
Orthotopic AML Transplant Models 
MLL/AF9 
NRAS 
MV4-11 THP-1 MOLM-13 
Syngeneic/xenograft Syngeneic Xenograft Xenograft Xenograft 
Mouse strain C57Bl/6 
(immune 
competent) 
NSG (immune 
deficient) 
NSG (immune 
deficient) 
NSG 
(immune 
deficient) 
Ethical endpoint 
reached (days post-
transplant) 
14 21 N/A 
(experiment 
terminated at 
52 days) 
14 
Spleen enlargement Yes Yes Subtle Yes 
Ovary enlargement No Yes, 
occasionally. 
No Yes, 
common. 
Lymph node 
enlargement 
No Yes, 
occasionally. 
Yes Yes 
Weight loss at 
endpoint 
No Yes. <10% of 
initial weight. 
No Yes. >10% of 
initial weight. 
Hind limb paralysis 
at endpoint 
No Yes, ~25% of 
mice. 
No Yes, all. 
Other features Enlarged liver.  Numerous 
solid tumours 
on liver. 
Tumours 
behind eyes 
and under the 
skin, 
occasionally. 
 
 
Table 4-2: Comparison of disease characteristics of orthotopic AML models 
Characteristics of each of the orthotopic AML transplant models were summarised from 
trial experiments to determine engraftment and survival time, and from vehicle-only 
treated mice from drug treatment experiments. NSG = NOD-Scid-gamma. 
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(MOLM-13 GFP luc cells) or day 7 (MV4-11 GFP luc cells) post-transplant to confirm 
tumour cell engraftment, randomised into treatment groups and dosing commenced. 
A modified dosing regime of 30mg/kg CX-5461 + 50mg/kg chloroquine was used in 
order to avoid the side effects observed in the MLL/AF9 NRAS experiment (Figure 4-6). 
As previously, “survival” was defined as the time post-transplant until the mice 
reached an ethical endpoint and required euthanasia due to symptoms such as weight 
loss, reluctance to move and hunching. Median survival times and subsequent 
statistical analysis of survival times are shown in Appendix Tables 4-1 and 4-2. 
 
 CX-5461 + chloroquine in MOLM-13 xenograft 
Chloroquine treatment at 50mg/kg did not improve survival compared to vehicle 
treatment, with a median survival time of 14 days post-transplant in both groups 
(Figure 4-8a). CX-5461 treatment at 30mg/kg improved survival significantly to 15 days 
post-transplant, as did combination treatment. There was no significant difference 
between the survival of the CX-5461 and combination-treated groups. 
 
The spleens of the vehicle-treated mice were enlarged (Figure 4-8b), which is 
consistent with Figure 4-7b. Chloroquine treatment did not significantly impact on 
spleen enlargement, whereas the spleens of CX-5461 and combination-treated mice 
were significantly smaller than the vehicle-treated mice, although still enlarged. The 
addition of chloroquine to CX-5461 treatment did not further reduce disease burden in 
the spleen. 
 
The bioluminescent imaging (Appendix Figure 4-5) shows disease patterns consistent 
with the characterisation experiment (Figure 4-6c). Quantification of the 
bioluminescent imaging showed that the total BLI (supine) of the treatment groups 
was similar, whereas the prone BLI of the chloroquine treated mice was significantly 
higher than the vehicle and the combination-treated groups (Figure 4-8d). The same 
trends in rapid weight loss from day 10 onwards were observed for all the treatment 
groups, likely due to the hind limb paralysis which is a previously confirmed feature of 
this model (Figure 4-8e), rather than toxicity of the drugs. 
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Figure 4-8: Combination therapy with CX-5461 and chloroquine does not improve 
survival in vivo in the MOLM-13 AML cell line xenograft model 
Mice were transplanted with MOLM-13 cells via the tail vein, imaged by bioluminescence 
to confirm engraftment at day 4 and therapy initiated. Mice were dosed with vehicle 
(50mM NaH2PO4), 50mg/kg chloroquine (CQ) daily Monday-Friday, 30mg/kg CX-5461 
Monday, Wednesday, Friday, or the combination, until reaching an ethical endpoint. N=8 
mice/treatment group. A) Kaplan-Meier survival curves. Log-rank test with Bonferroni 
corrected threshold was applied for comparison of multiple survival curves, such that a P 
value of <0.0083 was considered significant. Key comparisons: * = significant compared to 
vehicle. The grey area indicates the dosing period. B) Spleen weight at ethical endpoint. 
Mean weight ± SD shown. One-way ANOVA was performed with a Tukey’s multiple 
comparison test, the adjusted p-value is shown. NS P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001, **** P ≤ 0.0001. Compared to vehicle, unless indicated by a bar. C) The total 
bioluminescence (BLI) of each mouse was quantified from the bioluminescent images 
(Appendix Figure 4-5). Mean BLI ± SD shown. Issues with the background levels on day 4 
of imaging meant many of the mice had a negative BLI value, so quantification was not 
shown for this timepoint. One-way ANOVA was performed with a Tukey’s multiple 
comparison test, the adjusted p-value is shown. Compared to vehicle, unless indicated by 
a bar. D) The weights of the mice were monitored daily during the dosing period and the 
weight changes as % of initial weight shown. 
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 CX-5461 + chloroquine in MV4-11 xenograft 
 
In the MV4-11 GFP luc xenograft model the vehicle-treated mice had a median survival 
of 22 days post-transplant, consistent with the characterisation experiment (Figure 
4-7a), CX-5461 treatment or chloroquine treatment did not significantly change 
median survival (Figure 4-9a). Combination treatment resulted in a small, statistically 
significant survival advantage of 2-3 days over the other 3 groups, but this may not be 
biologically significant. 
 
The spleen weights of the vehicle-treated group (Figure 4-9b), as observed in Figure 
4-7b, and the chloroquine group were similarly enlarged. The CX-5461 treated mice 
had significantly smaller spleens than the vehicle mice, but this was not further 
decreased with the addition of chloroquine. 
 
The bioluminescent imaging (Appendix Figure 4-6) of the treatment groups over the 
course of the experiment was consistent with the characterisation experiment (Figure 
4-7). There was no significant difference in the BLI quantification (Figure 4-9c) between 
the groups at day 7, 14 and 21 post-transplant, although there is a large amount of 
variation in the vehicle and combination-treated groups at day 21 post-transplant. 
 
The weights of the mice remained quite stable, in fact increased in a number of cases, 
over the course of the experiment (Appendix Figure 4-7). The exceptions were spread 
across the different treatment groups, where rapid weight loss in a 1 day period was 
likely due to the development of hind limb paralysis. These weight results indicate that 
the treatment regimes were tolerated in this model. 
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Figure 4-9: Combination therapy with CX-5461 and chloroquine improves survival in 
vivo in the MV4-11 AML cell line xenograft model 
 
Mice were transplanted with MV4-11 cells via the tail vein, imaged by bioluminescence to 
confirm engraftment at day 4 and therapy initiated. Mice were dosed with vehicle (50mM 
NaH2PO4), 50mg/kg chloroquine daily Monday-Friday, 30mg/kg CX-5461 Monday, 
Wednesday, Friday, or the combination, until reaching an ethical endpoint. N=8 
mice/treatment group. A) Kaplan-Meier survival curves. Log-rank test with Bonferroni 
corrected threshold was applied for comparison of multiple survival curves, such that a P 
value of <0.0083 was considered significant. Key comparisons: * = significant compared 
to vehicle, # = significant compared to CX-5461. The grey area indicates the dosing 
period. B) Spleen weight at ethical endpoint. Mean weight ± SD shown. One-way ANOVA 
was performed with a Tukey’s multiple comparison test, the adjusted p-value is shown. 
NS P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. Compared to vehicle, 
unless indicated by a bar. C) The total bioluminescence (BLI) of each mouse was 
quantified from the bioluminescent images (Appendix Figure 4-6). Mean BLI ± SD shown. 
One-way ANOVA was performed with a Tukey’s multiple comparison test, the adjusted p-
value is shown. Compared to vehicle, unless indicated by a bar. NS = not significant. 
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MV4-11 xenograft: CX-5461 + Chloroquine 
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4.2.5 Summary of results 
Consistent with the literature, CX-5461 is effective in improving survival and reducing 
tumour burden in the spleen in the syngeneic MLL/AF9 NRAS model 1. In the human 
cell line xenograft models, CX-5461 resulted in limited or no survival advantage, 
however, it did significantly reduce tumour burden in the spleen. These results show 
that CX-5461 can target human AML cells in vivo, but requires adjustment to the 
dosing schedule or combination therapy to improve efficacy. Synergism between 
CX-5461 + chloroquine was shown in vivo, with combination therapy significantly 
improving survival in the MLL/AF9 NRAS and MV4-11 GFP luc models, however it did 
not reduce tumour burden in the spleen compared to CX-5461 alone. 
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4.3 Discussion 
4.3.1 Combination treatment outcomes 
 Combination treatment outcomes in the syngeneic model 
Three drug combinations were tested in the syngeneic MLL/AF9 NRAS model in order 
to determine if they provided a survival advantage compared to the individual drugs. 
The combination of CX-5461 plus orlistat (Figure 4-4) or DCA (Figure 4-5) did not alter 
survival compared to the single agents. However, the combination of CX-5461 with 
chloroquine significantly increased survival compared to the vehicle, chloroquine and 
CX-5461 alone (Figure 4-6). As a result, this drug combination was evaluated in human 
cell line xenograft models (Figure 4-8, Figure 4-9). 
 
This well-established MLL/AF9 NRAS model has benefits, but also limitations, 
compared to the human cell line xenograft models. Since the cells for the MLL/AF9 
NRAS model and the host mice are genetically matched the cells can be transplanted 
into an immune-competent host. This is important as immune cells are an integral part 
of the bone marrow microenvironment and play a role in attacking tumour cells 
(Section 4.1.1) so it is important to evaluate drug efficacy in this context. A limitation 
using this model specifically related to evaluating CX-5461 is that CX-5461 treatment 
as a single agent slows the growth of tumour cells in most areas of the mouse body 
except for the head region (Figure 4-4). This results in the mice eventually developing 
breathing difficulties for which they required euthanasia, despite minimal disease in 
the midsection including in vital organs such as the liver. Analysis of the location of the 
tumour cells revealed they are in the nasal passages, rather than the brain (Hein, 
unpublished), which may be due to medullary expansion of the turbinates, an area rich 
in lymphatics 232. Infiltration of AML cells in the nasal passage is not a reported feature 
of human disease. A comparison of the features of the MLL/AF9 NRAS model, and the 
human cell line xenograft models, with those of human AML patients is covered in 
Section 4.3.3. If the disease levels could be controlled in this region, the survival 
advantage with CX-5461 treatment would be greatly improved, however, none of the 
combination therapies tested in the MLL/AF9 NRAS model achieved this outcome. 
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There are several future experiments which could be conducted in this model. Due to 
time constraints tolerability testing of the combination of CX-5461 with ritonavir or 
omeprazole was not completed, and neither were the survival experiments to 
determine if these combination therapies improved survival of MLL/AF9 NRAS-bearing 
mice. Of the 3 drug combinations evaluated in the MLL/AF9 NRAS model, CX-5461 + 
chloroquine was the only one which resulted in a survival advantage (Figure 4-6). In 
order to evaluate the mechanism behind this survival advantage short term treatment 
experiments (for example a single dose of individual drugs or the combination for 6 h 
in mice 10 days post-transplant when tumour levels are high but the mice are not yet 
compromised) should be performed to determine the initial effects of the drugs on 
parameters such as cell cycle arrest, apoptosis and cell death, as well as on-target 
mechanisms of action of the drugs. 
 
 Combination treatment outcomes in the xenograft experiments 
The efficacy of CX-5461 with chloroquine was tested in 2 human AML xenograft 
models, the MOLM-13 GFP luc and MV4-11 GFP luc. Despite observing a robust 
synergistic effect of CX-5461 with chloroquine in vitro, this did not translate to 
improved survival in the MOLM-13 GFP luc model (Figure 4-8), however a small 
survival advantage was observed in the MV4-11 GFP luc model (Figure 4-9). This 
survival difference, while statistically significant, may not be biologically significant. 
 
To date there are no published accounts of CX-5461 or chloroquine being testing in 
MOLM-13 xenograft models. However, CX-5461 efficacy has been tested in an MV4-11 
xenograft model, where the cells were injected into the flank of the mouse 
(heterotopic) and tumour volume compared between mice dosed with either vehicle 
or CX-5461 at 125mg/kg week by intraperitoneal injection for 3 weeks. CX-5461 was 
found to significantly inhibit tumour growth by 3-fold compared to the vehicle-treated 
mice. This astounding result contrasts with the lack of efficacy of CX-5461 and CX-5461 
with chloroquine observed in this thesis (Figure 4-9). Several factors could account for 
this discrepancy. Firstly, the location of the tumour cells differs; in the orthotopic 
model it is possible the bone marrow microenvironment supports the AML cells so 
they are more drug-resistant (Section 4.1.1). Secondly, the dosing schedule and route 
of administration differs, specifically in the heterotopic model CX-5461 was 
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administered intraperitoneally, compared to orally in the orthotopic models, which 
can alter the accessibility of the drug to the tumour cells as the peritoneum is in close 
proximity to the flank. CX-5461 was also dosed at a higher dose of 125mg/kg/week, 
compared to the 30mg/kg 3 times a week used in these studies, which will affect the 
pharmacodynamics of the drug. Lastly, the strains of mice differed between the 
experiments. In the heterotopic model used immunocompromised athymic nude mice 
(CrTac:Ncr-Foxn1nu), compared to the NSG mice used in the orthotopic models. 
Athymic nude mice only lack functional T cells 233, whereas NSG mice lack functional B, 
T and NK cells 204. Thus, if an anti-tumour immune response is important for the 
efficacy of CX-5461 (further discussed in Section 4.3.6), this would be more impaired in 
the NSG mice compared to the nude mice. There are no published reports of 
chloroquine being tested in any MV4-11 xenograft models. 
 
While the combination of CX-5461 + chloroquine was not effective in either of these 
human cell line xenograft models tested, based on the in vitro experiments perhaps in 
vivo testing with the SKM-1 cell line, which demonstrated a robust combination effect 
(Figure 3-18) would be justified. In order to do so the SKM-1 cell line would require 
tagging with GFP and luciferase (as completed for the MV4-11, THP-1 and MOLM-13 
models, Methods Section 2.9) and disease characterisation, as in Figure 4-7. 
 
 Correlating drug treatments in vitro and in vivo 
The experiments in this chapter illustrated a discrepancy between the in vitro and in 
vivo results. The most obvious example was the strong combination effect of CX-5461 
with chloroquine in vitro in the MOLM-13 cell line, which was not observed using the 
MOLM-13 GFP luc model in vivo. Several factors could contribute to this inconsistency 
including the role of the bone marrow microenvironment on the AML cells and the 
drugs not reaching effective levels or combination ratios in vivo. 
 
As mentioned previously, in vivo studies, unlike in vitro studies, take into account the 
role of bone marrow microenvironment in the response of AML cells to drugs (Section 
4.1.1). It is possible that the bone marrow stroma is providing a permissive 
environment for the AML cells and affecting their sensitivity to the drugs. Thus 
perhaps a more accurate method of evaluating drug combinations in vitro would be 
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stromal co-culture experiments. Interestingly there have been studies demonstrating 
that co-culturing primary AML patient samples with stromal cells reduced their 
sensitivity to various inhibitors, including topoisomerase II and tyrosine kinase 
inhibitors, compared to standard culture conditions 234. 
 
Alternatively, the drugs did not reach optimal concentrations in vivo, as was achieved 
in vitro. The in vitro experiments provide a controlled environment with direct contact 
between the cells and the drugs. In vivo, the drugs undergo a more complicated route 
to the tumour cells, including the requirement for its absorption, possible protein 
binding in the bloodstream, drug metabolism and excretion by various methods, which 
can alter the drug concentration in the blood and various tissues 235. For example, 
MLL/AF9 NRAS cells were sensitive to DCA and chloroquine as a single agent in vitro 
(Figure 3-8) but not in vivo (Figure 4-5, Figure 4-6), perhaps these drugs are not 
reaching the tumour cells at a concentration to have an effect. In such a situation 
increasing the drug dose would be ideal, which is possible for DCA but not for 
chloroquine due to toxicity (Figure 4-3). Alternatively, the dosing schedule could be 
altered, such as increasing the frequency to achieve a higher or more sustained drug 
concentration in the body. In order to determine if the drugs reached the AML cells at 
an effective dose, a short term drug treatment experiment could be performed. 
Specifically, tumour-bearing mice would be treated with the drugs of interest for 3, 6, 
or 24 h and tumour cells harvested to detect drug levels by mass spectrometry, as well 
as perform on-target assays for the activity of the individual drugs. 
 
A third possibility is that the drugs are not reaching the optimal ratio in vivo for 
synergy. In the in vitro studies, the ratio of CX-5461 to the metabolism modifying 
agents was critical to observe synergy. However, for the in vivo studies, the maximum 
tolerated doses were utilised rather than a set ratio. For example, in the in vitro 
experiments, 1µM of CX-5461 was found to be highly synergistic with 5µM chloroquine 
(1:5 molar ratio), while for the in vivo experiments they were dosed at a molar ratio of 
approximately 1:1.7 or 1:2.7. In this case, CX-5461 should have potentially been used 
at a lower dose, in which case it is unlikely to be effective, based on unpublished 
observations by the laboratory. Alternatively, chloroquine should be used at a higher 
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dose, however experiments presented here showed this was not possible due to 
toxicity (Figure 4-3). 
 
Pharmacokinetic (PK) drug-drug interactions, where one drug modulates the 
absorption, distribution, metabolism, or excretion of another drug 236, could also play a 
role in the lack of combination efficacy in vivo, as well as toxicity. The PK drug-drug 
interactions of CX-5461 are, as of yet, not well known. PK analysis of the plasma of 
patients in the first-in-human, Phase I dose-escalation study of CX-5461 in advanced 
hematologic cancers suggests that CX-5461 undergoes enterohepatic recirculation 82. 
Specifically, the liver and the intestine cooperate to ‘recycle’ a drug for secondary 
absorption, results in increased drug exposure 237. Disruption of this process could 
account for the decrease in survival advantage observed in mice treated with the 
combination CX-5461 + orlistat, compared to CX-5461 alone in the MLL/AF9 model 
(Figure 4-4). If orlistat is affecting hepatic metabolism (this has not been established in 
the literature, as the normal route of orlistat intake is orally, with minimal systemic 
exposure), then the concentration and efficacy of CX-5461 could be reduced. 
 
The effects of the drugs on expression and activity of drug-metabolising enzymes in 
the liver must also be considered. The effects of CX-5461 administration on the 
expression and activity of drug-metabolising liver enzymes is not yet well-
characterised. Chloroquine has been shown to inhibit activity of the enzyme 
cytochrome P450 (CYP) 2D6 in humans, up to 18% after 7 daily doses of 250 mg 
chloroquine diphosphate 238. If the metabolism of CX-5461 is dependent on this 
enzyme, then administration of chloroquine could affect the metabolism of CX-5461. 
The major enzymes involved in metabolism of chloroquine to its main metabolite 
desethylchloroquine are CYP3A4/5 and CYP2C8 239, thus if CX-5461 affects the 
expression or activity of these enzymes then the metabolism of chloroquine could be 
affected. 
 
Drug-drug interaction studies between CX-5461 and the metabolism modifying agents 
will be required to determine if it is the pharmacokinetic interactions that are altering 
the efficacy of the combinations in vivo. 
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4.3.2 Importance of disease location over total tumour burden 
A prominent feature of the different AML models used was that the location of the 
disease, rather than the total tumour burden, was important for the survival time of 
the mice. For example, in the syngeneic MLL/AF9 NRAS experiments the CX-5461 
treated mice exhibited a higher total BLI at ethical endpoint compared to the vehicle-
treated mice (Figure 4-4). As outlined in Section 4.3.1.1, the reason that the CX-5461-
treated mice required euthanasia was due to the drug not reducing disease 
progression in the nasal passages, while still having efficacy in vital organs such as the 
liver. Another example is that the THP-1 GFP luc injected mice survived weeks longer 
than the MV4-11 and MOLM-13 GFP luc injected mice, despite having a higher total 
BLI (Figure 4-7). This indicates that the THP-1 GFP luc cells either do not expand as fast 
or do not cause as much damage to vital organs as the other cell lines. While the THP-1 
GFP luc cells are clearly highly associated with liver involvement, as is evident from the 
numerous lesions observed (Figure 4-7f), these were superficial and perhaps had 
minimal effects on liver function, whereas the MLL/AF9 NRAS cells mediated 
hepatomegaly without discrete lesions (Table 4-2). 
 
4.3.3 Characteristics of AML transplant mouse models and 
comparison to human AML 
A characterisation experiment was performed where the human AML cell lines were 
injected into NSG mice and the resulting disease monitored (Figure 4-7). The 
characteristics of each of the syngeneic and xenograft were compiled (Table 4-2) and 
compared to human AML symptoms in order to determine if the mouse models 
recapitulate the human disease. In particular, bone marrow involvement and the 
spread of the disease out of the bone (extramedullary disease) was investigated. 
 
 Bone marrow involvement 
Engraftment in the bone marrow, particularly of the hind limbs and sternum, was 
visible in all 4 in vivo models of AML used in these experiments (Figure 4-4-Figure 4-9), 
as early as 3-7 days post engraftment indicating the bone marrow is the major site of 
engraftment and proliferation of the AML cells. This is consistent with the bone 
marrow being the normal site in which AML cells are found in patients, with the 
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associated bone marrow microenvironment supporting their growth (Section 4.1.1). As 
all four transplant models feature bone marrow involvement they are consistent with 
the predominant feature of the human disease in this aspect. 
 
 Hind limb paralysis 
Hind limb paralysis was observed in all mice engrafted with MOLM-13 GFP luc cells and 
in some mice engrafted with the MV4-11 GFP luc cells (Table 4-2). A possible cause of 
this paralysis is infiltration of the cells into the central nervous system (CNS) or 
enlarged organs pressing on the spinal cord. For example, the enlarged ovaries which 
were observed in the MOLM-13 and MV4-11 models (Figure 4-7f) may be causing a 
pressure point on the spine, thus contributing to the limb paralysis. This could be 
tested by following the progression of disease in male mice injected with MOLM-13 
and MV4-11 GFP luc cells. 
 
In adult human patients, the involvement of the CNS is rare, less than 1% at initial 
diagnosis increasing to 3% at relapse 240. In paediatric AML cases, the incidence of CNS 
involvement is more common at 7-29% 241,242. Furthermore, paralysis as a feature of 
CNS involvement of AML is rare, with only a limited number of reported cases, of 
which all presented with solid AML tumours (further discussed in the next paragraph) 
compressing on the spine 243,244. While it might be considered that hind limb paralysis 
in the human AML xenograft mouse models is not highly representative of the human 
disease, it is likely to be due to extramedullary spread of the AML cells, which itself is a 
common feature of AML. 
 
 Solid tumours on the liver 
A striking feature of the THP-1 GFP luc model was the numerous solid tumours present 
on the liver (Figure 4-7f) which is a previously reported feature of this model 207. In 
patients, extramedullary AML (also known as chloroma) occurs in up to 24% of AML 
patients and primarily involves the lymph nodes, and to a lesser extent the spleen, 
liver, skin, gingiva and (as previously mentioned when discussing hind limb paralysis) 
the CNS 245. Around 5% of AML patients have extramedullary AML associated with the 
liver which is associated with a poorer prognosis 245. In paediatric AML cases, 
extramedullary disease is most common in the very young patients, with an incidence 
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of greater than 30% of cases in children 1-year-old or younger 246. The THP-1 cell line is 
derived from a 1-year-old patient with AML (Table 3-1), thus could explain why this 
particular model features multiple sites of extramedullary disease, including the liver, 
multiple lymph nodes throughout the body and in the spleen (Table 4-2), whereas the 
other cell lines, which are derived from older patients, feature this less predominately. 
Thus, the THP-1 xenograft model could be a useful model for paediatric AML with 
extramedullary disease. 
 
 Spleen enlargement 
Spleen enlargement was observed in all four orthotopic models; 3-4 times normal 
spleen weight in the MLL/AF9 NRAS, MOLM-13 GFP luc and MV4-11 GFP luc models 
and 1.3 times normal spleen weight in the THP-1 GFP luc model. Splenic 
extramedullary AML is the second most common accumulation of AML cells (after the 
lymph nodes), and is found in just over 7% of patients 245. Splenic involvement is a 
consistent feature in the mouse models used in these studies, and is representative of 
human disease. 
 
 Enlarged ovaries 
Enlarged ovaries were observed in the MOLM-13 and MV4-11 GFP luc models (Figure 
4-7f). As with limb paralysis, ovarian involvement of AML is rare in patients, with only a 
few reported cases, some even preceding the development of the standard AML 
phenotype blood and bone marrow disease 247. Thus, it would be interesting to 
determine if such tumours would develop in the testes of male mice injected with the 
same human AML cell lines. It is possible that female sex hormones such as oestrogen 
may play a role in the infiltration and growth of the AML cells in the reproductive 
organs, thus the ovary enlargement may be less pronounced in older female mice. 
 
 Summary of AML xenograft versus patient features 
The main characteristic of human AML, bone marrow involvement, occurs in all four 
models used in these studies. In addition, all four, but particularly the three human cell 
line xenograft models, show features of extramedullary spread, which is a common 
occurrence in AML. Alone these observations validate these models as consistent with 
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the main features of human AML, and can be considered useful as preclinical models 
to test potential treatments for human AML. 
 
4.3.4 Targeting AML in sanctuary sites 
As outlined in the previous section, extramedullary disease is a common feature of 
AML both in human patients and the mouse models used in these studies. This is 
clinically significant, as the CNS and gonads are considered sanctuary sites that is have 
chemical and immunological privilege 248 249 250. In order to target AML cells in these 
sites, agents capable of penetrating the blood:brain or gonad barrier must be utilised. 
 
CX-5461 does not cross the blood:brain barrier 251, however, second generation Pol I 
transcription inhibitors are currently in development that have improved blood:brain 
barrier penetrance, such as PMR-116 252. Whether second generation Pol I inhibitors 
like PMR-116 cross the gonad barrier is yet to be determined. Chloroquine crosses the 
blood:brain barrier 253, as does metformin 254 and DCA 255 256, however, it is not clear if 
these agents also penetrate the gonads. Utilising these metabolism-modifying agents 
in vivo with a second generation Pol I inhibitor that can penetrate the blood:brain 
barrier, such as PMR-116, could potentially result in greatly improved survival as the 
AML cells in some sanctuary sites will be accessible. 
 
4.3.5 Limitations of the disease measurements used in the 
survival experiments 
In order to compare the efficacy of the different drug treatments, various parameters 
were collected as a measure of disease burden in the mice, including overall survival, 
spleen weight, bioluminescent imaging and weight changes. However, these methods 
suffer from limitations which can impact on the interpretation of the outcomes of the 
experiments. Spleen weight is generally a robust measure of disease burden, however 
this can also be impacted by the presence of an infection 257, for example. The mice are 
housed in a pathogen-free environment and handled in sterile conditions (and the NSG 
mice were given antibiotics for the duration of the experiments) so this is unlikely to 
occur. The bioluminescent imaging could be influenced by injection errors with the 
luciferin. If the luciferin is injected into the fat pads, or internal organs, rather than the 
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peritoneum, this will influence its distribution through the body and thus affect the 
imaging results. The location of the tumour cells can also affect the imaging, 
specifically tumour cells closer to the skin will give a stronger bioluminescent signal 
than tumour cells that are deeper internally. This will also be relevant if a drug 
treatment changes the distribution of the tumour cells to, for example, move them 
closer to the skin of the mouse which would result in an apparent increase in total 
tumour burden. An example of this is orlistat treatment (Figure 4-4), which increased 
the total BLI of the mice compared to the vehicle, however this might have simply 
been due to the changed distribution of the leukaemia cells to the periphery. Overall 
survival was defined as the time taken post-transplant until the mice reached an 
ethical endpoint based on symptoms such as weight loss, reluctance to move and 
hunching. This ethical endpoint does present a source of human error as the severity 
of the symptoms being displayed by the mice, and whether these are significant 
enough to require euthanasia, can be subjective. In order to remove as much of this 
subjectivity as possible, a clear mouse symptom scoring sheet was utilised in all mouse 
experiments and observations were made by the same person. 
 
For these reasons, the results of the various measures of disease burden were 
considered in order to draw conclusions about the efficacy of the drug treatments. Of 
the disease measurements, weight changes are considered the most robust and 
accurate, as they reflect the health of the mouse and thus disease burden. 
 
4.3.6 Differences in the outcomes of the syngeneic and xenograft 
models 
Despite the combination of CX-5461 + chloroquine demonstrating synergy in vitro in 
the MLL/AF9 NRAS, MOLM-13 and MV4-11 cell lines, the survival advantage in vivo 
was less robust and significant only in two models. Surprisingly, there was no survival 
advantage in MOLM-13 GFP luc model (Figure 4-8), despite this cell line having the 
strongest combination effect in vitro (Figure 3-12). Clearly there is a discrepancy 
between the efficacy of this drug combination between the syngeneic and human cell 
line xenograft models, where the combination effect appears to be improved from in 
vitro to in vivo in the syngeneic model, and the combination effect is much less 
pronounced in the human cell line xenograft models. A possible reason for the 
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differences in efficacy of CX-5461 + chloroquine between the different types of models 
is the absence of an immune response in NSG mice, while the C57Bl/6 mice used in the 
MLL/AF9 NRAS experiments have an intact immune system. In particular, T cells are 
important for an anti-tumour response, thus a higher level of T cells, as well as 
lymphocytes and NK cells, in the bone marrow of AML patients is associated with an 
improved outcome for patients 258. It is possible that in vivo the efficacy of CX-5461 
and/or chloroquine is also dependent on this anti-tumour immune response. An 
experiment to address this would be to inject the MLL/AF9 NRAS cells into NSG mice, 
and evaluate the combination of CX-5461 + chloroquine with respect to survival. If the 
combination was less effective in the same cells in the NSG mice compared to the 
C57Bl/6 mice, this would support the need for an intact immune system for this 
response. Thus using a humanised mouse model, such as implanting human 
mesenchymal stem cells to create a humanised bone marrow niche 259, would be 
required to test the drug combination in human cell line xenografts experiments or for 
the engraftment of primary AML patient samples. 
 
As outlined in Section 4.3.1.3, enterohepatic recirculation of CX-5461 has been 
indicated to occur in patients 82. Interestingly, intestinal bacteria are known to play a 
key role in the process of enterohepatic recirculation 237. It is possible that the 
antibiotic treatment used in the immunocompromised mice in the human cell line 
xenograft models (Methods Section 2.6.2.2) compromises the gut microflora, resulting 
in decreased exposure to CX-5461, and thus reduced efficacy in the xenograft models 
compared to the syngeneic model. As the antibiotic is provided continuously in the 
drinking water, supplementation with probiotics would not be feasible in these 
models. 
 
4.3.7 Outcomes of tolerability testing and limitations of the 
approach 
In order to evaluate the promising combination therapies identified in vitro (Chapter 3) 
in in vivo transplant models of AML, tolerability testing of the metabolism-modifying 
drugs was performed first in non-tumour bearing mice (Figure 4-2, Figure 4-3). 
Tolerable doses of the drugs as single agents or in combination with CX-5461 were 
identified for all of the promising drugs and evaluated in survival experiments. In the 
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case of CX-5461 with orlistat (Figure 4-4) and CX-5461 with DCA (Figure 4-5) these 
dosing regimes were also tolerated in MLL/AF9 NRAS tumour bearing mice, as 
indicated by no significant weight loss during the course of the experiment. However, 
treatment with CX-5461 + chloroquine (Figure 4-6) was not tolerated over the course 
of the experiments and thus lower doses were used when tested in the human AML 
cell line xenograft experiments. This highlights the limitation of tolerability testing in 
non-tumour bearing mice as it does not always completely predict the tolerability of 
the drugs in tumour bearing mice as tumour cells place additional burdens on the mice 
which can lower their tolerability to the drugs 260. 
 
4.3.8 Concluding remarks 
CX-5461 + chloroquine was confirmed as a combination therapy of interest based on 
the survival results in the MLL/AF9 NRAS model, and to a lesser extent the MV4-11 
GFP luc xenograft model. However, it is possible that chloroquine levels were not 
sufficient in vivo to have efficacy. In order to understand why CX-5461 + chloroquine 
act synergistically, and therefore identify alternative, more potent drugs which could 
be utilised instead of chloroquine to improve the effects of CX-5461, mechanistic 
analysis was performed (Chapter 5). 
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Chapter 5 Determining the 
mechanisms of synergy between CX-
5461 and chloroquine 
 
5.1  Introduction 
Previous in vitro experiments identified the metabolism-modifying agent chloroquine 
as acting synergistically with CX-5461 to reduce AML cell viability in 6 genetically 
different cell lines (Chapter 3). This drug combination was also tested using in vivo 
orthotopic transplant models of AML (Chapter 4). The combination of CX-5461 + 
chloroquine resulted in a statistically significant improvement in survival in the 
syngeneic MLL/AF9 NRAS model and the MV4-11 GFP luc xenograft model, but not the 
MOLM-13 GFP luc model despite the drug combination having a robust synergistic 
effect in this cell line in vitro. It is possible that in vivo the dose of chloroquine the AML 
cells was exposed to was not high enough to have efficacy. This is based on the 
observation that the dose of chloroquine administered in the in vivo experiments was 
limited by toxicity in combination with CX-5461, consequently, this limits the clinical 
potential of this drug combination in humans. However, by understanding the 
mechanisms by which CX-5461 + chloroquine were acting synergistically, may uncover 
other suitable targets and clinically relevant drugs that may not be as toxic. 
 
The following chapter addresses Aim 3: ‘Investigate the mechanism/s of synergy for 
promising drug combinations’. Given the published effects of CX-5461 and chloroquine 
as individual agents, mechanistic and end-point analysis was performed to determine 
how the drugs act synergistically together. 
 
5.1.1 Reported effects of CX-5461 
 Background 
As outlined in Section 1.2.3, CX-5461 was identified as a potential cancer therapeutic in 
a screen for inhibitors of rRNA synthesis 81 and has since shown efficacy in a variety of 
different blood 1,78 and solid cancers 81,83,84 in vitro and in vivo, leading to the 
commencement of clinical trials. CX-5461 is a potent and selective inhibitor of rDNA 
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transcription that can act within 30 minutes of treatment through disruption of the 
interaction between SL-1 and Pol I81. Interestingly, while CX-5461 exhibits similar 
efficacy on rDNA transcription initiation in both non-malignant and malignant cells, 
non-malignant cells are approximately 30 times less sensitive to CX-5461 in terms of 
viability, highlighting the addiction of malignant cells to rDNA transcription 81. 
Depending on the cancer type and underlying genetics, the downstream effects of Pol I 
inhibition by CX-5461 varies. 
 
 Cell cycle arrest, apoptosis, cell death and senescence 
CX-5461 has been reported to induce cell cycle arrest, apoptosis and/or senescence in 
various cancer types. For example, in the lung cancer cell line A375 and pancreatic 
cancer cell line MIA PaCa-2, CX-5461 induces autophagic cell death (a mechanism of 
programmed cell death) and cellular senescence but not apoptosis or necrotic cell 
death 81. Alternatively, in the Eµ-Myc mouse lymphoma cell model rapid 
p53-dependent apoptotic cell death is induced 78. CX-5461 also mediates apoptosis 
and G2/M cell cycle accumulation in acute lymphoblastic leukaemia (ALL) cell lines and 
patient samples in vitro, independent of p53 status 261. Cell cycle progression defects 
were also reported in AML cells within 24 h of CX-5461 treatment, predominately 
G2/M phase accumulation 1. 
 
 Activation of the nucleolar stress response 
CX-5461 acts on rDNA transcription which occurs in the nucleolus. Historically known 
as the site of ribosome biogenesis, the nucleolus has more recently been recognised as 
a sensor of cellular stress (reviewed in 262). In response to perturbations of ribosome 
biogenesis and nucleolar disruption, mediated by inhibition of Pol I transcription by 
Cx5461 treatment or inactivation of UBF 263 or TIF-1A 264, p53 levels are elevated 
leading to cell cycle arrest or apoptosis. Under normal growth conditions, p53 is bound 
and inactivated by MDM2, promoting the rapid degradation of p53 265. In response to 
certain stresses there is excess ribosomal proteins in the cell results in the 
accumulation of the RPL5/L11/5S ribonucleolar protein (5SRNP) complex, that can bind 
and sequester MDM2, resulting in increased levels of p53 266. This activation of the 
nucleolar stress response was observed in Eµ-Myc lymphoma cells, with low doses of 
CX-5461, in as little as 1 hour of treatment78. Similarly, in mouse and human AML cells 
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accumulation of p53 and phosphorylated p53 can be observed as early as 1 hour after 
CX-5461 treatment1. 
 
 Activation of ATM/ATR signalling 
As outlined in Section 5.1.1.2, cell cycle progression defects are observed in a variety 
of cancer types following CX-5461 treatment, and this often correlated often with 
activation of known components of the DNA damage pathway. For example, in acute 
lymphoblastic leukaemia cells, 24 hour treatment with CX-5461 induced ATM/ATR 
signalling, as assessed by phosphorylation of Chk1 and Chk2 261. Whereas 
phosphorylation of Chk1 and Chk2 occurred rapidly (1 hour) in AML cells in vitro 1. 
Typically DNA damage is required to activate the kinases ataxia-telangiectasia mutated 
(ATM) and ATM and Rad 3-related (ATR), these mediate a signalling cascade through 
cell cycle checkpoints, such as p53-dependent activation of Chk1 (ATR mediated) and 
Chk2 (ATM-mediated) resulting in cell cycle arrest so the DNA can be repaired or 
apoptosis 267.  
 
Interestingly, in the case of CX-5461 treatment of immortalised human fibroblast cells, 
there is no global DNA damage, thus the pathway activated has been described as 
‘DNA damage-like’ signalling 268. The proposed mechanism by which CX-5461 induces 
this DNA damage-like signalling is due to the reduction of Pol I binding to the rDNA 
promoter and transcribed regions, resulting in ‘exposed’ regions of rDNA repeats in 
open conformation stably bound by UBF, the abnormal configuration of which is 
hypothesised to induced DNA damage signalling in the absence of DNA damage 268. 
 
 Effects on the mitochondria 
There is no published literature evaluating any direct effects of CX-5461 on the 
mitochondria. However, from collaborations with the Pearson Lab (Kusnadi et al. Peter 
MacCallum Cancer Centre), we know that lymphoma cells with acquired resistance to 
the combination of CX-5461 and everolimus (mTORC1/mRNA translation inhibitor) are 
significantly more metabolically active compared to drug naïve cells, particularly in 
terms of their baseline mitochondrial activity 269. These results suggest that elevated 
mitochondrial activity is a resistance mechanism to the dual targeting of ribosome 
biogenesis and function in lymphoma cells, however, it remains to be determined such 
effects on mitochondria would also be observed in AML or normal cells. Unpublished 
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work in our laboratory has demonstrated that acute CX-5461 treatment of mouse AML 
cells in vivo alters the mRNA abundance of numerous metabolic genes including the 
upregulation of transcription of enzymes involved in fatty acid and cholesterol 
synthesis (Figure 1-5), suggesting that CX-5461 treatment alone may induce functional 
changes in the mitochondria. 
 
 Summary 
In summary, the reported effects of CX-5461 mediated Pol I transcription inhibition 
include cell cycle arrest, apoptosis and or/senescence, activation of the nucleolar 
stress response and DNA damage-like signalling, depending on the cell type. Direct or 
indirect effects of CX-5461 on mitochondrial activity have not as yet been published, 
however, our laboratory has unpublished data suggesting this occurs. 
 
5.1.2 Reported effects of chloroquine 
 Background 
As briefly outlined in Section 3.1.2.3 chloroquine, a synthetic 4-aminoquinoline 
molecule, has a long history of use in humans as an anti-malarial drug270. Chloroquine, 
a weakly basic molecule, accumulates in a pH-dependent manner in the acidic food 
vacuoles of the malarial parasite 271, affecting the pH and function of the food vacuole 
272, thus leading to toxic accumulation of heme, a by-product of haemoglobin 
degradation 273,274. Other than nausea, vomiting and diarrhoea, the most serious, 
although uncommon, side effect of chloroquine treatment is permanent retinal 
toxicity, that is associated with long-term use 275. Hydroxychloroquine is a derivative of 
chloroquine that is currently used in the clinic and has a reduced risk of retinal toxicity 
275,276. Both chloroquine and hydroxychloroquine have been approved for clinical use 
in rheumatoid arthritis 139,277,278 and lupus 279,280 due to immune-modulatory 
capabilities through affecting auto-antigen processing in antigen-presenting cells 281, 
inhibiting T cell proliferation 282 and inhibiting NK cell activity 283. 
 
During the decades of clinical use of chloroquine, various mechanisms of action have 
been identified including autophagy inhibition, DNA intercalation, ATM activation, 
mitochondrial effects, modulation of lysosomal nutrient signalling, cell cycle arrest, 
apoptosis and cell death. 
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 Inhibition of autophagy 
5.1.2.2.1 Overview of autophagy 
 
A well-studied mechanism of action of chloroquine is that of autophagy inhibition. 
Macroautophagy (hereafter referred to as autophagy) is a conserved intracellular 
recycling process by which cellular material such as damaged organelles and misfolded 
proteins are degraded in double-membrane-bound structures, then the nutrient and 
metabolites are released back to the cell. The process of autophagy is multi-step with 
many players involved, including autophagy-related proteins (ATGs, Figure 5-1).  
 
 
Figure 5-1: Overview of the process of autophagy 
Nutrient sensor mammalian target of rapamycin (mTOR) acts as a negative regulator of 
autophagy in nutrient rich conditions, while in stress conditions the activity of mTOR is 
inhibited and autophagy is induced. Autophagy begins with the formation of an isolation 
membrane or phagophore. Initiation (or nucleation) of the phagophore begins when the 
Beclin-1 (ATG6) complex is activated. Following the nucleation of the phagophore the 
membrane is elongated, requiring the incorporation of phosphatidylethanolamine-
lipidated microtubule-associated protein 1B-light chain 3 (LC3B-II/ATG8), which is formed 
when the cytosolic LC3-I is conjugated to phosphatidylethanolamine (PE), requiring ATG7. 
Adaptor proteins such as p62 guide cargo for degradation to the phagophore through 
interactions with LC3-II. The membrane of the phagophore eventually fuses around the 
cargo, forming an autophagosome. The phagophore then fuses with lysosomes containing 
degradative enzymes to form an autolysosome, and the contents are subsequently 
degraded. P62 and LC3B-II on the inner membrane are also degraded. Chloroquine and 
bafilomycin A1 interfere with lysosomal function, preventing the fusion of 
autophagosomes and lysosomes. 
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Autophagy reduces oxidative stress as dysfunctional mitochondria, a major source of 
reactive oxygen species (ROS), are removed, thus reducing ROS-induced genomic 
instability 102. Under stress conditions, such as nutrient deprivation, autophagy rates 
increase in order to provide the cell with nutrients and the building blocks required to 
cope with the stress 101. If the stress in the cell reaches an unacceptable level then 
programmed cell death via degradation of essential cell components (autophagic cell 
death) can occur 284. Chloroquine inhibits autophagy through interfering with 
lysosomal function, in a similar mechanism to the food vacuole of the malaria parasite, 
thus preventing the fusion of lysosomes with autophagosomes 143. 
 
5.1.2.2.2 Dual role of autophagy in cancer 
 
In the context of cancer cells, there is evidence for both tumour suppressive and 
tumour permissive effects of autophagy, depending on the cancer type and cellular 
assault. 
 
A reduced rate of autophagy mediates an increase in the number of damaged 
organelles 111, increasing ROS levels 112, genome instability 102 and inflammation 113, 
which creates a tumour permissive environment, both for the initiation and 
progression of cancer. Allelic loss of autophagy gene Beclin 1, which plays a critical role 
in the initiation stage of autophagy (Figure 5-1), has been reported in 40–75% of 
sporadic ovarian and breast cancers 285 and its expression is significantly reduced in 
human brain tumours, which is correlated with a higher disease grade 286. In mice, 
heterozygous deletion of Beclin 1 (homozygous deletion is embryonic lethal) renders 
mice more prone to mammary hyperplasia, lung cancer, liver cancer and lymphoma 
287,288. 
 
However, autophagy has also been reported to have a pro-survival role in many 
cancers, where it acts to help the cell cope with metabolic stresses, for example, 
increased stress accompanying a high metabolic rate, hypoxia and response to 
chemotherapy. In hepatocellular carcinoma 289 290 and pancreatic cell lines 289, 
treatment with standard chemotherapeutics have been reported to induce autophagy, 
and genetic or chemical inhibition of autophagy has been shown to synergise with 
chemotherapy in vitro and in vivo 290. 
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In AML the role of autophagy is not straightforward. Heterozygous loss of ATG5 in an 
MLL/ENL AML model mediated increased proliferation in vitro and decreased survival 
of transplanted mice in vivo 114. Decreased expression of autophagy-related genes, 
including through hemizygous deletion in some cases, and reduced autophagic flux as 
assessed by imaging flow cytometry was also reported in AML patient bone marrow 
samples 114. Autophagy has also been reported to promote chemoresistance in AML. In 
human AML cell lines and patient samples treatment with cytarabine, autophagy was 
induced through inactivation of mTOR, and chemical inhibition of autophagy with 
bafilomycin or chloroquine, or knockdown of autophagy-related proteins sensitised 
the cells to the effects of cytarabine by increasing oxidative stress, DNA fragmentation, 
caspase activation and apoptosis 291. Cytoprotective autophagy has also been shown to 
play a role in the maintenance of leukemic stem cells, with inactivation of autophagy 
by Atg5 or Atg7 knockout resulting in a reduction of leukemic stem cells and prolonged 
survival in an MLL-ENL mouse model 115. The role of autophagy in AML cells in the 
context of CX-5461 treatment remains to be determined. 
 
5.1.2.2.3 Studying autophagy: knockdown approach 
 
As outlined previously in Section 5.1.2.2.1, there are many ATGs which are critical for 
the process of autophagy. In order to study the combined effects of ribosome 
biogenesis inhibition (with CX-5461) and autophagy inhibition, the two ATGs Beclin1 
and ATG7 (Figure 5-1) were selected to be targeted using an inducible shRNA 
knockdown approach. Beclin1 (or ATG6) induces autophagy through the formation of 
the Beclin1-Vps34-Vps15 core complex, leading to the nucleation of the phagophore 
292, and control of crosstalk between autophagy and apoptosis through caspase-
mediated cleavage 293. Whereas ATG7, along with ATG3 and ATG12-ATG5-ATG16L 
multimers, are involved in the conjugation of a phosphatidylethanolamine (PE) moiety 
to LC3-I, forming LC3-II which subsequently integrates into the forming 
autophagosome 294. In the literature both Beclin and ATg7 have been successfully 
targeted with an shRNA approach. 
 
Significant knockdown of Beclin 1 protein has been reported in sarcoma cells 
(approximately 50% knockdown, 295) and the ipsilateral thalamus of rats 
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(approximately 80% knockdown, 296). In liver cancer cell line Huh7, 60% knockdown of 
ATG7 protein was achieved in 48 h using shRNA 297 and up to 90% in human CD34+ 
hematopoietic stem-progenitor cells 298. Thus genetic knockdown of Beclin 1 and ATG7 
is an achievable approach and in this thesis an inducible shRNA knockdown approach 
was selected. This was based on the observation that constitutive knockdown or 
knockout of autophagy genes can mediate compensatory mechanisms in the cell over 
time, which would make the results difficult to interpret 181. 
 
 DNA intercalation, changing chromatin structure and ATM activation 
It has been recognised for decades that chloroquine can mediate its effects as a DNA 
intercalator and thus alter chromatin structure. In a cell-free assay, chloroquine 
reversibly binds calf thymus DNA, with stronger binding to purines 299. In nuclei or DNA 
isolated from CV-1 (monkey kidney cell line), chloroquine intercalated almost 
exclusively to the DNA of the nucleosomal linker regions without affecting nucleosome 
structure 300 at concentrations of 3mM or higher, but not at 400 or 800µM. Whereas in 
studies using intact human K562 (erthyroleukaemia) cells, chloroquine intercalated 
with the DNA of nucleosomal linker regions at concentrations as low as 600µM, again 
without disruption of the nucleosomes themselves, however this did significantly 
affect folding of high order chromatin structures 176. Subsequently, chloroquine has 
been reported to activate ATM signalling without causing DNA damage (as indicated by 
the lack of increased gamma H2AX signal), both in vitro 301 and in vivo 302, improving 
survival in response to lethal low dose radiation through activation of DNA damage 
repair pathways. 
 
 Effects on mitochondria 
Chloroquine not only inhibits autophagy, but can inhibit mitophagy, a subset of 
autophagy specifically involved in the clearance of dysfunctional mitochondria, thus 
dysfunctional mitochondrial accumulate and ROS increases 303. In other studies, 
chloroquine is reported to have direct effects on mitochondria function. In primary rat 
neurons, chloroquine and an alternative autophagy inhibitor bafilomycin A1, not only 
reduced mitochondrial quality but modified mitochondrial function 111. In these cells, 
24 hours treatment with chloroquine or bafilomycin did not change mitochondrial 
number although mitochondrial bioenergetics were reduced including basal 
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respiration, maximal respiration and spare respiratory capacity, and also reduced the 
activity of complexes I, II and IV. Metabolomic analysis revealed a significant decrease 
in Krebs cycle intermediates and an increase in mitochondrial DNA damage. However, 
in this same study, acute (30 minutes) treatment with chloroquine did not alter 
mitochondrial respiration, thus it is not conclusive as to if the mitochondrial effects 
mediated by chloroquine are direct, or an indirect effect of autophagy inhibition. 
 
 Effects on lysosomal function and nutrient signalling 
As previously outlined in Section 5.1.2.2, chloroquine acts an autophagy inhibitor via 
raising the lysosomal pH and inducing lysosomal dysfunction. However, the cellular 
effects of this drug is not just limited to inhibiting autophagy. Previously thought to 
simply be a site for degradation the lysosome has more recently been recognised as a 
subcellular structure that plays a key role in multiple processes including nutrient 
signalling. mTOR complex 1 (mTORC1), which regulates cell growth through 
modulating processes such as autophagy 304, mitochondrial biogenesis 305,306 and 
nucleotide biosynthesis 307, localises to the lysosomal membrane 308. Here it is 
activated by amino acid levels, including through a sensing mechanism involving the 
proton pump vacuolar H+-ATPase 309 and lysosomal amino acid transporter SLC38A9 
310. In this manner, the lysosome acts as a hub for nutrient homeostasis and thus 
inhibition of lysosomal function with chloroquine has the potential to impact on 
multiple metabolic processes. 
 
 Cell cycle arrest, apoptosis, and cell death 
In the breast cancer cell line Bcap-37, 16µM chloroquine treatment for 48 h resulted in 
a significant G2/M arrest and elevated expression of apoptotic markers 311. Whereas 
200nM chloroquine induced G2/M phase cell cycle arrest and apoptosis in pancreatic 
cell lines in vitro 312. In the NB4 cell line (an acute promyelocytic AML cell line) 10µM 
chloroquine induced apoptosis significantly within 48 hours147 and an S phase arrest, 
concomitant with a reduction in the S phase cell cycle regulators cell division cycle 25 A 
(CDC25A) and cyclin-dependent kinase 2 (CDK2). 
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5.1.3 Potential mechanisms of synergy 
As outlined in Sections 5.1.1 and 5.1.2 there are multiple known mechanisms of action 
and consequences for CX-5461 and chloroquine treatment as single agents, and 
interestingly, some of these overlap between the two drugs (Figure 5-2). Potentially, 
the overlapping mechanisms of action and consequences of exposure may mediate an 
enhanced effect when the drugs are used in combination (i.e. synergy). Alternatively, 
the individual effects of the drugs alone may mediate an elevation of cellular stress, 
thus affecting viability. In this thesis the potential mechanisms of synergy that were 
assessed included inhibition of autophagy and altering mitochondrial activity or 
quality, with synergy being assessed via the endpoints of cell cycle arrest and cell 
death. 
 
 
  
 
Figure 5-2: Potential mechanisms of synergy between CX-5461 and chloroquine 
There are several reported processes altered by CX-5461 and chloroquine that could 
account for their synergistic action as a drug combination, including mechanisms of 
action of the drugs and endpoints of exposure to the drugs. Some, like cell cycle arrest, 
are altered by both drugs alone which could be enhanced when combined. Other effects 
are unique and in response to the drug combination these effects may combine to cause 
high levels of cellular stress, thus alter viability. Potential mechanisms of synergy that 
were investigated in this chapter are shown in red. 
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5.2 Results 
5.2.1 Cell cycle and cell death analysis 
Based on the literature demonstrating that CX-5461 exposure results in endpoints of 
cell cycle arrest and cell death in AML cell lines 1, and that chloroquine causes S phases 
arrest in the NB4 AML cell line 147, it was hypothesised that CX-5461 and chloroquine 
act synergistically via an enhancement of their effects on cell cycle arrest and cell 
death. To test this hypothesis, MV4-11, THP-1, MOLM-13 and MLL/AF9 cells were 
treated with vehicle, CX-5461, chloroquine or the drugs in combination for 24, 48 and 
72 h, then pulsed with BrdU to label newly synthesised DNA, and cell cycle or cell 
death analysed by determining DNA content and BrdU signal (Section 2.7). The 
proportion of cells in sub G1, G0/G1, S and G2/M phases are shown (Figure 5-3), with 
the sub G1 population considered to be indicative of “dead” or non-viable cells 
(including apoptotic cells) 124. 
 
The percentage of cells in the various cell cycle phases differed significantly between 
the cell lines treated with vehicle, ranging from 19% to almost 50% of cells in S phase 
(actively dividing; Figure 5-3). Chloroquine treatment did not alter the cell cycle 
distribution for any of the four cell lines, whereas CX-5461 treatment induced a G0/G1 
cell cycle arrest in 3 cell lines (MV4-11, MOLM-13 and MLL/AF9 NRAS cells) and an S 
phase delay followed by a G2/M arrest in the THP-1 cell line. This disruption in cell 
cycle progression in dividing cells following CX-5461 treatment is consistent with the 
literature findings 1. In the MOLM-13 cell line, CX-5461 treatment almost completely 
prevented cells from actively dividing, which was consistent with the plateaued dose-
response curve of CX-5461 as a single agent (Figure 3-6). Despite chloroquine not 
altering the cell cycle as a single agent, chloroquine synergised with CX-5461 to 
enhance its effects on the cell cycle, specifically by further reducing the S phase 
population in the MV4-11, MOLM-13 and MLL/AF9 NRAS cells, and also by enhancing 
the G2/M phase arrest and reduced S phase population in the THP-1 cells. 
 
Sub G1 analysis (Figure 5-3) revealed that as single agents, chloroquine treatment did 
not alter the percentage of dead cells compared to vehicle treatment, whereas CX-
5461 treatment induced cell death in the MV4-11, MOLM-13, and MLL/AF9 NRAS cells, 
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but not the THP-1 cells, consistent with the insensitivity of THP-1 cells to CX-5461 in 
the cell viability assays (Table 3-4). Interestingly, despite chloroquine not altering the 
sub G1 population as a single agent, chloroquine synergised with CX-5461 to induce 
cell death in the THP-1, MOLM-13 and MLL/AF9 NRAS cells, but not in the MV4-11 
cells. The synergistic drug effect observed with cell death was particularly pronounced 
in the p53 WT MOLM-13 cells, increasing from approximately 30% (CX-5461 alone) to 
60% (combination treatment) of the cells classified as SubG1, which is consistent with 
the strong synergism observed when total viable cell number using the MTT assays 
was assessed (Figure 3-12). The greatest fold increase (~6-fold) was observed in the 
p53 null THP-1 cells. 
 156 
 
 
Figure 5-3: Chloroquine enhances the effects of CX-5461 on cell cycle progression and 
cell death 
Quantitation of cell cycle distribution by BrdU incorporation and DNA content (DAPI) was 
analysed by flow cytometry (Methods Section 2.12) after treatment with CX-5461, 
chloroquine or the combination of the two after the indicated timepoints. The sub G1 
population was considered indicative of cell death. Graphs show the mean  SD of n=3 
experiments. CX = CX-5461, CQ = chloroquine. 
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5.2.2 Effect of CX-5461 and chloroquine on autophagy protein 
expression 
Chloroquine is well characterised as an autophagy inhibitor (see Section 5.1.2.2). If CX-
5461 and chloroquine were to act synergistically via chloroquine-mediated inhibition 
of autophagy, this would suggest that cells, in this case, AML cells may upregulate 
autophagy as a survival mechanism to overcome the effects of CX-5461, as has been 
published to occur in response to other chemotherapies (Section 5.1.2.2). To test this, 
three human AML cell lines (MV4-11, THP-1 and MOLM-13) were treated over a time 
course with a range of concentrations of CX-5461 as a single agent (based on in vitro 
sensitivity determined by viability assay, (Table 3-4)) and the abundance of the 
autophagy protein LC3B-II was measured by western blot (Figure 5-4). Acute treatment 
(6 hours) with CX-5461, chloroquine and the combination of drugs was also performed 
(Figure 5-5). The LC3B-II protein is part of the autophagosome membrane, and thus 
levels of LC3B are indicative of the number of autophagosomes (Figure 5-1). Thus, if 
autophagy is upregulated the flux rate (number of autophagosomes) and LC3B-II 
abundance will increase. If autophagy is blocked at a late stage, such as is observed 
with chloroquine treatment, autophagosomes will be prevented from merging with 
lysosomes, leading to their accumulation and LC3B-II expression will increase. If 
autophagy is also upregulated by CX-5461, there may be a synergistic increase in LC3B-
II levels with the combination treatment. 
 
As expected, given the established effect of chloroquine as an autophagy inhibitor, 
chloroquine treatment mediated an increase in LC3B-II abundance compared to the 
vehicle in the MV4-11 (Figure 5-5a), THP-1 (Figure 5-5b) and MOLM-13 (Figure 5-5c) 
cells lines. 
 
The MV4-11 cells (Figure 5-4a) are the most sensitive of the 3 cell lines to CX-5461 in 
terms of viability (Table 3-4) and interestingly CX-5461 mediated a dose-dependent 
increase in LC3B-II levels at 3 h, which was maintained at 6 h treatment. By 24 h LC3B-
II levels had returned back to basal in the presence of CX-5461, indicating a transient 
induction of autophagy. In the THP-1 cells (Figure 5-4b), which are insensitive to CX-
5461 in terms of viability (Table 3-4), also mediated a dose-dependent increase in 
LC3B-II abundance detectable at 3 h and 6 h of treatment, with a maximum increase of 
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3.4 fold compared to the vehicle. However, unlike that observed in the MV4-11 cells, 
LC3B-II levels remained elevated at 24 h of CX-5461 treatment, indicating that CX-5461 
mediated a sustained increase in autophagy in the THP-1 cells. Interestingly, in the 
MOLM-13 cells (Figure 5-4c), which displayed moderate sensitivity to CX-5461 as a 
single agent (Table 3-4) and of the 3 cell lines tested displayed the highest degree of 
synergy with the combination of CX-5461 + chloroquine (Figure 3-12), there were 
minimal changes in LC3B-II levels detected, in fact at some doses there was a decrease. 
Together these results suggest that CX-5461 induces autophagy in a cell-dependent 
manner, and there is no correlation between sensitivity to CX-5461 treatment with 
respect to viability and induction of autophagy. 
 
The effect of the combination of CX-5461 + chloroquine on LC3B abundance was also 
evaluated in these cell lines. Human AML cell lines were treated with a single dose of 
CX-5461, chloroquine or the combination (with the concentration based on in vitro 
sensitivity by viability assay, Table 3-4) for 6 h and the abundance of autophagy marker 
LC3B-II assessed by western blot. CX-5461 treatment lead to an increase in LC3B-II 
levels in the MV4-11 cells, but not the THP-1 or MOLM-13 cells, indicating autophagy 
was not being upregulated at this particular timepoint in these two particular cell lines. 
This is consistent with the previous results of the single-agent treatment for MV4-11 
and MOLM-13 cells, but not the THP-1 cells (Figure 5-4). In all three cell lines, there 
was no further increase in LC3B-II abundance with combination treatment when 
compared to chloroquine or CX-5461 treatment alone, indicating that the combination 
of drugs is not having a synergistic effect on autophagy, or perhaps that the maximum 
dynamic range of the assay has been reached. 
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Figure 5-4: Autophagy flux in response to a CX-5461 time course 
AML cell lines a) MV4-11, b) THP-1 and c) MOLM-13 were treated with CX-5461 for 3, 6 or 
24 h. Protein was extracted and equal amounts of protein separated using SDS-PAGE, 
followed by immunoblotting for LC3B-II protein levels (Section 2.6). Beta actin was used as 
a loading control. A representative western blot image of n=3 experiments is shown. 
Quantification of band intensity was performed and LC3B-II protein levels expressed as a 
fold-change over the vehicle, after normalising to beta-actin levels. Graphs show the mean 
 SD of n=3 experiments. 
 
 
 161 
 
 
 
Figure 5-5: Autophagic flux following short term CX-5461 and chloroquine treatment 
AML cell lines a) MV4-11, b) THP-1 and c) MOLM-13 were treated with vehicle (Veh), CX-
5461 (CX; 125nM for MV4-11, 1000nM for THP-1 and MOLM-13), chloroquine (CQ; 20µM 
for MOLM-13, 40µM for MV4-11 and THP-1) or the combination of the two drugs (Com) 
for 6 h. Protein was extracted and 30µg protein separated using SDS-PAGE, followed by 
immunoblotting for LC3B-II protein levels (Section 2.6). Beta actin was used as a loading 
control. A representative western blot image of n=2 experiments is shown. 
 
 162 
5.2.3 Ultrastructural changes by transmission electron 
microscopy 
 Transmission electron microscopy (TEM) was performed to visualise and count the 
autophagy structures (autophagosomes, autolysosomes and lysosomes, as outlined in 
Figure 5-1). The human AML cell lines MV4-11, THP-1 and MOLM-13 were treated with 
vehicle, 1µM CX-5461, 40µM chloroquine or a combination of the two drugs for 24 h, 
then processed for TEM (Section 2.9). An alternative autophagy inhibitor, bafilomycin, 
as well as serum starvation, were also included as controls for inhibition and induction 
of autophagy, respectively. Two representative cells from each treatment are 
illustrated in Figure 5-6, which also includes a higher magnification view of the 
cytoplasm for each treatment. In the MV4-11 cells, the number of structures in 10 
randomly selected cells were counted (Figure 5-7), however, due to time constraints 
this experiment was only performed once. 
Figure 5-6: Ultrastructural changes following CX-5461 and chloroquine treatment 
Human AML cell lines a) MV4-11, b) THP-1 and c) MOLM-13 were exposed to vehicle, 
serum starvation, 20nM bafilomycin (Baf), 1µM CX-5461, 40µM chloroquine (CQ) or CX-
5461+chloroquine (CX+CQ) for 24 h, fixed and processed for transmission electron 
microscopy (TEM; Section 2.7). Representative cells of each treatment are shown. Scale 
bar on higher power images = 1µM. N = nucleus, M = mitochondria, A = autophagy 
structure. n=1. 
 
 163 
 
 
 164 
 
 
 165 
 
 
 166 
In the vehicle-treated samples, the nuclei and mitochondria are readily visible, as are 
some small vacuoles and autophagy structures in the cytoplasm. There were relatively 
few vacuoles in the MV4-11 (Figure 5-6a) and MOLM-13 (Figure 5-6c) vehicle-treated 
cells compared to the THP-1 cells (Figure 5-6b) which had more and larger vacuoles. 
Consistent with the LC3B-II levels (Figure 5-5), in chloroquine-treated cells, across all 
three cell lines, there was an increase in the size and number of vacuoles and 
autophagy structures, including autophagosomes containing large, electron-dense 
structures. These were also present in the bafilomycin- and CX-5461 + chloroquine-
treated cells. As chloroquine and bafilomycin are late-stage inhibitors of autophagy, 
specifically blocking the fusion of the autophagosomes with lysosomes, the increased 
number of autophagosomes containing un-degraded cargo is unsurprising. Serum 
starvation also mediated an increase in the number and size of cytoplasmic vacuoles 
and autophagy structures in all 3 cells lines, particularly in the THP-1 cell line. In some 
of the MV4-11 cells CX-5461 treatment led to a loss of contrast and granular texture in 
the nucleus and cytoplasm, which may indicate a loss of viability, consistent with the 
sensitivity of these cells to CX-5461 with respect to viability (Figure 3-5). No obvious 
changes in the number or size of autophagy structures was observed with CX-5461 
treatment, consistent with LC3B-II levels at this timepoint (Figure 5-4). In the THP-1 
and MOLM-13 cells CX-5461 treatment mediated an increase in the size and number of 
vacuoles and autophagy structures, also consistent with the changes in LC3B-II 
abundance (Figure 5-4). 
 
In addition to visualising autophagy structures, another aim of TEM was to count these 
structures, however this proved difficult due to limited resolution of the membranes 
and some uncertainty as to the nature of the structures observed with autophagy 
inhibitor treatment. A trial counting of autophagy structures, based on guidance from 
the literature 313 181 314, was performed in the MV4-11 samples in order to determine 
the numbers of autophagosomes, autolysosomes and lysosomes (Figure 5-7). 
Consistent with the LC3B-II results the number of autophagosomes/cell in the CX-5461 
treated samples slightly increased compared to the vehicle, while a 3-fold change was 
observed in the serum-starved, chloroquine, CX-5461 + chloroquine, and bafilomycin-
treated samples compared to vehicle. Autolysosomes were rarely detected across all 
the samples, and were predominantly identified in the vehicle, serum starved and 
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CX-5461 -treated samples, with none observed in the chloroquine, CX-5461 + 
chloroquine and bafilomycin-treated cell. While this was consistent/correlated with 
the extent of autophagy inhibition, since the overall numbers of structures identified 
were small definitive conclusions cannot be drawn. Lysosomes were also rarely 
detected in the samples, with slightly more in the chloroquine, CX-5461 + chloroquine 
and bafilomycin samples, again consistent with autophagy inhibition. 
 
 
 
Figure 5-7: Quantification of autophagy structures observed by TEM in MV4-11 cells 
The human AML cell line MV4-11 was exposed to vehicle, serum starvation (SS), 20nM 
bafilomycin (Baf), 1µM CX-5461 (CX), 40µM chloroquine (CQ) or CX-5461+chloroquine 
(CX+CQ) for 24 h, fixed and processed for transmission electron microscopy (Section 2.7). 
Samples were de-identified and 10 cells were imaged/treatment. Counting of autophagy 
structures was performed and then the samples were re-identified. N=1. 
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5.2.4 Combining alternative autophagy inhibitor bafilomycin with 
CX-5461 
To further evaluate if autophagy inhibition synergises with CX-5461 treatment, 
combination testing was performed with an alternative autophagy inhibitor, 
bafilomycin A1 (bafilomycin). Bafilomycin blocks autophagosome-lysosome fusion 315, 
thus is a late-stage autophagy inhibitor like chloroquine and demonstrated similar 
effects on the ultrastructure of the AML cells as chloroquine treatment (Figure 5-6). 
This analysis was performed in the MOLM-13 cell line which demonstrated the most 
synergy of the four cell lines tested with the combination of CX-5461 + chloroquine 
(Figure 3-12). Synergy testing was performed as previously (Methods section 2.5.5). 
Figure 5-8 shows that bafilomycin alone at concentrations up to 15nM had no effect 
on cell viability. 11/15 of the combinations of CX-5461 with bafilomycin had a 
synergistic effect on the total viable cell number of MOLM-13 cells, particularly at 
300nM CX-5461 or higher. This indicates that bafilomycin, like chloroquine, is 
synergistic in combination with CX-5461 in vitro, supporting the conclusion that 
autophagy inhibition mediates the synergy between the two drugs. However, like 
many drugs depending on the concentration evaluated, bafilomycin can mediate other 
effects in cellular processes, such as directly altering mitochondrial function 316,317, so 
this evidence should be considered supportive but not definitive. In order to 
conclusively determine the role of autophagy inhibition in combination with ribosome 
biogenesis inhibition, a genetic approach is required. 
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Figure 5-8: Alternative autophagy inhibitor bafilomycin A1 synergises with CX-5461 to 
reduce AML cell number 
MOLM-13 cells were cultured for 96 h in the presence of CX-5461 or bafilomycin (baf), 
as single agents or in combination. Total viable cell number was determined using the 
MTT assay (Methods section 2.5). Graphs show the meanSD of n=3 experiments. In 
order to determine if a combination was synergistic the combination index (CI) of each 
data point was calculated using CompuSyn (Methods Section 2.5.5) and displayed in 
the inlayed table (synergism was designated as a CI value <0.75, shown in green). 
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5.2.5 Combining CX-5461 treatment with genetic knockdown of 
autophagy proteins 
Human AML cell lines MV4-11, THP-1 and MOLM-13 with stable doxycycline-inducible 
shRNA constructs to Beclin 1 (BECN1) or ATG7 (2 targeting sequences per gene) were 
generated using lentiviral transduction (Section 2.10). Induction of shRNA expression 
with doxycycline was performed for 72 h, and the cells then treated with CX-5461 for a 
further 96 h before cell viability was analysed using the MTT assay (Section 2.5). 
Knockdown of the autophagy proteins was also assessed by western blot analysis 
(Section 2.8). 
 
Analysis of the controls (Figure 5-9) shows that the sensitivity of the non-targeting cell 
lines to CX-5461 is consistent with the viability results of the parental cell lines in 
Chapter 3 (Table 3-4) and that doxycycline treatment alone did not affect viability in 
any of the three cell lines compared to the no-doxycycline controls. Western blot 
analysis revealed that partial knockdown of protein expression was achieved in all the 
cell lines with the targeting shRNA sequences, but not in the non-targeting control. 
Neither BECN1 shRNA target nor the two ATG7 shRNA targets lead to a significant 
change in viability in combination with CX-5461 treatment when compared to the non-
targeting control in the 3 cell lines tested (Figure 5-9). Thus, the genetic knockdown of 
autophagy proteins did not synergise with CX-5461 treatment, which suggests that the 
synergy observed between CX-5461 + chloroquine (or bafilomycin) is not due to 
autophagy inhibition. 
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Figure 5-9: Genetic knockdown of autophagy-related genes BECN-1 and ATG-7 does not 
synergise with CX-5461 to reduce AML cell number 
 
AML cell lines containing inducible shRNA sequences to BECN1 or ATG7 were treated with 
doxycycline (dox) for 72 h to induce shRNA expression, then treated with CX-5461 for a 
further 96 h. Cell viability was assayed with the MTT assay (Section 2.5) and expression of 
BECN1 and ATG7 protein was assayed by western blot analysis (Section 2.6). A repeated 
measure two-way ANOVA with Tukey’s multiple comparison correction was used to 
compare the viability between the cell lines with different concentrations of CX-5461. No 
significant differences were observed. N=3 for the MTT assay, n=1 western blot. 
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5.2.6 Metabolic flux analysis 
Given the reported effects of chloroquine altering mitochondrial function (Section 
5.1.2.4), and the appearance of mitophagic-like structures in the TEM in the 
chloroquine and CX-5461 + chloroquine-treated samples (Figure 5-6), alterations in 
mitochondrial function were analysed as a potential mechanism of synergy through 
performing a mitochondrial stress test (Section 2.11). Following 24 h drug pre-
treatment, the oxygen consumption rate (OCR) was measured as an indicator of 
mitochondrial respiration and the extracellular acidification rate (ECAR) as an indicator 
of glycolysis using the Seahorse Extracellular Flux Analyser. In addition, drug-naïve cells 
were treated at the time of the assay (acute treatment). Two cell lines were evaluated; 
the THP-1 cell line (limited sensitivity to CX-5461 + chloroquine by viability assay), and 
the MOLM-13 cell line (very sensitive to the combination; Figure 3-12). 
 
For the MOLM-13 cells, consistent with them being much more sensitive to 
combination treatment in terms of viability, the shifts in the energy profile were 
pronounced (Figure 5-10a). CX-5461 treatment shifted the flux towards mitochondrial 
respiration and away from glycolysis, whereas the combination treatment shut down 
both mitochondrial respiration and glycolysis resulting in a quiescent phenotype, 
represented by a significantly lower rate of basal respiration compared to the vehicle, 
CX-5461 or chloroquine-treated cells (Figure 5-10b). Consistent with the THP-1 cells 
being less sensitive to the drugs, both individually and in combination, any shifts in the 
energy profile (Figure 5-10a) were minimal. Specifically, CX-5461 treatment 
significantly increased the maximal respiration (Figure 5-10c) and spare respiratory 
capacity (Figure 5-10d) in the MOLM-13 cells, with an upward trend observed in the 
THP-1 cells, while chloroquine significantly decreased the maximum respiration rate in 
the MOLM-13 cells. Interestingly, combination treatment had the opposite effect on 
the respiratory capacity of the two cells lines. In the THP-1 cells combination 
treatment significantly increased the maximal respiration and spare respiratory 
capacity, while in the MOLM-13 cells it was significantly decreased. These results 
suggest that CX-5461 mediates mitochondrial stress and the cells are adapting to this, 
however, combination treatment mediates loss of mitochondrial viability due to the 
effects of chloroquine, explaining why MOLM-13 cells are particularly sensitive to the 
combination treatment in terms of viability. 
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Acute drug treatment at the time of the assay indicated that CX-5461 and chloroquine 
as single agents did not significantly affect respiratory capability compared to vehicle 
(Appendix Figure 5-1), indicating that these drugs are not likely to be directly affecting 
the mitochondria. 
 
Figure 5-10: CX-5461 and chloroquine synergise to alter mitochondrial function 
AML cell lines THP-1 and MOLM-13 were treated with vehicle, 1µM CX-5461 (CX), 40µM 
chloroquine (CQ) or CX-5461+chloroquine (CX+CQ) for 24 h, equal cell number plated, 
then metabolic flux analysed using a mitochondrial stress test on the Seahorse XFe97 
analyser (Section 2.11). a) Energy map of basal levels of oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR), b) Basal respiration rates c) Maximal 
respiration rate following mitochondrial uncoupling with FCCP, d) Spare respiratory 
capacity (difference in the OCR between the maximum respiration rate and basal rate). 
One-way ANOVA was performed with a Tukey’s multiple comparison test, the adjusted p-
value is shown. Not significant P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 
0.0001. Significant results only marked. N=3. Compared to vehicle, unless indicated by a 
bar. 
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5.3 Discussion 
5.3.1 Summary of results and synergy hypothesis 
In this chapter, four potential mechanisms and endpoints of synergy between CX-5461 
and chloroquine were assessed; cell cycle, cell death, inhibition of autophagy and 
altered mitochondrial activity. Chloroquine enhanced the cell cycle and cell death 
endpoints of exposure to CX-5461. While CX-5461 induced autophagy in some cell 
lines and the alternative autophagy inhibitor bafilomycin also synergised with CX-5461 
to reduce AML cell viability, however, the genetic knockdown of autophagy genes did 
not synergise with CX-5461 treatment, suggesting that autophagy does not play a 
significant role in the synergy between CX-5461 and chloroquine. Interestingly, 
metabolic flux analysis revealed that the combination of drugs caused significant 
changes in mitochondrial respiration which is a potential mechanism of synergy. 
 
Based on the results presented in this chapter, the following hypothesis was devised to 
account for the synergy observed between CX-5461 and chloroquine in AML cells 
(Figure 5-11). As an established autophagy inhibitor chloroquine blocks autophagy, 
including mitophagy (the recycling of mitochondria), thus can result in an 
accumulation of dysfunctional mitochondria in the cell. In addition, metabolic flux 
analysis suggests that the combination of CX-5461 and chloroquine may indirectly 
impact on the mitochondria, placing the cells under a high degree of metabolic stress 
and leading to the endpoints of cell cycle arrest and cell death. 
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Figure 5-11: Hypothesis of the mechanisms of synergy between CX-5461 and chloroquine 
Based on the results presented in this chapter the following hypothesis was devised to 
account for the synergy observed between CX-5461 and chloroquine in AML cells. As an 
established autophagy inhibitor chloroquine blocks autophagy, including mitophagy (the 
recycling of mitochondria) leading to an accumulation of dysfunctional mitochondria which 
causes some degree of metabolic stress. Flux analysis results also indicate that the 
combination of the drugs might be having indirect effects on the mitochondria, placing the 
cells under a high degree of metabolic stress and leading to cell cycle arrest and cell death. 
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5.3.2 Autophagy as a potential mechanism of synergy 
Interestingly, mechanistic analysis indicated that the synergy observed between CX-
5461 and chloroquine is not due to autophagy inhibition by chloroquine, its major, 
well-characterised mechanism of action (Section 5.1.2.2). It is also surprising that CX-
5461 does not appear to robustly induce autophagy in all AML cell lines (Figure 5-4) 
given the link between inhibition of Pol I transcription and autophagy induction. 
Specifically, inhibition of Pol I transcription with adriamycin and actinomycin-D, or 
knockdown of Pol I transcription factors in a breast cancer cell line induces nucleolar 
disruption mediated autophagy 318 and CX-5461 induces autophagic cell death in 
osteosarcoma cell lines 83. While LC3B-II levels usually indicate changes in autophagic 
flux there are some exceptions. In ovarian cancer cell lines elevated LC3B-II following 
oxidative stress was shown not to be associated with induction of autophagy but 
rather anoikis (detachment-induced programmed cell death) 319. Furthermore, 
accumulation of LC3B-II protein is cell line dependent following autophagy induction 
by nutrient starvation 320. An alternative method of measuring autophagic flux 
following CX-5461 and combination treatment would be to use the long-lived protein 
degradation assay, where the degradation of radiolabelled long-lived proteins is used 
as a readout of autophagic activity, as has been utilised to study autophagic flux in 
AML cells in response to differentiation induction 321, providing a more direct measure 
of autophagy. 
 
TEM analysis is also considered a reliable method of observing autophagic activity, 
however counting the number of autophagy structures proved challenging. Overall, 
while the results are consistent with the changes in LC3B-II abundance, the variation 
was consistently high across all the samples (Figure 5-7), and counting 3D structures in 
a 2D context is not ideal. Thus, an alternative assay to count the number of autophagy 
structures would be to perform immunofluorescence with the LC3B antibody and 
count the number of LC3B positive puncta, which mark the membrane of the 
autophagosomes and autolysosomes 322. A technique known as correlative light and 
electron microscopy (CLEM), which combines light and electron microscopy on the 
same sample, would also be a beneficial technique to utilise here as the data of light 
and electron microscopy could be correlated on the same sample to identify the 
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membrane of the autophagy structures based on LC3B expression, then characterise 
the structures as autophagosomes or autolysosomes based on appearance by TEM. 
 
Due to the multiple effects of chloroquine (Section 5.1.2), a genetic approach is also 
recommended to assist in the identification of mechanisms of action181. Interestingly, 
genetic knockdown of autophagy-related genes Beclin 1 and ATG7 did not synergise 
with CX-5461 to reduce AML cell number (Figure 5-9), indicating that CX-5461 and 
chloroquine are not acting synergistically through the action of chloroquine as an 
autophagy inhibitor. However, the success of the knockdown needs to be considered. 
Western blot analysis confirmed that partial, but not complete, knockdown of Beclin 1 
and ATG7 protein expression was achieved. Other studies confirmed that a 50% 
knockdown of expression of these proteins has functional effects in other cell types 
295,297; whether this knockdown is sufficient to inhibit autophagy in AML cells is 
unknown and should be assessed through methods such as LC3B-II expression by 
western blot (as in Figure 5-4) or long-lived protein degradation assay 321, particularly 
in the context of autophagy induction through serum starvation, for example. It is also 
possible that there was some kind of compensatory mechanisms that occurred over 
the course of the experiments, and this could be further analysed by knocking down 
two or more autophagy-related genes. Gene editing technology (for example CRISPR 
deletion) could be employed as an alternative approach to knockdown 181. 
 
5.3.3 Mitochondrial effects as a potential mechanism of synergy 
TEM analysis revealed numerous electron-dense structures in the bafilomycin, 
chloroquine, and CX-5461 + chloroquine-treated cells. Such electron-dense structures 
have previously been identified as mitophagy structures (autophagosomes containing 
mitochondria) in a study evaluating the effect of the MDM2 inhibitor Nutlin 3a in AML 
cell lines 323. As chloroquine and bafilomycin are late-stage inhibitors of autophagy, 
blocking the fusion of autophagosomes with lysosomes, the increased appearance of 
autophagosomes containing un-degraded cargo is unsurprising. However, the 
frequency of autophagosomes containing mitochondria suggests that mitophagy is 
upregulated, thus the autophagy inhibitors could be indirectly affecting mitochondrial 
function, as has been previously suggested 111. A technique to identify the contents of 
these electron-dense structures would be immunofluorescence using the autophagy 
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marker LC3B in combination with mitochondrial or lysosomal markers in order to 
evaluate co-localisation, a technique which has been used to study mitophagy in the 
context of heart infarctions 324. CLEM could also be used to correlate autophagy, 
mitochondrial and lysosomal markers by immunofluorescence with the electron-dense 
structures identified by TEM. This technique has been used to study autophagosome 
biogenesis in HeLa cells 325 and to study the autophagy in the context of 
Mycobacterium infection in a whole organism Zebrafish model 326. 
 
Mitochondrial flux analysis indicated that the combination of CX-5461 and chloroquine 
lead to significant changes in mitochondrial function, perhaps due to inducing 
mitochondrial stress (Figure 5-10). Changes in the OCR, such as elevated maximal 
respiration and spare respiratory capacity in MOLM-13 following CX-5461 treatment 
(Figure 5-10b,c), could be due to changes in mitochondrial number, expression and/or 
the activity of mitochondrial complexes or mitochondrial viability. Mitochondria 
number can be assessed by determining mitochondrial DNA content using qPCR 111,327 
or digital droplet PCR 328. The expression of mitochondrial complexes, including 
aconitase, citrate synthase and complex IV subunits, can also alter cellular respiration 
rate which can be assessed by western blot 111. Activity of the individual mitochondrial 
complexes can be determined by permeabilising the cells and measuring the OCR with 
Complex I, II or IV-linked substrates using the Seahorse, as has been performed in 
primary neurons with chloroquine and bafilomycin treatment 111. Changes in 
mitochondrial viability can be assessed using flow cytometry and the membrane-
permeant fluorescent dye JC-1, with its localisation in the mitochondria, forming 
aggregates and leading to a shift in the wavelength of fluorescence emission, being a 
measure of mitochondrial membrane potential, which has also been utilised to assess 
mitochondrial changes in AML cell lines treated with chemotherapeutics 106. 
 
A potential mechanism via which CX-5461 and chloroquine are synergising through the 
mitochondria is by the production of ROS. Autophagy plays a role in controlling ROS 
levels through removing dysfunctional mitochondria 102, as such is in unsurprising that 
blocking autophagy (genetically or chemically) mediates increased ROS levels in 
various cell types 329, including cancer cells such as hepatocellular carcinoma 330. It has 
also been shown that inhibition of ribosome biogenesis with CX-5461 leads to ROS 
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accumulation in aortic medial smooth muscle cells 331, however, the effects of CX-5461 
on ROS levels in AML cells is not yet characterised. If CX-5461 does elevate ROS levels 
in AML cells, this could be a mechanism by which CX-5461 and chloroquine synergise, 
which presumably is mitochondria-dependent, to affect AML cell viability. Since AML 
cells are more sensitive to oxidative stress than normal cells 332 this would fit with our 
hypothesis. To evaluate this possibility, the level of intracellular ROS following CX-
5461, chloroquine or combination treatment could be measured using flow cytometry 
331. 
 
Narrowing down the mechanism of action in the mitochondria will greatly assist in 
guiding the rational choice of alternative inhibitors to combine with CX-5461. Further 
discussion of targeting mitochondria in cancer, including mitochondrial inhibitors with 
its clinical potential, is explored in Chapter 6. 
 
5.3.4 Other potential mechanisms of synergy 
There are multiple other potential mechanisms of synergy that, due to time 
limitations, were not assessed in this thesis. These include the nucleolar stress 
response, DNA damage signalling, effects on Pol I transcription and lysosomal effects 
(Figure 5-2). 
 
 Nucleolar stress response 
The nucleolar stress response is activated by multiple cellular stresses, including Pol I 
transcription inhibition, resulting in accumulation of p53 (Section 5.1.1.3). It was 
recently demonstrated that autophagy induction is a downstream consequence of 
such stress signalling. Chemical inhibition of Pol I transcription and siRNA knockdown 
of basal Pol I transcription factor Transcription Initiation Factor IA (TIF-IA) resulted in 
nucleolar disruption and autophagy induction, and this was dependent on nucleolar 
protein nucleophosmin (NPM) 318. By inhibiting autophagy with chloroquine this may 
enhance nucleolar stress signalling resulting in reduced cell viability. This can be 
assessed by determining p53 and p21 expression by western blot 1 and assessing the 
translocation of the nucleolar marker protein nucleolin through immunofluorescence 
as a measure of nucleolar disruption 318. 
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 DNA damage signalling 
Chloroquine has long been known to have DNA intercalating properties, mediating 
activation of ATM signalling (Section 5.1.2.3) which may be the focal point for synergy 
with the DNA damage-like signalling induced by CX-5461 (Section 5.1.1.4). In 
erythroleukaemia cells, a subset of AML, DNA intercalation was not observed below 
600µM chloroquine treatment 176, thus as the highest concentration of chloroquine 
used in these in vitro experiments was 40µM, it is unlikely to have a significant DNA 
intercalating effect. However, there is the potential that chloroquine might accumulate 
to higher levels in different AML cell lines so it should still be considered. This could be 
assessed through western blot analysis of p53, Chk1, Chk2, pChk1 and pChk2 
expression 1, in addition to expression of the DNA double-strand break marker γH2AX 
to check for global DNA damage 268. 
 
 Pol I transcription inhibition 
While CX-5461 is a well-established inhibitor of Pol I transcription, including in AML 
cells 1, the effects of chloroquine on Pol I transcription have not been reported thus 
far. Due to its DNA intercalating properties 176, there is the potential that chloroquine 
could disrupt rDNA transcription. This could be assessed with qRT-PCR for 45S pre-
rRNA 81 or [32P] orthophosphate labelling to measure 45S pre-RNA synthesis 1,78. If 
chloroquine was to also inhibit ribosome biogenesis, this may be the focus of the 
synergy observed in combination with CX-5461. 
 
 Lysosomal effects 
As outlined in Section 5.1.2.5, in addition to a role in autophagy, lysosomes also act as 
hubs for nutrient signalling through mTORC1. Metabolic flux analysis revealed that the 
combination of CX-5461 and chloroquine altered mitochondrial respiration (Figure 
5-10), which may be due to chloroquine inhibiting lysosome function, specifically the 
nutrient signalling pathways. This could also explain why the alternative inhibitor 
bafilomycin A1 also synergises with CX-5461 and reduces AML cell number (Figure 
5-8), specifically bafilomycin A1 inhibits lysosomal function through its actions on the 
vacuolar-ATPase 315 (which is known to play an important role in the nutrient signalling 
of the lysosome through mTORC1 309). Activation of mTORC1 following CX-5461, 
chloroquine or combination treatment can be assessed by western blot for 
phosphorylation of mTORC1 downstream target S6K1 (pT398) in the presence or 
 183 
absence of amino acids, also using immunofluorescence to evaluate co-localisation of 
mTORC1 and the lysosomal marker lysosomal-associated membrane protein 1 
(LAMP1) 309. 
 
5.3.5 Conclusion 
Thus far, the mechanistic and endpoint analysis of the synergy between CX-5461 and 
chloroquine indicates that cell cycle arrest, cell death and altered mitochondrial 
activity are likely to be the processes involved in the synergy. The drug’s effects on the 
mitochondria are novel and a promising finding. While there appears to be limited 
clinical potential for the use of chloroquine in combination with CX-5461 (as addressed 
in Chapter 4) this data does present an alternative avenue for combination therapy, 
thus narrowing down the search for drugs that may have improved efficacy and 
reduced toxicity when combined with CX-5461, further discussed in Chapter 6. 
 
  
 184 
Chapter 6 Discussion 
 
6.1  Summary of results 
Targeting ribosome biogenesis, a cellular process frequently upregulated in cancer, 
with the novel Pol I transcription inhibitor CX-5461 is highly efficacious in pre-clinical 
models of solid and haematological cancers 1,81, which lead to Phase I and I/II clinical 
trials 82,85. However, as is common with single-agent therapies, the in vivo studies 
demonstrated that eventually, resistance to CX-5461 occurs, highlighting the need for 
a drug combination approach. Based on the well-established link between ribosome 
biogenesis and cellular metabolism, both in normal cells and also a cancer setting, it 
was hypothesised that targeting these two processes in combination would prove 
more efficacious in AML, a model of aggressive malignancy with poor therapeutic 
options when compared to the single drugs alone. In vitro synergy testing in AML cell 
lines was performed to identify promising drug combinations of interest (Chapter 3), 
which were then tested for efficacy in in vivo transplant models of AML (Chapter 4). 
Finally, in vitro mechanistic analysis of the most promising drug combination was 
performed (Chapter 5). 
 
In vitro testing of the novel ribosome biogenesis inhibitor CX-5461 in combination with 
10 clinically-approved metabolism-modifying drugs (Chapter 3) confirmed that of 
these 5 drugs (orlistat, DCA, ritonavir, omeprazole and chloroquine) acted 
synergistically with CX-5461 to reduce AML cell viability (Figure 3-19), with the 
autophagy inhibitor chloroquine being the most effective (Figure 3-12). Three 
synergistic combination therapies were further evaluated in an in vivo syngeneic 
mouse AML model (Chapter 4). Orlistat and DCA treatment did not improve survival 
when combined with CX-5461 and compared to CX-5461 alone (Figure 4-4, Figure 4-5), 
whereas chloroquine did (Figure 4-6). CX-561 + chloroquine treatment was also 
evaluated in human cell line xenograft mouse models, but found to have limited 
efficacy (Figure 4-8, Figure 4-9), despite robust in vitro synergy. As the dosing of CX-
5461 and chloroquine could not be increased further due to toxicity, mechanistic 
analysis was then performed in order to identify an alternative to chloroquine with 
reduced toxicity, and potentially improved efficacy (Chapter 5). CX-5461 + chloroquine 
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synergy was observed at the level of cell cycle arrest and cell death in all four cell lines 
tested (Figure 5-3), and the upstream mechanisms of synergy leading to this was then 
assessed. The role of autophagy in the synergy between CX-5461 and chloroquine was 
not definitive. CX-5461 induced autophagy in some cell lines but not others, and this 
did not correlate with sensitivity to CX-5461 with respect to viability (Figure 5-4, Figure 
5-5). In addition the autophagy inhibitor bafilomycin also synergised with CX-5461 
(Figure 5-8), however genetic knockdown of autophagy-related genes, Beclin 1 and 
ATG7, did not synergise with CX-5461 treatment (Figure 5-9), suggesting autophagy 
may not be the mechanism of synergy between CX-5461 and chloroquine, although 
the knockdown was partial (and the phenotypic consequences of the knockdown on 
autophagy are yet to be confirmed) and there might have been compensatory 
mechanisms involved (as outlined in Section 5.3.2), thus conclusions regarding the role 
of autophagy cannot be drawn yet. Metabolic flux analysis revealed that the drug 
combination significantly affected mitochondrial activity (Figure 5-10), decreasing 
respiration in the MOLM-13 cell line which was very sensitive to the drug combination 
with respect to viability, whereas increased respiration in the THP-1 cell line which had 
limited sensitivity to the drug combination. These results indicate that the combination 
of CX-5461 and chloroquine can place cells under mitochondrial stress and that drug 
combination sensitivity may be dependent on the cells ability to adapt/respond to 
such stress. Therefore, direct drug targeting of the mitochondria was identified as a 
promising combination with ribosome biogenesis inhibition, and potentially more 
efficacious than CX-5461 plus chloroquine. 
 
6.2  Targeting mitochondria in AML 
Mechanistic analysis of CX-5461 and chloroquine in Chapter 5 revealed that 
combination therapy with these drugs significantly affected mitochondrial respiration 
(Figure 5-10), which is a published effect of chloroquine via inhibition of mitophagy 
and perhaps other indirect effects on the mitochondria 111, however, this is a novel 
response to CX-5461 treatment. Interestingly, in the AML cell lines, a significant 
decrease in maximum mitochondrial respiration was observed in the MOLM-13 but 
not the THP-1 cell line, thus the response was not common to all cell lines. Potentially 
a more selective mitochondrial inhibitor is required to: 
- Directly target mitochondrial activity; 
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- Reduce side effects that might make some cells not responsive; 
- Obtain a more uniform response in all cells. 
Thus ,directly targeting mitochondrial function was identified as a promising approach 
in combination with ribosome biogenesis inhibition. There are currently several 
clinically-used medications that target well defined mitochondrial functions including 
metformin, phenformin, tigecycline and doxycycline (Figure 6-1). 
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6.2.1 Clinical agents for targeting mitochondria 
Metformin is an anti-diabetic medication that interferes with mitochondrial function 
by inhibiting complex I of the mitochondrial electron transport chain (Section 
3.1.2.2)132. Metformin was selected as a candidate for evaluation with CX-5461 in vitro 
in Chapter 3, but was not evaluated further as it interfered with the mechanism of 
 
Figure 6-1: Targeting cancer mitochondria 
Various clinically approved drugs target the mitochondria and could be repurposed as 
cancer therapeutics. Chloroquine is known to inhibit mitophagy (the recycling of 
damaged mitochondria) through inhibition of autophagy, and potentially has direct 
effects on mitochondrial function through unknown mechanisms. Anti-diabetic 
medications metformin and phenformin target complex I of the electron transport chain 
(ETC). Antibiotic tigecycline inhibits the function of the mitochondrial ribosome to 
translate components of the ETC complexes. 
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action of both viability assays used (Figure 3-3, Figure 3-4). Entry of metformin into 
cells is mediated by organic cation transporters (OCTs), particularly OCT1 333,334, which 
are highly expressed only on certain cell types including hepatocytes 334 and adipocytes 
335, facilitating the effects of metformin as an anti-diabetic. In other cell types 
expression of OCTs is often low, including in AML patient bone marrow samples 336. 
Metformin has shown efficacy in AML cells in vitro but only at concentrations of 10mM 
134, which is more than 10-fold higher than plasma concentrations achieved in human 
patients 178, and this is likely due to the low expression of OCTs in these cells. In the 
same study daily dosing of metformin by IP injection significantly reduced tumour 
volume in a subcutaneous AML cell line xenograft model, however as discussed in 
Section 4.3.1.2, dosing via IP might result in higher concentrations of drug reaching the 
subcutaneous AML cells than achieved in a orthotopic model and also does not 
represent the normal oral dosing route for human patients. In a retrospective analysis 
of diabetic patients with AML, metformin treatment did not have an effect on overall 
survival or disease-free progression337, potentially due to the drug not reaching the 
cancer cells at a high enough concentration to have efficacy. Together these factors 
suggest that metformin could be useful for in vitro mechanistic analysis with CX-5461, 
but potentially have limited clinical use in AML, unless a novel formulation is devised 
to improve uptake and targeting to the mitochondria (for example metformin coupled 
to a mitochondrial vector showed efficacy in pancreatic cancer in vitro and in vivo 338). 
 
Phenformin is an alternative to metformin, another anti-diabetic medication that 
inhibits complex I of the electron transport chain339. While phenformin is also 
transported into hepatocytes by OCT1, it displays a higher affinity for the transporter 
and transport activity compared to metformin 333, and thus could be a better 
alternative to treat cancer cells that have low OCT expression. However, the clinical 
use of phenformin has been stopped due to the incidence of lactic acidosis in patients, 
particularly those with renal or liver insufficiency 340,341 which would also limit its 
clinical potential as a therapy in cancer (although the risk: benefit profile can vary 
greatly between diseases such as diabetes and cancer). There is certainly a need for 
third-generation derivatives of metformin with improved efficacy and reduced toxicity. 
A novel metformin derivative HL010183 showed increased efficacy against triple-
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negative breast cancer 342 and cutaneous squamous cell carcinoma 343 compared to 
metformin in vitro and in vivo, however, it is yet to be assessed in clinical trials. 
 
Tigecycline is a broad-spectrum antibiotic that binds to the bacterial 30S ribosomal 
subunit, inhibiting translation and thus killing the bacteria 344. Tigecycline is 
administrated intravenously and has a favourable clinical profile, causing only mild side 
effects in most patients, including nausea, diarrhoea and vomiting, which are thought 
to be due to the drug irritating the gastric mucosa 345. Due to the similarities between 
the bacterial and mitochondrial ribosomes, tigecycline has also been shown to affect 
mitochondrial function in eukaryotic cells by inhibiting the mitochondrial ribosome to 
translate the 13 proteins encoded by the mitochondrial genome, which comprise 
components of the mitochondrial electron transport chain complexes I-IV 106, making it 
of interest as a potential cancer therapeutic. Tigecycline has been shown to have 
strong efficacy in AML as a single agent 106. In a panel of 9 human and mouse AML cell 
lines in vitro treatment with tigecycline significantly reduced AML cell viability within 
72 hours, and induced apoptosis within 6 hours. Importantly, 20 human patient AML 
samples, but not normal hematopoietic cells, displayed a similar or greater sensitivity 
in terms of viability to tigecycline compared to the AML cell lines. Pre-treatment with 
tigecycline significantly reduced the clonogenic potential of primary AML cells but not 
normal hematopoietic cells in vitro, and similarly reduced the repopulating potential of 
the AML cells in vivo in NSG mice, thus targeting leukaemia-initiating cells. The effects 
of tigecycline on mitochondrial ribosome translation were confirmed, with a reduction 
of protein levels and increase in mRNA of the respiratory complex IV subunits 
cytochrome C oxidase-1 and 2 (cox 1 and 2) which are translated by mitochondrial 
ribosomes, but not grp78 and X-linked inhibitor of apoptosis protein (XIAP) which are 
translated by cytosolic ribosomes. Incorporation of [3H]-leucine into mitochondria was 
also significantly reduced with tigecycline treatment. In the same study 106, in a 
subcutaneous human cell line xenograft model, twice daily IP injections of 50 or 
100mg/kg tigecycline for three weeks significantly reduced tumour growth compared 
to the control, without gross changes (toxicity) to the organs. Based on these findings a 
Phase I dose-escalation study of tigecycline in 27 AML patients was commenced, with 
daily IV dosing 5 or 7 days a week for 2 weeks, followed by 1 week off the drug, and 
this cycle continued until disease progression 346. Up to four cycles of treatment were 
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completed and the maximum tolerated dose was determined to be 300mg/day single 
dose. Despite reaching a peak serum concentration (Cmax) of approximately 12μM, 
which has been demonstrated to be efficacious in vitro 106, no partial or complete 
responses were observed (as measured by number of blasts in the bone marrow, 
neutrophil count and platelet count) and there was no consistent increase in Cox1 
mRNA or decrease in protein (due to inhibition of translation) in peripheral blood 
mononuclear cells, indicating the drug was not hitting its target. The biological half-life 
(t1/2) was found to be approximately 9.5 hours, 2–6‐fold lower than that reported in 
non-cancer patients 347-349, perhaps explaining the lack of a response. Clearly, further 
adjustments to the dosing schedule are required in order to achieve efficacy in AML 
(such as twice daily as performed in non-cancer patients 347-349), however overall the 
toxicity results were promising. 
 
Doxycycline is another broad-spectrum antibiotic drug that is being investigated as a 
potential cancer therapeutic. The semi-synthetic tetracycline drug, doxycycline has 
been used for decades as an anti-microbial in both animals and humans, with either 
oral or intravenous administration 350. Like tigecycline, doxycycline targets bacterial 
ribosome translation through binding the 30S ribosomal subunit 351 and inhibits 
mitochondrial ribosome translation in a variety of eukaryotic models at a 
concentration as low as 0.5µg/mL in some 352. Doxycycline is commonly used in both in 
vitro and in vivo models for research to control gene expression, known as the Tet-
On/Off systems (as in Methods 2.10). In the genetic knockdown of autophagy 
experiments presented in this thesis, there was no synergy between CX-5461 and 
chloroquine in the context of 1µg/mL doxycycline treatment to induce shRNA 
expression (Figure 5-8), which does not support the hypothesis that ribosome 
biogenesis synergises with inhibition of mitochondrial function. However, it is possible 
that this concentration of doxycycline was insufficient to inhibit mitochondrial 
translation in the AML cell lines, as was observed in the lung cancer cell line A549 
where 1µg/mL doxycycline was insufficient to inhibit mitochondrial ribosome 
translation and 5µg/mL or higher was required 352. This requires confirmation 
experimentally in the AML cell lines, and can be done so by evaluating the protein 
levels of the mitochondrial ribosome-translated protein Cox 1 352. In a variety of solid 
tumours including breast, prostate and lung cancer mitochondrial biogenesis was 
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identified as a feature of cancer stem cells and thus targeting this with doxycycline 
inhibited tumour sphere formation, particularly at 10µM or higher 353. In a small 
clinical pilot study of 15 breast cancer patients, 14 days of oral doxycycline therapy 
significantly reduced biomarkers of stemness CD44 and aldehyde dehydrogenase 1 
(ALDH1; markers of cancer stem cells) in almost 90% of patients, however, inhibition of 
mitochondrial translation was not confirmed 354. 
 
While these clinically-used mitochondria-inhibiting agents directly target 
mitochondrial activity, some issues with concentration/dosing required to achieve this 
inhibition, as outlined above, suggests that novel drugs with increased potency for 
inhibiting mitochondrial activity would be an even more promising approach. 
 
6.2.2 Novel mitochondrial inhibitors 
Novel mitochondrial-targeting agents are also in development as cancer therapeutics. 
One example is the novel compound CCI-006 which has shown efficacy in MLL-
translocated AML cell lines through inhibiting mitochondrial respiration, although the 
exact mechanism of action is still to be determined 355. A relatively small subset of AML 
cell lines were not responsive to CCI-006 although they did display a similar reduction 
in mitochondrial respiration as the CCI-006 sensitive cell lines and had a stronger 
glycolytic phenotype, highlighting the variability of AML cell lines with respect to 
reliance on mitochondrial function. Such novel therapies could provide a more 
targeted approach to inhibiting mitochondrial function in cancer, compared to the 
clinically-used drugs outlined in Section 6.2.1, but will require considerable study to be 
translated to the clinic. 
 
6.2.3 Combining CX-5461 with mitochondrial inhibitors 
Mitochondrial flux analysis (Figure 5-9) suggested that CX-5461 and chloroquine 
synergised at the level of mitochondrial function, as such combining drugs that 
specifically target the mitochondria is a promising approach to improve the efficacy of 
CX-5461. As outlined in Section 6.2, there are currently several clinically approved 
drugs that target mitochondrial function that warrant evaluation in combination with 
CX-5461.  
 
 192 
Ideally, these mitochondrial-targeting drugs would be evaluated for synergy with CX-
5461 following the experimental approach used in this thesis. Specifically they would 
first be tested in vitro in AML cell lines first (as in Chapter 3), however, a different 
readout to that used in this thesis may be required since metformin interfered with 
the readouts for both the neutral red and MTT assays (Figure 3-3, Figure 3-4). One 
such assay could be using high throughput flow cytometry to determine cell number 
via physical particle counting (cell size and granularity), which is not dependent on 
biochemical functions, including mitochondrial function. If synergy is observed with 
these mitochondrial-targeting agents in combination with CX-5461 in multiple AML cell 
lines (as in Figure 3-19), as done in Chapter 4 the combination therapy will be 
evaluated for efficacy using in vivo mouse models of AML. Issues with the in vivo 
efficacy of the mitochondria-targeting drugs, as well as clinical translatability, as 
outlined above, must be kept in mind when testing any promising combinations in 
vivo, so it will be important to include markers of on-target effects in these studies. 
 
If the drug combination improves survival in the mouse models of AML, mechanistic 
analysis such as those performed in Chapter 5 will be required to confirm the 
mechanisms of action. Specifically, the drugs effect on mitochondrial function will be 
evaluated. For metformin and phenformin; inhibition of complex 1 activity will be 
assessed using the Seahorse XFe analyser 111, for tigecycline; inhibition of 
mitochondrial translation will be confirmed by measuring mRNA and protein levels of 
Cox 1 and 2 which are translated by mitochondrial ribosomes 106,352 and comparing 
these to the levels of cytoplasm-translated succinate dehydrogenase 352, grp78 or XIAP 
106 to confirm that global translation is not inhibited. For all 4 drugs metabolic flux 
analysis, including a mitochondrial stress test and individual complex activity, will be 
conducted using the Seahorse XFe analyser. These assays will also be conducted with 
CX-5461 as a single agent and in combination with the mitochondrial-inhibitors. The 
hypothesis developed in Chapter 5 regarding the mechanism of synergy between CX-
5461 and chloroquine (Figure 5-11) would suggest that directly targeting cancer 
mitochondrial activity in combination with CX-5461 will result in increased synergy in 
vitro and improved efficacy and reduced toxicity in vivo, compared to CX-5461 and 
chloroquine, providing a drug combination with the potential of clinical translation. 
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6.3  Alternative approaches for improving CX-5461 
efficacy 
6.3.1 CX-5461 and immunotherapy 
Evaluation of promising drug combinations in in vivo AML transplant models revealed 
the interesting suggestion that CX-5461 was more effective in the syngeneic MLL/AF9 
NRAS model compared to the xenograft models (Figure 4-6, Figure 4-8, Figure 4-9), 
which is a trend has also been observed by others in the laboratory (unpublished). 
Other than the mouse-derived MLL/AF9 NRAS cells being 10 times more sensitive to 
CX-5461 than the human cell lines (Table 3-4), the major difference between these two 
types of models is the immunodeficiency of the mice used, suggesting that the 
immune system could play a role in the response of the AML cells to CX-5461. As 
suggested in Section 4.3.6, this could be examined by transplanting the mouse-derived 
MLL/AF9 NRAS cell line into the immunocompromised mice normally used for the cell 
line xenograft experiments, and comparing the efficacy of CX-5461 treatment. This is 
important for the clinical development of CX-5461, including any potential of 
combining it with immunotherapy with the aim to improve efficacy in patients. As 
outlined in Section 4.1.1, leukaemia cells can influence the surrounding 
microenvironment, including through preventing the normal immune response to the 
presence of cancer cells. Immunotherapy has shown astounding results in numerous 
cancers including through chimeric antigen receptor (CAR) T cells targeting CD-19 in 
large B cell lymphoma 356 and acute lymphoblastic leukaemia 357. The most striking has 
been through blockade of programmed cell death protein 1 (PD-1)/programmed cell 
death ligand 1 (PD-L1), which mediates an immune checkpoint blockade, in advanced 
melanoma patients 358, which has opened up this field as viable therapies also in the 
treatment of AML 359. Gemtuzumab ozogamicin, a CD33-targeted drug conjugate, is 
the only currently approved antibody-targeted therapy for AML 360, although others 
are in clinical development, including immune checkpoint inhibitors 361. The human cell 
line xenograft models used in this thesis, could be used to evaluate the efficacy of CX-
5461 in combination with immune checkpoint inhibitors including, for example, the 
THP-1 cell line which highly expresses programmed death receptor ligand 1 (PD-L1) 362. 
Testing CX-5461 in combination with PD-1 inhibitors such as pembrolizumab 363 or 
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nivolumab 364, which are also in clinical trials for use in AML, would be rational choices 
to evaluate based on the results presented in this thesis. 
 
6.3.2 Potential mechanisms of synergy not explored in this thesis 
As outlined in Section 5.3.4 there are other potential mechanisms mediating the 
synergy between CX-5461 and chloroquine which were not assessed in this thesis. 
These involve the nucleolar stress response, DNA damage signalling, Pol I transcription 
inhibition and lysosomal effects. One or more of these mechanisms could also be 
contributing to the synergy observed between the two drugs, and thus may also reveal 
novel combination therapy strategies, thus warrant investigation. 
 
6.4  Concluding statement 
The results of this thesis support the well-established link between ribosome 
biogenesis and cellular metabolism within the cell, however importantly for the first 
time, it also demonstrates that targeting these two processes can effectively treat 
AML. Specifically, targeting mitochondrial function in combination with inhibition of 
ribosome biogenesis by CX-5461 is a novel therapeutic approach for AML. Critically, 
this combination was effective in AML, a model of aggressive disease that currently 
has limited therapeutic options in the clinic and thus has the potential to have a 
profound impact on patient care. 
 
While the combination effect of CX-5461 and chloroquine observed in vitro, did not 
always translate well in vivo and toxicity issues were observed, the results in this thesis 
provide a solid platform and rationale to develop similar combinations with limited 
drug toxicity. This may be achieved by repurposing already clinically-approved 
metabolism-modifying drugs, such as metformin or tigecycline which directly target 
the mitochondria and have few side effects, in combination with CX-5461 as cancer 
therapeutics. Such results, if positive, also mean a more rapid translation of promising 
combination therapies to the clinic compared to unapproved drugs. Speeding up the 
process of translating research observations to the clinic from the traditional decades 
to just years, and would be highly beneficial to patients. 
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While in a number of cases significant inroads have been made into the treatment, and 
even cure, in many cancers there are still many where this is not the case. Indeed, for 
some cancers, the treatments have changed little for decades, such as AML. Thus, this 
work has provided an important insight into combinations to utilise with CX-5461 in 
cancer, but especially in an aggressive model of AML. After decades, there is promising 
data that may facilitate a novel approach to tackle this disease. 
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Appendix Figure 4-1: Weight changes from combination therapy of CX-5461 and 
orlistat in the syngeneic MLL/AF9 NRAS AML model 
The weights of the mice were monitored daily during the dosing period and the weight 
changes as % of initial weight shown. Dosing occurred daily. 
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Appendix Figure 4-2: Bioluminescent images from combination therapy of CX-5461 
and DCA in the syngeneic MLL/AF9 NRAS AML model 
Imaging was performed weekly from 7 days post-transplant. The day 7 images are 
shown on a lower image colour scale to the subsequent weeks images, in order to show 
that engraftment has occurred. 
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Appendix Figure 4-3: Weight changes from combination therapy of CX-5461 and DCA in 
the syngeneic MLL/AF9 NRAS AML model 
The weights of the mice were monitored daily during the dosing period and the weight 
changes as % of initial weight shown. Dosing days are shown in grey. 
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Appendix Figure 4-4: Bioluminescent images from combination therapy of CX-5461 and 
chloroquine in the syngeneic MLL/AF9 NRAS AML model 
Imaging was performed weekly from 7 days post-transplant. The day 7 images are shown 
on a lower image colour scale to the subsequent weeks images, in order to show that 
engraftment has occurred. 
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Appendix Figure 4-5: Bioluminescent images from combination therapy of CX-5461 
and chloroquine in the xenograft MOLM-13 GFP luc model 
Imaging was performed weekly from 4 days post-transplant. The day 4 images are 
shown on a lower image scale to the subsequent weeks images, in order to show that 
engraftment has occurred. 
 
Appendix Figure 4-5: Bioluminescent images from combination therapy of CX-5461 
and chloroquin  in the xenograft MV4-11 GFP luc model 
Imaging was performed weekly from 7 days post-transplant. The day 7 images are 
   l  i  l      i , i      
engraftment has occurred. 
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Appendix Figure 4-6: Weight changes from combination therapy of CX-5461 and 
chloroquine in the xenograft MOLM-13 GFP luc model 
The weights of the mice were monitored daily during the dosing period and the weight 
changes as % of initial weight shown. Dosing days are shown in grey. 
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Median 
survival 
(days) 
Model 
MLL/AF9 NRAS 
MOLM-13 
GFP luc 
MV4-11 GFP 
luc 
Treatment regime 
CX-5461 + 
orlistat 
CX-5461 + 
DCA 
CX-5461 + 
chloroquine 
CX-5461 + 
chloroquine 
CX-5461 + 
chloroquine 
Vehicle 17 15 15 14 22 
Metabolism 
drug 
17 14.5 14 14 21 
CX-5461 29 20 20 15 22 
Combination 25 19.5 23 15 24 
 
Appendix Table 4-1: Survival times from in vivo combination treatment experiments 
Median survival times of treatment groups were calculated from combination 
treatment experiments in Sections 4.2.2 and 4.2.4. 
 
 
P values 
Model 
MLL/AF9 NRAS 
MOLM-13 
GFP luc 
MV4-11 GFP 
luc 
Treatment regime 
CX-5461 + 
orlistat 
CX-5461 + 
DCA 
CX-5461 + 
chloroquine 
CX-5461 + 
chloroquine 
CX-5461 + 
chloroquine 
Veh vs. Met 0.0926 N.S. 0.1172 N.S. 0.0455 N.S. 0.2888 N.S. 0.2151 N.S. 
Veh vs. CX 0.0023 * 0.0001 *** 0.0001 *** 0.0027 * 0.1750 N.S. 
Met vs. CX 0.0035 * 0.0001 *** <0.0001 **** 0.0017 * 0.0338 N.S. 
Veh vs. combo 0.0023 * 0.0001 *** 0.0003 *** 0.0007 ** 0.0007 ** 
Met vs. combo 0.0035 * 0.0001 *** 0.0002 *** 0.0004 ** 0.0003 ** 
CX vs. combo 0.0083 * 0.3840 N.S. 0.0049 * 0.1759 N.S. 0.0032 * 
 
Appendix Table 4-2: Statistical analysis of survival times from in vivo combination 
treatment experiments 
Log-rank test with Bonferroni corrected threshold was applied for comparison of 
multiple survival curves, such that a p-value of <0.0083 was considered significant. Not 
significant (NS) P > 0.0083, *P ≤ 0.0083, **P ≤ 0.015, ***P ≤ 0.001, **** P ≤ 0.0001. 
Veh = vehicle, met = metabolism modifying drug, CX = CX-5461. 
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Appendix Figure 5-1: Acute effects of CX-5461 and chloroquine as individual agents on 
mitochondrial function 
Metabolic flux of AML cell lines THP-1 and MOLM-13 was analysed using a mitochondrial 
stress test on the Seahorse XFe97 analyser (Section 2.11), with injection of vehicle, 1µM 
CX-5461 (CX), 40µM chloroquine (CQ) performed during the assay. a) Basal respiration 
rates, b) Respiration rates following drug injection, c) Maximal respiration rate following 
mitochondrial uncoupling with FCCP, d) Acute response (difference in the OCR following 
drug injection and basal respiration, e) Spare respiratory capacity (difference in the OCR 
between the maximum respiration rate and basal rate). One-way ANOVA was performed 
with a Tukey’s multiple comparison test, the adjusted p-value is shown. Not significant P > 
0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. Significant results only marked. 
N=3. 
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